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INTRODUCTION 
The public has placed great hope in scientists, who “grow new organs and tissues in the 
labs” in the past decades. Nevertheless, the journey from the in vitro experiments to clinical 
applications of “off-the-shelf” tissues still presents numerous technical challenges; a native 
tissue is far more complex than just a mass of cells glued together, and the signals that regulate 
the extracellular matrix development in vivo are still poorly understood. Different test systems 
and animal models have been developed to qualify the intermediate in vitro results of tissue 
engineering. Whereas human individuals differ in age and many genetic determinants, rodent 
animal models (mouse, rat) can be manipulated to yield minimal intra-individual variation. 
Much characterization is needed, however, to find parallelisms between animal models and 
human systems. Whereas numerous biomaterials used as scaffolds show good in vivo 
performance, the most promising cell sources for tissue engineering are adult stem cells; they 
are present in every adult individual and give rise to differentiated cells of tissues or organs. 
Two main branches of stem cell research have been booming since the 1960s, when 
Friedenstein and his colleagues documented in vitro colony forming fibroblasts from the bone 
marrow, now called mesenchymal stem / progenitor cells (MSC). First, more detailed basic 
research deepens into “stemness”, differentiation potency and their molecular code, whereas, on 
the other hand, the more applicative other branch uses the advantages of MSC as cells for 
cellular therapies (gene delivery, immunosuppression) and neogenesis of mesenchymal tissues 
(tissue engineering). Both fields are strongly interdependent, providing useful information to the 
“sister” branch. Likewise, this thesis encompasses both approaches to stem cell research. The 
first phase included the characterization of MSC from the rat bone marrow, characterization of 
“accompanying” hematopoietic, cells and their influence on osteogenic differentiation. The 
outcomes of cell characterization lead us further to test for bone tissue engineering applications 
as a means of finding biomaterial for selective adhesion of pure MSC.  
The materials used as bone substitutes often have the disadvantage of causing fibrous 
tissue development at the interface with the surrounding tissue when implanted. This process 
follows the natural wound healing process of fibrin clot formation and inflammation by 
infiltration of macrophages and other cells of the immune system to the site of an implant1. 
Also in vitro, cells often fail to adhere or fail to differentiate and produce enough ECM when 
seeded onto raw biomaterials. To circumvent these issues, modification of the biomaterial 
surface can enable the adhesion of desired cells to the biomaterial surface and enhance their 
differentiation. One possibility is to covalently bind adhesion-promoting sequences, i.e. 
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ligands for integrins, which are cell adhesion receptors, to the biomaterial surface and at the 
same time prevent nonspecific cell adhesion to the hydrophobic biomaterial surface using a 
hydrophilic poly-ethylene-glycol (PEG) layer. To this end, the ligands, for which receptors on 
the target cells are highly expressed, are bound to the biomaterial surface. Therefore, it is a 
prerequisite to determine which integrin receptors are actually expressed on “desired cells” (in 
our case rat MSC) and to which level. Then, the decision has to be made, which ligand will to 
be bound to the biomaterial surface, to ensure the desired adhesion and cell differentiation.  
 
 
Figure 1: The primary goal of the thesis was to discover integrins expressed only on MSC 
(e.g. Cell 1) to achieve selective surface immobilization and improved differentiation. 
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MESENCHYMAL STEM / PROGENITOR CELLS 
(MSC) 
Bone marrow mesenchymal stem / progenitor cells (MSC) were first described in the 60s 
and 70s by the group lead by Alexander Friedenstein. He and his colleagues showed that bone 
marrow stroma contains cells that adhere to tissue culture plastic. He determined that these cells 
(1) belong to a rare population in the bone marrow, (2) did not enter “S” phase until up to 60 
hours after initial plating, (3) showed a high replicative capacity in vitro, (4) were clonogenic, and 
(5) formed colonies of irregular shape and density2. More importantly, he showed that the cells 
were capable of forming bone in vivo, even after multiple passages in vitro.  
MSC are isolated mostly from the bone marrow and organs of mesenchymal origin 
that can be expanded in vitro over several passages (unlimited self renewal) and differentiated 
into cells of some mesenchymal tissues, such as osteoblasts, chondrocytes, adipocytes, 
myocytes, tenocytes, and haematopoiesis supporting stromal cells2-9. With appropriate 
culturing conditions (very low seeding density, medium pre-selection, etc.), distinct colonies 
of spindle-shaped / fibroblastic cells are formed, each of which is derived from a single 
precursor cell, the colony forming unit – fibroblast (CFU-F)5. In addition to bone, cartilage, 
marrow adipocytes, and formed fibrous tissue could arise from single cell or CFU-F in vivo5. 
Due to their high frequency in the bone marrow stroma, they are often named also marrow 
stromal (mesenchymal stem) cells, although they are also moderately present in the bone 
marrow (0.001-0.01% of all nucleated cells in the marrow10). “Stromal cells” play an 
important role as a microenvironment (stroma) for the developing hematopoietic stem and 
progenitor cells in the bone marrow11. MSC-like cells have been isolated from periosteum, 
trabecular bone, adipose tissue, synovium, skeletal muscle, lung and deciduous teeth4 and 
human umbilical cord perivascular cells11. Scientists still argue, whether the site of isolation is 
also the site of the MSC origin, or if circulating MSC exist12.  
MSC are generally isolated from an aspirate of bone marrow harvested from the 
superior iliac crest of the pelvis in humans, though other sites have also been reported, e.g. the 
tibial and femoral compartments and thoracic and lumbar spine. In larger animals, marrow is 
often obtained from the same site, and in rodents it is generally harvested from the mid-
diaphysis of the tibia or femur4. Human bone marrow in particular is often subjected to 
density gradient centrifugation to enrich the MSC-containing fraction. The cell suspension is 
placed into tissue culture flasks and cultured in pre-tested medium, supplemented with fetal 
bovine serum (FBS), and the adherent fraction of cells is expanded and passaged. After 
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isolation, MSC adhere rapidly and can easily be separated from the non-adherent 
hematopoietic cells by repeated washing. Non-adherent hematopoietic cells (HC) are removed 
with media changes, whereas adherent HC disappear from the cultures within several 
passages or are depleted using immunoselection techniques4,13. One of the most important 
features of MSC culturing is the selection of an appropriate FBS lot, so that it allows for: (1) 
selective attachment of MSC to the tissue culture flasks, (2) mitotic expansion of MSC, and 
(3) maintenance of MSC phenotype14. Enrichment of CFU-F or increasing their frequency, 
compared to whole bone marrow seeding, can be achieved by negative immunoselection 
(CD34+/CD11b+/CD31+ cell depletion) or by positive immunoselection using antibodies 
against Stro-1, CD49a, D7-FIB and LNGFR (low-affinity nerve growth factor receptor)5,15. 
Multilineage differentiation potential & unlimited self-renewal 
According to the definition of a stem cell, MSC should have unlimited proliferative 
capacity and multilineage differentiation potential. Pittenger at al.16 showed that only 2 of 6 
individual colonies express multilineage differentiation capacity and therefore confirmed the 
previously observed heterogeneity of CFU-F with regards to size, morphology, and potential 
for differentiation5,17,18. Aubin et al.3 explain that CFU-F belong to a lineage hierarchy in 
which only some of the cells are multipotential stem cells or primitive progenitors, whereas 
others are more restricted. Muraglia et al.19 demonstrated that only 30% of the in vitro derived 
MSC clones exhibit a tri-lineage (osteo/chondro/adipo) differentiation potential, while the 
remainder displayed a bi-lineage (osteo/chondro) or uni-lineage potential (osteo). More 
importantly, the multi-potential clones progressively loose their adipogenic and chondrogenic 
potential with repeated passages2. 
When considering the unlimited self-renewal of MSC, it is necessary to stress that the 
published data are variable, because MSC proliferative capacity depends on a number of 
culture conditions, including the supplementation of basic media with growth factors (e.g. 
FGF-2, PDGF, EGF, TGF-β, IGF) and the seeding density (low seeding density increases the 
fold expansion / population doublings in vitro)5,11. Nevertheless, these cell populations, often 
prematurely named stem cells, are a heterogonous population with regards to their 
differentiation potential and self-renewal ability. It is believed that multipotent mesenchymal 
stem cells exist, but that they are lost from the pool of MSC during long-term culturing due to 
their low frequency in the primary tissue source3. Nonetheless, some subclasses of MSC can 
be enriched and cultured up to 70 population doublings (PD) under select culture conditions, 
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and they retain the multipotent differentiation potential up to 50 PD11. Tri-potent and bi-
potent procursor cells are morphologically similar to the multipotent MSC, but differ in their 
gene transcription repertoire. The progression of MSC to precursor cells (from asymmetric to 
symmetric division) is considered the first step in stem cell commitment11. 
In vitro osteogenic activation requires the presence of β-glycero-phosphate (phosphate 
for the mineralization), ascorbic acid (collagen synthesis), dexamethasone (transcriptional 
activation) and FBS. When cultured in monolayers in the presence of these supplements, the 
cells acquire an osteoblastic morphology with up-regulation of alkaline phosphatase activity 
and deposition of a calcium-rich mineralized extracellular matrix4. Chondrogenic 
differentiation occurs when MSC are grown under conditions that include a three-dimensional 
culture format (e.g. micro mass cultures), a serum-free nutrient medium, and the addition of a 
member of the TGF-β super-family (especially TGF-β2 and TGF-β3)4. When these 
conditions are met, the cells rapidly loose their fibroblastic morphology and begin to initiate 
expression a number of cartilage-specific extracellular matrix components, e.g. 
glycosaminoglycan4. MSC cultured in monolayers in the presence of isobutylmethylxanthine, 
dexamethasone, and indomethacin become adipocytes with the production of lipid-filled 
vacuoles15,20. Adipogenic differentiation is induced by the nuclear receptor and transcription 
factor peroxisome proliferator-activated receptor-gamma (PPAR-γ) as well as fatty acid 
synthetase4. MSC myogenesis has been induced in vitro using 5-azacytidine or amphotericin 
B, resulting in the formation of multinucleated fibers, resembling myotubes20. For stromal 
differentiation, which enables the maintenance of hematopoietic stem cells, horse serum is 
added to the culture as well as i-inositol, folic acid, 2-mercaptoethanol, L-glutamine, and 
hydrocortysone21. The differentiation pathways from the MSC to mature mesenchymal 
lineages are presented in Figure 2. 
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Figure 2: Mesengenic lineage pathway. The process of mesengenesis involves the generation 
of multiple mesenchymal end-stage phenotypes from the differentiation of a multipotent 
mesenchymal stem cell (MSC) through a multistep series of developmental changes in 
response to microenvironmental stimuli. The lineages are illustrated from left to right in the 
order of most to least characterized (from Caplan et al. 14).  
Surface marker characterization of MSC 
Beside morphological descriptions of MSC, in the past years research has been 
devoted to finding specific surface markers on MSC that would make them detectable by flow 
cytometry and would enable the isolation by FACS (fluorescence-activated cell sorting) or 
MACS (magnetic-associated cell sorting) from freshly isolated tissues. The problem of 
finding MSC-specific markers is that MSC are described only as cells yielded in vitro. Beside 
that, they express similar features with fibroblastic cells (expression of matrix proteins), 
endothelial (endoglin and MUC-18), epithelial and muscle cells (α-smooth muscle actin)5,11. 
Several laboratories have developed monoclonal antibodies using MSC as immunogen in 
order to identify one or more markers suitable for identification and sorting of stromal cell 
preparations. The nearest approximation has been production of Stro-1, which is highly 
expressed by stromal cells that are clonogenic5. There is a general agreement that MSC lack 
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typical hematopoietic antigens, namely, CD45, CD34, CD133, CD14 or CD11b and an 
endothelial marker CD314,11. The most important surface markers expressed on human MSC 
are listed in Table 1. Detailed reviews of MSC surface marker expression can be found in 
Deans and Moseley22, Pittenger et al.23 and Minguel et al9. Data reviewed in Table 1 result 
from characterization of in vitro expanded MSC. There is increasing evidence that MSC-like 
cells in vivo also express some hematopoietic and other markers and therefore the “true in 
vivo MSC” characterization is still a challenge. Rapidly self-renewing cells (RS cells) 
observed in vitro are an MSC subpopulation of highly mitotic small cells that can be enriched 
by very low density culturing and can be discriminated by the differential expression of 
several antigens, including TrkA, Flk-1 and c-kit receptors2. 
However, more primitive adult stem cells than MSC can be isolated from bone 
marrow and expanded in vitro: Multipotent adult progenitor cells (MAPC) can be co-purified 
with MSC and are actually a pluripotent population, being able to differentiate not only to 
mesenchymal cells, but also to visceral mesoderm-, neuroectoderm- and endoderm-like 
cells24. Murine MAPC express low levels of Flk-1, Sca-1, and Thy-1 and higher levels of 
CD13, stage specific antigen I (SSEA-I), and high levels of telomerase, enabling them the 
expansion over 100 PD. Young et al.25 isolated so called pluripotent lineage-uncommitted 
stem cells from several tissues. These cells are small (6-20µm) and lack some typical MSC 
markers (CD105, CD71, CD117), but express CD10, CD13, CD66e and show telomerase 
activity25. For instance, pluripotent mesodermal stem cells can differentiate to several 
mesoderm-derived cell types, including hematopoietic cells and intramembranous 
osteoblasts25. 
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Table 1: Some common stated MSC typical surface markers. 
CD 
locus Marker MSC HSC OB EC. Reference 
Stem cell markers      
 Stro-1 + - +26 +/- 2,5,9,12,15,20,20,22,27-29 
CD166 SB-10 / ALCAM + - +26  2,4,12,20,23,30,31 
CD105 SH-2 / endoglin / TGFβ Rp + - -26 + 11,12,14,20,22,23,27,29,31 
CD73 SH-3, SH-4 + - -  4,11,12,23,29 
CD44 H-CAM + + +32  9,11,12,23,28-31 
CD71 Aka, transferring Rp. +    11,28 
CD90 Thy-1 + +   11,22,23,27-30,33 
CD106 V-CAM +   + 11,12,22,27,28,30 
CD120a Aka, TNF Rp. +    11,23 
CD124 IL-4 Rp +    11,23,28 
CD271 P75 LNGF Rp +    11,22 
CD133 Prominin / AC133 +/- +   11,15,23 
CD34 Adhesion Rp, HSC marker -(+) +   9,11,22,22,29,33 
CD10 CALLA, neutr.endpeptidase +/-  +32  22,23 
CD13 Aka, aminopeptidase N +  +32  22,23,28,29,31 
CD146 MUC-18 +   + 27,30 
CD117 c-kit + / - +   23,33 
 Sca-1 + +   29,30,33 
Adhesion molecules      
CD29 Integrin β1 +    4,12,22,23,28,28,30 
CD49a Integrin α1 +    4,12,22,23,27,28,30 
CD49b Integrin α2 Low    12,20,22,23,28 
CD49c Integrin α3 Low    12,20,22,23 
CD49d Integrin α4 - +   20,22,23 
CD49e Integrin α5 +    4,12,22,23,29 
CD61 Integrin β3 Low    12,22 
CD54 ICAM-1 +  +32  12,22,23,31 
CD62 selectins + / -    12,23,29,30 
CD31 PECAM -   + 23,29 
CD38 Adhesion: lymphocytes + EC -    22,30,33 
CD50 ICAM-3, CD54 ligand - +   22 
Hematopoietic markers      
CD45 LCA  - + -32  9,11,11,20,22,23,28-30 
CD11a Integrin αL - +   20,23 
CD11b Integrin αM - + +32  11,20,29,30 
CD14 LPS Rp -  -32  9,23 
CD18 Integrin β2 - +   11,20,23 
Other  MHC-Class I / HLA-ABC +    4,20,23,29 
 MHC-Class II / HLA-DR -  +32  4,20,22,23,29,30,33 
CD40 Cell- and Ab-reg.immunity -    29 
CD80 Aka B7-1, BB1; binds CD28 -  +32  23,29 
CD86 Aka B7-2, binds CD28 -  +32  23,29 
CD140 PDGF Rp +    22,30 
 EGF Rp +    22,30 
 IGF-1 Rp +    22 
CD: cluster of differentiation; MSC: mesenchymal progenitor cells; HSC: hematopoietic stem cells; OB: osteoblasts, osteocytes; EC: endothelial cells.
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Adhesion molecules 
Cells communicate with each other directly via heterotypic or homotypic cell-cell 
contacts as well as indirectly using their secreted molecules (paracrine, autocrine pathways). 
The latter can be triggered by a signal from the ECM, which cells (1) adhere to, (2) migrate 
onto, and (3) produce or degrade. Loss of attachment to the matrix causes apoptosis in many 
cell types34. The bone marrow is an ideal example of MSC communication with surrounding 
ECM and other cells, including hematopoietic stem and progenitor cells (HSC), endothelial 
cells, adipocytes, macrophages, reticular cells, fibroblasts, and smooth muscle cells. When 
isolated from the bone marrow and injected into a host, both MSC and HSC are readily 
retained in the bone marrow or at the injury site, as observed in cell “homing” studies4. 
Homing depends upon adhesion molecule interactions, which influence the localization, 
proliferation, and differentiation of the injected cells.  
Cell adhesion has been an important part of tissue engineering research, where it was 
shown that the biomaterial surface dictates how cells adhere and form tissue in contact with 
the surface. Attachment, adhesion, and spreading belong to the first phase of cell / substrate 
interactions and the quality of this first phase will influence the cell's capacity to proliferate 
and differentiate in contact with the implant. 
Studies in vitro demonstrated the role of adhesion molecules in cell shape, 
polarization, cytoskeletal organization, cell motility, and survival35. Cell adhesion receptors 
are characterized by their capacity to interact with a specific ligand. These ligands can be 
situated on the membrane of neighboring cells or can be ECM proteins. Cell adhesion 
molecules can be divided into 4 major classes: selectins, the immunoglobulin superfamily, 
cadherins and integrins. Integrins, in contrast to other receptors, primarily mediate adhesion to 
ECM and to a lesser extent mediate heterotypic cell-cell adhesion to immunoglobulin 
adhesion receptors (leukocyte integrins).  
Integrins 
Integrins are transmembrane heterodimers consisting of non-covalently associated 
alpha and beta subunits36,37. Each subunit is made up of a large extracellular domain, a 
transmembrane domain, and a short cytoplasmic domain. The integrin spanning the cell 
membrane acts as a linker between the intracellular and extracellular compartments and can 
translate the attachment of external ligands to internal information, referred to as outside-in 
signaling. Inside-out signaling can, for example, activate integrins and cause their clustering36. 
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Integrins do not bind nonspecifically to ECM proteins, but rather to specific binding sites. The 
most common binding site is the tripeptide amino acid sequence arginine-glycine-aspartic 
acid (RGD)37. This sequence is present in most of the ECM proteins, like fibronectin, 
vitronectin, bone sialoprotein, osteopontin, trombospondin, fibrinogen, laminin, collagen, 
nectipepsin, and others37,38. However, binding sites are not always accessible and do not 
always mediate cell attachment. For instance, an RGD sequence may not always be present at 
the surface of the protein or may require a second site to perform its function36.  
After the binding of a ligand, the integrins cluster together into focal contacts. This is 
an area of close contact between a cell and the ECM, consisting of additional cytoskeletal 
proteins, adapter molecules, and kinases36, as presented in Figure 3. Integrin activation results 
in the recruitment of signaling molecules, the reorganization of the cytoskeleton, signal 
transduction, and the expression of distinct transcription factors. However, integrins can be 
present on the cell surface in an inactive state, in which they do not bind ligands, and cannot 
trigger signaling cascades36. The activity of an integrin may depend upon a ligand as well as 
on integrin subtype. Furthermore, some integrins require a second binding site (synergy site) 
on the ligand for optimal function36. Integrins are able to cooperate with growth factor 
receptors in the regulation of cellular processes in a way that with integrin clustering also 
growth factor receptors are recruited36.  
Gene deletion studies showed the importance of integrins not only for cell function, but 
also for the development of an organism. For example, the deletion of β1 can completely block 
development of blastocyst, and the deletion of α4, α5, αV and β8 can cause major 
developmental defects or be fatal (deletion of α3, α6, α8, αV, β4, β8). Furthermore, by deleting 
genes, defects in leukocyte function (αL, αM, αE, β2, β7), inflammation (β6), haemeostasis 
(αIIb, β3, α2), bone remodeling (β3), and angiogenesis (α1, β3) were observed 39. 
Integrins are selective towards their substratum ligand / ligands, although an integrin 
may target more than a single ECM protein. Integrins α1β1, α2β1, α10β1, α11β1, αIIbβ3, 
and αVβ8 can all bind collagens, α3β1, α4β1, α5β1, α8β1, αVβ1, αIIbβ3, αVβ3, 
αVβ6, α4β7, and αVβ8 bind fibronectin, integrins αVβ1, αIIbβ3, αVβ3, and αVβ5 bind 
vitronectin, and α1β1, α2β1, α6β1, α7β1, α6β4, and αVβ8 bind laminins36. 
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Figure 3: Matrix binding promotes 
integrin clustering and association 
with the cytoskeleton. This in turn 
promotes further integrin clustering 
and matrix organization in a 
positive feedback system.  
RGD, Arg-Gly-Asp integrin-binding 
motif; Tal, talin; Pax, paxillin; Vin, 
vinculin; CAS, p130CAS; FAK, focal 
adhesion kinase; Src, kinase family. 
(from Giancotti and Ruoslahti 34) 
 
MSC express a large spectrum of cell adhesion molecules of potential importance in 
cell binding and homing interactions. The characterization of freshly isolated MSC (Stro-1 
positive immunoselection) from the human bone marrow showed the expression of α1β1 
(VLA-1), α2β1 (VLA-2), α5β1 (VLA-5), α6β1 (VLA-6), αVβ3 and αVβ5 integrins and 
substrate / integrin dependent CFU-F colony formation40. Cultured human MSC exhibit a 
high expression of integrins α1, α5 and β1, low expression of α2, α3, α6, αV, β2, and β4, 
and no expression of α4, αL, and β241.  
MSC in cell therapies 
The fundamental principle of stem cell therapy (SCT) is that undifferentiated cells 
(autologous or allogenic) can be locally or systemically delivered to the injured host, will 
migrate to the site of injury, and, under the influence of local signals, will differentiate to the 
cells of the appropriate phenotype4,42. These differentiated cells then contribute to the repair 
of the injured tissue4. It seems clear that MSC, when delivered by intravenous infusion, are 
capable of specific migration to a site of injury20. MSC have already demonstrated efficacy in 
the treatment of children with osteogenesis imperfecta, for osteoporosis, ostoarthrosis, 
meniscectomy, hematopoietic recovery as well as cardiovascular repair, lung fibrosis, spinal 
cord injury, and muscular dystrophy4,8,9,11,15. Interestingly, MSC help regenerate not only 
tissues of mesenchymal origin, but also the tissues of other embryonic layers, including 
neurons, epithelia, skin, lung, liver, intestine, kidney, and spleen, as shown in animal 
studies4,8,9,11,15.  
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It is also noteworthy that neither autologous nor allogenic MSC induce any 
immunoreactivity in the host upon local or systemic administration8,11. This proposes MSC as 
an ideal carrier to deliver genes into the tissues of interest for gene therapy applications8,11. 
Moreover, there is accumulating evidence of the hypo-immunogenic nature of MSC. In other 
words, MSC may actually inhibit inflammation and immunologic responses in the host15, 
which leads to the MSC application in reducing so called GVHD (graft versus host disease), a 
common complication after cell or organ transplantation4,15. Although early pre-clinical and 
clinical data demonstrate the safety and effectiveness of MSC therapy, there are still many 
questions to be answered surrounding the mechanism of action4. 
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BONE 
The skeleton consists of highly specialized cells, mineralized and non-mineralized 
connective tissue matrix, and spaces that include the bone marrow cavity, vascular canals, 
canaliculi, and lacunae (Figure 4). During development and growth, the shape and the size of the 
skeleton is achieved by the removal of bone from one site and deposition another (modeling). 
Once the skeleton has reached maturity, regeneration continues in the form of periodic 
replacement of the old bone with new at the same location (remodeling)43. Removal of the bone is 
a function of osteoclasts, derived from blood-cell precursors, and new-bone formation is a 
function of osteoblasts, cells derived from mesenchymal stem / progenitor cells43.  
 
Figure 4: Morphological cross-section structure of a long bone with cancellous / spongy 
bone in the middle and compact / cortical bone surrounding the spongy bone (from 44). 
 
Bone is composed of an organic matrix that is strengthened by deposits of calcium salts. 
Type I collagen constitutes approximately 95% of the organic matrix; the remaining 5% is 
composed of proteoglycans and numerous non-collagenous proteins (which consist 90% of 
osteocalcin and osteonectin and the other proteins, e.g. osteopontin, bone sialoprotein)43,45. 
Crystalline salts deposited in the organic matrix of bone under cellular control are primarily 
calcium and phosphate in the form of hydroxyapatite. Morphologically, there are two forms of 
bone: cortical (compact) and cancellous (spongy). In cortical bone, densely packed collagen 
fibrils form concentric lamellae, and the fibrils in adjacent lamellae run in perpendicular planes 
as in plywood46. On the other site, cancellous bone has a loosely organized, porous matrix. 
Differences in the structural arrangements of the two bone types are related to their primary 
functions: cortical bone provides mechanical and protective functions and cancellous bone 
provides metabolic functions46. 
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Bone cells 
Bone is composed of four different cell types: osteoblasts, osteoclasts and bone lining 
cells are present on bone surfaces, whereas osteocytes permeate the mineralized interior. 
Osteoblasts are fully differentiated cells, originating from MSC. In culture, they are 
morphologically nearly indistinguishable from fibroblasts, but form cuboidal cells at confluent 
density, as observed in the middle of the compact colonies - bone nodules43,47. They are responsible 
for the production of bone matrix by secreting collagen I and other non-collagenous proteins46.  
Osteocytes are mature osteoblasts within the bone matrix and are responsible for 
matrix maintenance. These cells have the ability not only to synthesize the bone matrix, but 
also to resorb matrix to a limited extent. Each osteocyte occupies a space or lacunae within 
the matrix with its filopodial extensions in contact with neighboring adjacent cells enabling 
communications and nutrient / metabolite flow46. 
Bone lining cells are flat, elongated, inactive cells that cover quiescent, non-
mineralized collagenous bone surfaces. It has been suggested that these cells are either 
osteoblast precursors46 or “resting” osteoblast43, since no definitive role has been detected. 
Osteoclasts are large, multinucleated cells that resorb bone. In vitro maturation of 
hematopoietic stem cells / macrophages into osteoclasts requires the presence of marrow 
stromal cells or their osteoblast progeny43. Osteoclastogenesis is promoted by macrophage 
colony-stimulating factor (M-CSF) and requires contact between osteoclast precursors, 
expressing RANK (receptor for activation of nuclear factor kappa B), and stromal cells or 
osteoblasts, expressing RANK ligand (RANKL). RANKL and RANK are members of the 
tumor necrosis factor (TNF) and TNF receptor super-families, respectively43.  
Formation of the Skeleton 
Formation of the skeleton (ossification) occurs by either direct (intramembranous) or 
indirect (endochondral) processes. Both require a solid base and a vascular supply for the 
deposition of the mineralized extracellular matrix. 
Intramembranous ossification (Figure 5a) occurs by the direct transformation of 
mesenchymal cells into osteoblasts during embryonic development. This type of ossification 
is restricted to those of cranial vault, some facial bones, and parts of mandible and clavicle. 
The flat bones of the scull grow toward each other from primary ossification centers in each 
and meet at sutures. The center of a suture contains a proliferating cell population, whose 
progeny differentiate and move toward adjacent bone surfaces, becoming osteoblasts46. 
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Figure 5a: Intramembranous bone 
formation. Cellular relationships in a 
periosteum and a suture. F, fibroblast; OP, 
osteoprogenitor cell; OBL, osteoblast; OCY, 
osteocyte. 
(from Marks and Odgren46) 
Bones that participate in joints and bear weight are formed by endochondral 
ossification, which is presented in detail in Figure 5b. Endochondral bone formation is also a 
major factor in bone longitudinal growth, which is a precise balance between chondrocyte 
proliferation, cartilage matrix production, and mineralization, hypertrophy and vascular 
invasion46. Bone growth in diameter (central portion of the long cylindrical bones) is 
accomplished most basically by formation at periosteum (externally) and resorption at 
endosteum (internally, marrow site)46.  
 
Figure 5b: Endochondral bone formation. 
a - b: Mesenchymal cells condense and become 
chondrocytes (c, C). c, C at the centre stop 
proliferating and become hypertrophic (h, H). 
d, Perichondrial cells adjacent to H become 
osteoblasts . H direct the formation of 
mineralized matrix, attract blood vessels, and 
undergo apoptosis. e, vascular invasion. f, C 
continue to proliferate, lengthening the bone. 
Osteoblasts of primary spongiosa are 
precursors of eventual trabecular bone; 
osteoblasts of bone collar become cortical 
bone. g, growth plate and secondary 
ossification center formation.  
bc: bone collar, ps: primary spongiosa, soc: 
secondary ossification center, col: columns of 
proliferating chondrocytes, hm: hematopoietic 
marrow (from Kronenberg H.M.49) 
MSC differentiation to osteoblasts 
Two main osteoblast-specific transcripts have been identified and often reported: one 
encoding Cbfa1 (Runx2), a transcription factor, and the other encoding osteocalcin, a secreted 
molecule that inhibits osteoblast function46. Cbfa1 expression precedes osteoblast 
differentiation and is restricted to mesenchymal cells destined to become either chondrocytes 
or osteoblasts, playing a role in endochondral bone formation. Subsequently, Cbfa1 
expression becomes limited to the osteoblasts, with a lower level of expression in 
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hypertrophic chondrocytes. Other transcription factors may control osteoblast differentiation 
in a Cbfa1-dependent or -independent manner46. Cbfa1 binding sites are also present in the 
regulatory sequences of most genes required for the elaboration of a bone ECM. Interestingly, 
Cbfa1 gene deletion leads to an absence of osteoblasts and a skeleton made of cartilage, 
resulting from the incomplete terminal differentiation of chondrocytes (only partial 
hypertrophy)48,49. The existence of an even more specific osteoblast transcription factor has 
been reported recently: osterix (Osx) is a critical mediator of Cbfa1 action and its deletion 
leads to inhibition of osteoblastic differentiation without influence on chondrocyte 
differentiation and maturation50.  
Alkaline phosphatase (ALP) is an osteoblast-membrane bound enzyme expressed in 
proliferating preosteoblasts and is believed to play a role in mineralization process43. ALP 
activity increases at the beginning of differentiation and decreases when mineralization is well 
progressed43. The expression of the most frequently assayed osteoblast-associated genes, 
including collagen I (COLLI), alkaline phosphatase (ALP), osteopontin (OPN), osteocalcin 
(OCN), bone sialoprotein (BSP), and parathyroid hormone receptor (PTH1R), is up-regulated 
asynchronously, acquired, and/or lost as the progenitor cells differentiate and the matrix 
matures and mineralizes3. All these osteoblast specific markers are upregulated prior to the 
cessation of proliferation in osteoblast precursors except OCN, which is upregulated only in 
post-proliferative osteoblasts; in other words, differentiation is well progressed before 
osteoblast precursors leave the proliferative cycle3. Table 2 shows the time-profile of 
osteogenic marker expression from MSC to osteoblasts and of some differentiation-specific 
surface markers.  
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Table 2: Osteogenic differentiation from MSC to osteocyte with some differentiation markers. 
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proliferation ++ ++ ++ + - -  
differentiation 
 + ++ +++ ++++ ++++  
Cbfa1 
 ++   ++  3 
ALP (SB-1/RBM211.13/HOB-3) 
  + ++ +++  3,26 
Collagen 1 
 + ++ ++ ++ - 3 
Osteocalcin - - - - +++ - 3 
Bone sialoprotein - ++ - -/+++ -/+++ -/+++ 3 
Osteopontin -/+ -/+ -/+ -/+ -/+++ -/+++ 3 
Osteonectin / SPARC 
   + +  26 
PTH/PTHrP-R 
   +++ +++ ++ 3 
PTHrP 
   ++ ++ - 3 
CD44 
   + ++ ++ 3 
Galectin 3 / RCC 455.4 
   -/+ -/+++ -/+++ 26 
SH-2 +      26 
SB-10 + + +    26 
Stro-1 
  + + +  26 
SB-20 / SB21 
  + + +  26 
SB-3 
   + +  26 
SB-2 
    +  26 
E11 
    + + 26 
SB-5 
     + 26 
Legend: +: expressed, -: not expressed, + / - : variable data.  
Regulation of bone function 
Genetic-based studies have revealed how osteoblast differentiation is controlled through 
growth and transcription factors. In addition to autocrine, paracrine, and endocrine signals, cell-
cell and cell-matrix interactions are also required for the development of osteoclasts and 
osteoblasts. Such interactions are mediated by proteins expressed on the surfaces of these cells 
and are responsible for the contact between osteoclast precursors with stromal / osteoblastic cells. 
Adhesion molecules are also involved in the migration of osteoblasts and osteoclast progenitors 
from the bone marrow to the sites of bone remodeling as well as the cellular polarization of 
osteoclasts and the initiation and cessation of osteoclastic bone resorption43.  
The only factors capable of initiating osteoblastogenesis from uncommitted 
progenitors are bone morphogenic proteins (BMP). BMP-2 and BMP-4 in particular stimulate 
the transcription of Cbfa1, which in turns activates other osteoblast specific genes. Other 
growth factors, like transforming growth factor beta (TGF-β), platelet derived growth factor 
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(PDGF), insulin-like growth factors (IGF) and members of fibroblast growth factors (FGF), 
can all stimulate cell replication and differentiation, but only in committed progenitor cells 
and not from uncommitted MSC43,46. Cytokines are known to play roles in hematopoietic cell 
development and osteoclastogenesis in the bone marrow. Therefore, they can also influence 
osteoblast differentiation and bone remodeling. This group includes interleukins (IL-1, IL-3, 
IL-6, IL-11), leukemia inhibitory factor (LIF), oncostatin (OSM), ciliary neurotropic factor 
(CNTF), tumor necrosis factor (TNF), granulocyte-macrophage colony stimulating factor 
(GM-CSF), M-CSF, and c-kit ligand. IL-6 is produced by the cells of stromal / osteoblastic 
lineage in response to stimulation by a variety of other cytokines and growth factors such as 
IL-1, TNF, TGF-β, PDGF, and IGF-II43. 
Two systemic hormones of the calcium homeostatic system, namely the parathyroid 
hormone (PTH) and 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3, calcitriol), can stimulate 
osteoclast formation. Calcitonin and thyroid stimulating hormone (TSH), on the other hand, 
inhibit osteoclast development and activity and promote osteoclast apoptosis. PTH, PTH-
related peptide, and 1,25-(OH)2D3 stimulate the production of IL-6 and IL-11 by stromal / 
osteoblastic cells. Several other hormones, including estrogen, androgen, glucocorticoids, and 
thyroid hormone thyroxine, exert potent regulatory influences on the development of 
osteoclasts and osteoblasts by regulating the production and/or action of several cytokines43. 
Bone growth is principally guided already with growth hormone (GH), and also with some 
other proteins, like osteoprotegrin and leptin43. 
Bone Matrix 
Collagens can be defined as “structural proteins of the extracellular matrix, which contain 
one or more domains harboring the conformation of a collagen triple helix”51. The triple helix 
motif is composed of three polypeptide chains, whose amino acid sequence consists of Gly-X-Y 
repeats. Due to this particular peptide sequence, each chain is coiled in a left-handed helix, and the 
three chains assemble in a right-handed triple helix, where Gly residues are in a center of the triple 
helix and the lateral chains of X and Y residues are on the surface of the helix51. In about 1/3 of 
the cases, X is a proline and Y is a hydroxyproline; the presence of hydroxyproline is essential to 
stabilize the triple helix and is a unique characteristic of collagen molecules51. Type I collegen is a 
fibrillar collagen and is a most abundant protein in vertebrates. It is present in many tissues, being 
a major constituent of bone, tendons, ligaments, and skin51. Type I collagen is secreted as a 
soluble propeptide, which after cleavage by specific proteases looses its solubility, and assembles 
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spontaneously to form fibrils51. Finally, cross-linking processes join the collagen molecules 
covalently. In fibrils, molecules of collagen are parallel to each other. Collagen-forming sheets are 
composed of Type IV and VIII collagen. Type IV collagen forms a complex three-dimensional 
network, which is the major component of basement membranes51, an important component of 
MSC site of origin. 
In bone, hydroxyapatite crystals seem to lie in the gaps between collagen molecules51. 
However, collagen may not be the direct nucleator of hydroxyapatite deposition, but rather serves 
as scaffolding upon which nucleators - noncollagenous proteins - are oriented38. There are a large 
number of matrix proteins that have been found to bind to collagen, thereby forming fibrils. They 
belong to the proteoglycans (glycosaminoglycans bound to core proteins) and glycoproteins 
(noncollagenous proteins). The most prominent nucleator of hydroxyapatite deposition is 
osteonectin, which has the ability to bind to calcium and collagen38. Its constitutive expression in 
adults is limited to cells associated with mineralized tissues, such as hypertrophic chondrocytes, 
osteoblasts, odontoblasts, and ion-transporting cells38. 
Fibronectin (FN) exists in a soluble form in micromolar concentrations in blood 
plasma and in an insoluble form in the ECM52. It is synthesized by many connective tissue 
cells and during early stages of bone formation with upregulation in the osteoblastic cell 
layer38. Circulating FN does not polymerize itself; FN assembly takes place at specialized 
areas on the cell surface involving integrins α5β1 and αVβ352. Besides the RGD cell 
adhesion site, FN has adhesion sites for fibrin, heparin, collagen, and the RGD-independent 
integrin α4β138,52. Another serum protein, vitronectin, is also found at low levels in 
mineralized matrix, though its receptor αVβ3 integrin seem to play an important role in bone 
biology. Several bone ECM proteins are characterized by the presence of relatively large 
amounts of carbohydrate sialic acid (SIBLINGs), with osteopontin and bone sialoprotein 
(BSP) being the best characterized38. Both have a high affinity for calcium ions, though only 
BSP stimulates hydroxyapatite deposition38. Osteopontin and BSP both mediate cell adhesion; 
however, in BSP sequences other than RGD show higher adhesion activity38. Osteopontin is 
produced at late stages of osteoblast maturation just prior to mineralization38. Also BSP 
expression is tightly associated with mineralization phenomena; it is found in low levels in 
hyperthropic chondrocytes, in osteoblasts at onset of matrix mineralization, and in 
osteoclasts38.  
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TISSUE ENGINEERING 
Tissue engineering is an interdisciplinary field which exploits living cells or biological 
substitutes in a variety of ways to restore, maintain, or enhance tissues and organs53-56. In the 
future, the engineered tissues could potentially not only replace donor tissues and organs, but 
could also accelerate the development of new drugs, offering complex in vitro test 
systems53,57,58. In reconstructive surgery, there is an increasing demand for replacement 
material to fill defects, especially in bone and cartilage. Usually implants made of synthetic 
polymers, ceramics, or metals, as well as tissue allografts, are used for tissue repair57. 
However, none of these materials can provide the performance of the original tissue. These 
artificial materials show different elastic properties, sometimes fracture, induce 
immunological responses, and are difficult to anchor. In contrast to vital tissues, they lack any 
process of regeneration. Thus, the challenging goal of tissue repair is the autologous growth 
or regeneration of the original tissue without remnants of foreign biomaterials57. 
To engineer living tissues in vitro, cells are cultured on bioactive and biodegradable 
scaffolds that provide the physical and chemical cues (e.g. cell adhesion sites, growth factors) 
to guide cell adhesion, differentiation and assembly into three dimensional (3-D) tissues53. 
The general tissue engineering principle is presented in Figure 6.  
There are three principal strategies for treating diseased or injured tissues: 
• Implantation of freshly isolated or cultured cells with or without biomaterial 
scaffold (cell therapy)53,55 
• Implantation of tissues assembled in vitro from cells and scaffolds (3-D tissue is 
grown in vitro and, after reaching “maturity”, implanted)53,55,59 
• In situ tissue regeneration (scaffold is implanted directly into the injured tissue and 
stimulates the body’s own cells to promote local tissue repair)53,54 
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Figure 6: Schematic 
representation of the general 
tissue engineering approach. 
Specific cell populations are 
harvested from the appropriate 
tissue and seeded on a 
biomaterial scaffold. The cell / 
biomaterial constructs may 
undergo a period of dynamic 
tissue culture in a bioreactor 
prior to implantation. 
Organized structural and 
functional tissues may be 
produced in this way (from 
Marter et al.55)  
Cells for tissue engineering 
Sources of cells for implantation include autologous cells from the patient or allogenic cells 
from a human donor who is not immunological identical to the patient53,55,59. Each category may be 
further delineated in terms of whether the cells are stem cells (adult or embryonic) or a mixture of 
differentiated cells at different stages of maturation (including stem and progenitor cells); some 
approaches use cell mixtures, whereas others rely on separation or the enrichment of distinct cell 
subtype, e.g. stem cells53. Cells are most often acquired by biopsy and therefore their initial number 
has to be increased substantially in vitro57, which can bring additional complications.  
Allogenic cells have been used successfully to treat skin ulcers, diabetes and liver disease; 
patients with diabetes or skin ulcers have been treated with two US Food and Drug Administration 
(FDA) approved living skin products engineered in the lab53,59,60. The FDA has also approved an 
autologous cell product for the repair of articular cartilage, derived from patients own 
chondrocytes53,59,60. Similar defects have already been healed using human MSC53,54. MSC offer 
another advantage over differentiated cells, as they are less prone to undergo dedifferentiation 
during culture, as is commonly observed in two-dimensional chondrocyte cultures57. Tissue 
engineers are working to develop several other tissues and organs: besides skin and cartilage, also 
bone, tendon, liver, bladder, cornea, esophagus, heart valves, etc. 53,59-62. 
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Scaffolds 
Scaffolds are porous, ideally degradable structures fabricated from various materials, 
which can be divided in four groups: (1) biogenic (collagen, alginate, glycosaminoglycans, 
fibrin), (2) semisynthetic, (3) synthetic (polyglycolide (PGA), polylactide (PLA), polylactide 
coglycolide (PLGA)) and (4) inorganic (hydroxyapatite, tricalcium phosphate, titanium 
alloys)53,58,59,62,63. Scaffolds can be sponge-like sheets, gels or highly complex porous 
structures53,59. Materials utilized in tissue engineering have defined prerequisites, such as 
biocompatibility, sterilizability and the absence of toxicity or carcinogenicity59. In addition, 
their mechanical properties should include permeability, stability, elasticity, flexibility, 
plasticity, and resorbability at a rate congruent with tissue replacement55,59,61,63. However, 
there is practically no material corresponding to all of these demands. Depending on the tissue 
or organ to be restored, the optimal scaffold material is chosen.  
Biomaterials can be manipulated to direct the growth of cells in vitro and in vivo53,57. The 
ideal biomaterial for a scaffold would selectively interact with the specific adhesion and growth 
factor receptors expressed by target cells required for the repair of damaged tissue45,53. This “smart” 
scaffold could guide migration of the target cells and stimulate their growth and differentiation and 
extracellular matrix production53,59,64. Biogenic materials may most closely simulate the native 
cellular milieu, but their limitations include large batch-to batch variations upon isolation from 
biological tissues, as well as restricted biomechanical properties, not to mention the risk of viral 
infection and antigenicity55,64. Synthetic matrices can be precisely manipulated with regard to 
physical and mechanical characteristics; variables such as porosity and degradation rate can be 
systematically regulated by altering either the material employed or polymer processing methods55.  
Controlling cell-biomaterial interactions 
The fate of implants, from chronic inflammation or fibrous encapsulation to 
osseointegration or tissue regeneration, is determined by the response of cells to the material 
surface. In both cell culture and implantation, the initial presentation of foreign materials to 
cells is a layer of spontaneously adsorbed proteins, whose composition and bioactivity 
provide a biological interpretation of the material’s underlying physiological properties1,36. 
Several characteristics of the substrate have been shown to influence protein adsorption. The 
amount and composition of adsorbed protein and its conformational state subsequently 
regulate cell adhesion and the expression of ECM binding receptors (integrin)36,45.  
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Cell adhesion to the biomaterials in the presence of blood plasma is mostly mediated by 
vitronectin and fibronectin, although other proteins also adsorb to the surface (e.g. albumin and 
fibrinogen)1. Their adsorption reflects biomaterial surface hydrophilicity / hydrophobicity, surface 
charge, roughness, and chemistry. It is accompanied by the dehydration of protein and sorbent 
surfaces, the redistribution of charged groups in the interface and conformational changes in the 
protein molecule1. Independent of serum protein binding, the cells adhere better to hydrophilic 
surfaces, although proteins adsorb to hydrophilic, as well as to hydrophobic surfaces, resulting in 
different protein conformations1. Cell membranes adhere closely to positively charged surfaces, 
whereas contact occurs only at distinct points on near-neutral and negatively charged surfaces1. 
Most metals used for orthopedic implants exhibit a net negative charge at physiological pH 
(passivating oxide layer), as do ceramics such as hydroxyapatite and β-tricalcum phosphate 
(unsaturated oxygen bonds)1. Poly (D,L-lactic acid) also displays a negative zeta potential, although 
its hydrophobic character seems to dominate biological responses1. This numerous information 
show how nonspecific protein adsorption influences cell behavior and confirms the need to 
modulate the biomaterial to yield an optimal cell-construct performance in vivo. 
For enhanced cell adhesion, polymer scaffold surfaces can be modified with collagen, 
fibronectin, or other adhesion-promoting proteins36,55,63,64. The discovery of adhesion domains in 
fibronectin and other ECM glycoproteins containing the amino acid sequence Arg-Gly-Asp (RGD) 
has enabled the design of synthetic materials that can modulate cell adhesion45,53,65. Covalently bound 
peptides, however, don’t desorb from the surface, as often observed with classical surface coatings 
involving ECM proteins. Nevertheless, the optimal ligand density should allow for adequate cell 
adhesion, but not be too dense, in order to enable cell migration53. Though the biological activity of 
short peptides coated on substrates is often lower than that of the complete protein, some RGDs can 
interact with an inactive integrin, whereas binding to whole ECM usually requires an active integrin36.  
Ligands-antagonists for the cell adhesion receptors have been developed for the inhibition of 
platelet aggregation in restenosis (ligand for platelet integrin gpIIb-IIIa), neutrophils in sepsis (Mac-
1), monocytes in stroke (LFA-1), asthma and multiple sclerosis (α4β1 integrin), endothelial and 
smooth muscle cells in tumor angiogenesis and restenosis (αVβ3 integrin) and others37,66. In tissue 
engineering the biomaterials are modified with RGD-like peptides and peptidomimetics to control 
the bioactivity of the materials37. The affinity of the RGD peptides for integrin receptors may be 
affected by the steric conformation of the peptide37. In linear peptides, the fourth amino acid alters 
the binding specificity, whereas cyclization of the peptide shows an increase in activity and a change 
in integrin specificity from fibronectin to vitronctin37.  
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For some integrins, other peptide sequences may be more selective: for example, 
DGEA and GER are specific for integrin α2β1 and EILDV (or LDV) for α4β1 integrin52,67. 
All of these molecules have the potential to prevent cell adhesion when present in a soluble 
form, but when immobilized (covalently bound) to the surface of a biomaterial, this is a 
means to attach receptor-expressing cells. An extensive overview of the RGD peptides and 
peptidomimetics involved in bone biology has been written by Scaffner and Dard37.  
Bone Tissue Engineering 
A loss of bone tissue can occur through infection, loss of blood supply, disease, or as a 
complication of fracture55. Currently, defects can be (1) permanently replaced with a foreign 
material or (2) restored using transplanted biological material, such as autograft or allograft 
bone55. Nevertheless, the autologous bone grafts, represent the “gold standard” for site 
specific bone defect repair68. However, this technique is associated with complications, such 
as donor site morbidity, infection, malformation, and subsequent loss of graft function68.  
The need for bone substitutes has led to the formulation of a number of biomaterials geared 
to functionally replace host bone tissue, as well as to compensate for the limitations imposed by 
natural bone replacements. These biomaterials include hydroxyapatite [Ca5(PO4)3OH] and β-
tricalcium phosphate (β-TCP) ceramics, alumina and titanium alloys, synthetic polymers consisting 
of polyglycolic and polylactic acid, and natural polymers, such as silk fibroin and demineralized 
bone composites45,55,59,68. Material properties including surface roughness, porosity, and cell-binding 
motifs can be manipulated to further optimize conventional biomaterials to allow for maximal cell 
attachment, proliferation, osteogenic differentiation, and ultimately mineralized matrix deposition68. 
One major limitation of the creation of a system for bone repair is the development of a scaffold 
with the requisite mechanical competence as well as porosity and resorbability59. On one hand, 
many biocompatible scaffolds utilized in soft tissue repair often lack the structural integrity required 
for load bearing, whereas on the other hand, the materials that are appropriately strong are often not 
resorbable and may involve stress shielding59. However, considering improved implant 
osseointegration, load bearing is often not a primary goal of implantation and therefore FDA-
approved suture materials PLA and PLGA are frequently integrated into bone tissue engineering 
approaches69. In addition to suitable implant materials, bone tissue production can be enhanced with 
the supplementation of growth factors like BMP and other TGF-β family members, which play an 
important role in endochondral bone formation in vivo56. 
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GOALS OF THE THESIS 
Cell adhesion to the biomaterial surfaces can be directed by modifying the surface 
with cell adhesion promoting ECM proteins, or smaller peptides, like RGD37,64. Modification 
with synthetic peptides has advantages over the immobilization of natural-derived ECM 
molecules, because of a reduced risk of infection or immunoreactivity64. Cyclic RGD peptide 
[c(RGDfK)] was shown to be a selective peptide to bind integrins αVβ3 and αVβ5 and 
therefore its immobilization to the surface of biomaterials should enable adhesion of cells 
expressing high levels of these integrins, like osteoblasts37. Whereas human osteoblast 
showed RGD-dependent binding, rat bone marrow stromal cells, known to be 
osteoprogenitors, did not70. Therefore, the primary goal was to determine which integrins, and 
to which extent, are actually expressed on the rat marrow stromal cells. This led us first to 
characterize the primary cultures (up to 7 days in culture) of rat bone marrow cells adhered to 
the tissue culture polystyrene (TCPS). These cells are a commonly used source for tissue 
engineering studies. The characterization of their surface marker expression was performed 
by flow cytometry (FC, FACSCalibur, BD, USA). FC is a suitable method, as it enables the 
quantification of up to 6 parameters on a single cell basis in the shortest time. Usually at least 
10000 cells are evaluated in each measurement. 
The usual rat MSC enrichment protocols employing centrifugal bone marrow isolation 
from long bones, adherence for 3 days and removal of non-adherent cells following 1-week 
expansion of the adherent fraction showed that primary cultures are always “contaminated” 
with varying proportions of CD45-positive hematopoietic cells (HC). For the MSC 
characterization, a homogenous cell pool is needed. Therefore, in the first study (Chapter 2) 
we investigated the effects of varying adhesion times (1-4 days) in order to reduce the 
contamination with HC. In parallel, we assessed the yield of CD45-negative cells (MSC) 
resulting from the varied adhesion periods.  
Knowing that hematopoietic stem cells and MSC share the bone marrow environment and 
that HC always contaminate the primary MSC cultures, we determined the role of HC in MSC 
differentiation. It is known that MSC support haematopoiesis, whereas only sparse data is available 
concerning the opposite interactions. It was shown that megakaryocytes and platelets support MSC 
proliferation; therefore, we investigated the influence of plastic-adherent HC on MSC osteogenic 
differentiation (Chapter 3). In cooperation with Nazish Ahmed and Susanne Grässel from the 
Experimental Orthopedics Department at the University Regensburg-Bad Abbach, the influence of 
HC on chondrogenic gene expression was also studied (Chapter 2). 
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In a third step, we characterized surface marker expression on MSC and the 
contaminating HC. Multi-color FC enabled us to determine integrin-pattern and stem cell 
marker expression on rat MSC and HC at the same time, without mechanical separation of 
both populations (Chapter 4). Human and mouse MSC surface marker expression has been 
already studied by several groups, but for the development of a rat test system (primary goal), 
integrin expression on rat MSC still needed to be determined. Additionally, MSC-selective 
integrins and surfaces for selective MSC surface immobilization are discussed in Chapter 4. 
In Chapter 5, we describe attempts to enhance integrin expression on rat MSC by 
supplementation with growth factors. 
Since it is known that MSC change their phenotype after isolation and with extensive 
subculturing, we analyzed earlier cultures (day 3) and fresh bone marrow, as well as MSC that 
were expanded over several passages (Chapter 6). The data obtained could give some cues for 
further optimization of MSC selection and isolation. 
Finally, some data on the effects of two statins (atorvastatin, simvaststin) in our 
culture systems are reported (Chapter 7). Statins are known as lipid-lowering drugs, but recent 
data on osteoinductive effects makes them potential candidates for improving bone tissue 
engineering. Therefore we investigated their dose-dependent effects on MSC differentiation. 
 
Figure 7: Practical approach of MSC enrichment, the characterization of surface marker 
expression and differentiation, which was used in experiments described in the thesis. 
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ABSTRACT 
Adult mesenchymal stem cells (MSC) can be readily isolated from bone marrow, expanded 
in culture and subsequently subjected to differentiation into various connective tissue lineages. In 
general, for animal studies MSC separation from other bone marrow derived cells is achieved by 
sole adherence to plastic surfaces of tissue culture flasks, however, this procedure produces a 
heterogeneous cell population including CD45-positive hematopoietic cells (HC) and hematopoietic 
stem cells (HSC). It is well known, that such mixed cell cultures consisting of cocultures of 
differentiated somatic cells with adult stem cells promote differentiation towards specific cell 
lineages. For determining the effect of the CD45-positive cell population on the differentiation 
potential of MSC we have sorted out the bone marrow derived adherent cells by immunomagnetic 
technique (MACSTM) to attain a subpopulation of CD45-depleted cells. Here, we show that the 
presence of adherent CD45-positive HC not only promote expression of the chondrogenic marker 
genes Col2a1, COMP and SOX9, but also of Col1a1, Col10a1 and to a certain degree Cbfa1 in 
MSC when cultured in an appropriate three-dimensional environment. These observations constitute 
a step towards unravelling the influence of hematopoietic cells on chondrogenic differentiation of 
MSC.  
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INTRODUCTION 
Adult bone marrow stromal cells regarded as mesenchymal stem cells are progenitors 
of connective tissue cells, thus are excellent candidates for chondrogenic differentiation 
studies. The progeny of adult stem cells includes both daughter stem cells and committed 
progenitors with a more restricted differentiation potential. These progenitors in turn give rise 
to differentiated cell types. Mesenchymal stem cells (MSC) can differentiate under specific 
cultural and physical conditions into multiple mesenchymal lineages namely, osteocytes, 
chondrocytes, adipocytes, astrocytes and myocytes1,2. Bone marrow consists of primarily non-
adherent hematopoietic cells and hematopoietic stem cells (99%) along with a minor 
population of MSC (≤1 %). Both of the stem cell types are known to co-exist and have been 
suggested to cooperate in one another’s differentiation3. The role of MSC in hematopoietic 
microenvironment formation is beginning to unravel and it is assumed that the presence of 
adherent MSC and their progeny facilitates HSC differentiation into granulocytes and 
erythrocytes both in vivo and in vitro4-6. Conversely, in depth studies concerning the role of 
HSC in MSC commitment and differentiation towards a distinct lineage are lacking.  
Adult rat MSC are routinely isolated from tibio-femoral bone marrow by relying solely on 
their adherence to the plastic surface of tissue culture flasks7,8. The isolated cells constitute a 
heterogeneous population which always contains HC therefore; obtaining a pure population of non-
hematopoietic cells remains difficult. This hematopoietic cell fraction varies depending on the 
species; being relatively high in initial cultures of mouse marrow cells9 and less than 30% in human 
cell cultures. In rat marrow stromal cells this trend has not been studied thoroughly, although the 
presence of hematopoietic cells in primary (7 days) and secondary (18 days) bone marrow cultures 
has been indicated10. Human and murine MSC studies show subsequent loss of hematopoietic cell 
surface markers when cultures are maintained for 2 or 3 weeks. Prior to differentiation experiments 
the hematopoietic cell population is often separated from MSC by employing a magnetic associated 
cell sorting (MACS) system. The system immunologically separates different cell types by labelling 
cell surface antigens with magnetic beads followed by sorting through a magnetic column. As a 
unique identifying marker for MSC is still lacking a negative selection protocol is carried out using 
CD34 (My10) or CD45 (leukocyte common antigen) for exclusion of undesired positively labelled 
hematopoietic cells.  
One of the major differentiation pathways of MSC occurs along the chondrogenic 
lineage which can happen autonomously in three separate mesenchymal cell lines, cranial 
neural crest, sclerotome cells and lateral plate mesoderm cells11. The first stage of 
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chondrogenic differentiation is conversion of undifferentiated MSC to committed 
osteochondroprogenitor cells leading to cell condensation and growth arrest. The major 
proteins involved in condensation initiation are either fibronectin or belong to the 
transforming growth factor ß family of proteins (TGFß-1, -2 and -3). Cells present at the 
centre of the condensation nodules first form pre-chondrocytes and then chondrocytes which 
start to produce cartilage matrix marked by up regulation of structural protein genes as 
Col2a1, Col9a2, Col11a2, aggrecan and COMP. Expression of chondrocyte marker genes is 
controlled by members of the Sox-family, in particular Sox9 has been characterized as a 
master transcription factor with essential direct or indirect regulatory effects exerted along the 
entire chondrogenic differentiation pathway. It is expressed in all chondroprogenitor cells and 
also in differentiated chondrocytes12-15 .  
In this study we have evaluated the degree of hematopoietic cell coexistence in 
primary cultures of rat MSC and their influence on the chondrogenic differentiation potential 
of MSC. We have determined the difference in chondrogenic marker gene expression of 
heterogeneous MSC isolated by sole adherence to plastic surfaces compared to that of a more 
homogeneous subpopulation of MACS sorted CD45-depleted cells.  
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MATERIALS AND METHODS 
MSC isolation and primary cell culture  
A modified version of the MSC isolation procedure from rat bone marrow was 
optimized16,17. Briefly, 6 week old male Sprague - Dawley rats were killed under CO2 and tibiae 
and femora were aseptically removed. The bones were cut from the middle and centrifuged in a 
1.5 ml tube at 2000 rpm for 3 min (mini centrifuge - Eppendorf). The centrifuged bone marrow 
cells were collected and homogenized with 18 g, 21 g and 23 g needles and seeded at the rate of 
2.5 x 105 cells / cm2 in 175 cm² tissue culture flasks in proliferation medium containing 5 % 
glutamate, 1 % antibiotics/antimycotics (Gibco.) and 10 % FBS (Gibco, Invitrogen, UK; Lot No.: 
40F7430K) in α-MEM (Sigma Aldrich, Germany).. All non-adherent cells were removed on the 
3rd day and the adherent cells were proliferated.  
Magnetic separation of cells (MACS) 
When the flasks were ~75 % confluent (9 - 11 days) cells were harvested with trypsin 
digestion. Separation procedure was carried out according to the manufactures instructions; in short, 
cells were incubated with 4 µl of CD45 antibody / 106cells for 5 min at 37°C followed by washing 
and a second incubation with goat anti-mouse secondary antibody coupled with magnetic beads 
(Miltenyi Biotech) for 15 min at 4°C. The suspension was passed through a magnetic column 
(Miltenyi Biotec´s LS-MACS columns); while labelled cells got coupled to the magnetic field the 
flow through containing unlabelled CD45-negative fraction was collected. 
Immunofluorescence 
20,000 cells / chamber were seeded on chamber slides (Biocoat slides, BD, 
Bioscience) and incubated overnight at 37°C and 5 % CO2. Cells were blocked for 1 h at 37°C 
in Complete Mini 1:5 (Roche, Germany) plus 5 % normal goat serum and 1 % BSA in PBS. 
After washing with PBS cells were stained with monoclonal antibodies directed against CD45 
(Cb1 1502, Chemicon), CD68 and D7Fib (Acris, Germany) in 1:50 dilution ratio overnight at 
4°C. The appropriate Alexa568 or Alexa488 conjugated secondary antibodies (goat anti 
mouse, 5 µg / ml; Molecular Probes, US) were added for 1 h at RT. After washing slides were 
permanently mounted with DAKO fluorescent mounting medium (DAKO, USA) and covered 
with coverslips. Slides were evaluated with scanning laser microscopy (C1 confocal 
microscope from Nikon) and photos were taken with a Nikon C4 camera and software. 
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Flow cytometric analysis 
Cells obtained from 1 animal (approx. 8x 107 cells, as determined after NH4Cl lysis of 
the erythrocytes) were seeded in 4 x 150cm2 flasks (1.5 x 105 cells / cm2). The cells were left 
to adhere 1, 2, 3 or 4 days before non adherent cells were removed. Cells were trypsinized on 
day 7 after the isolation and resuspended in PBS. The cell suspension was first blocked for 15 
min at 4°C with sheep serum followed by incubation with antibodies against rat CD45-PE 
(mouse IgG1 against rat CD45, Acris Antibodies, Germany), CD29-FITC (Hamster IgM 
against rat CD29, BD Pharmingen, USA) and with corresponding isotype controls for 30min 
at 4°C. Cells were washed with PBS containing sodium azide and bovine serum albumin and 
resuspended. Shortly before the FACS – analysis propidium iodide was added to each sample 
in order to discriminate the dead cells which were excluded from the evaluation. All 
measurements were performed on a FACSCalibur® instrument (Becton Dickenson, USA) 
with CellQuest data acquisition software (Becton Dickenson, USA). Data analysis was 
preformed with WinMDI 2.8 software (free access on http://facs.scripps.edu/software.html). 
A minimum of 1x104 viable cells was acquired per data set.  
Chondrogenic differentiation 
A batch of adherent cells (undepleted) was subjected directly to chondrogenesis 
favourable condition, the other batch was depleted of CD45-positive cells by MACS prior to 
chondrogenic differentiation experiments. For chondrogenic differentiation, high density 3-D 
cultures were attained by preparing cell-alginate amalgam in 1.2 % alginate at a concentration 
of 107 cells / ml. 2 - 3 mm cell-alginate beads containing approx. 105 cells / bead, were 
formed by dropping the suspension into 102 mM CaCl2 solution. The culture was carried out 
in 12 well tissue culture plates for 4 weeks; medium was changed every 2 - 3 days. 10 alginate 
beads were removed every 7th day for RNA isolation and gene expression analysis. To 
release the cells from alginate the beads were incubated for 30 min at 37°C on a shaker in 55 
mM sodium citrate and 0.15 M sodium chloride buffer; cells were recovered after 3 min spin 
at 750 g. The chondrogenic medium contained; ITS+ premix (6.25 µg / ml insulin, 6.25 ng / 
ml selenium acid, 6.25 µg / ml transferrin, 1.25 mg / ml BSA and 5.35 µg / ml linoleic acid. 
BD Biosciences, USA.), 110 µg / ml pyruvate, 40 µg / ml proline, 0.1 µM dexamethasone, 50 
µg / ml ascorbic acid and 10 ng / ml TGFß-318 (R&D Systems) in α MEM high glucose 
(Gibco). Alginate sodium salts were acquired from Sigma Aldrich, Germany (Cat# A0682-
100G). 
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RNA Isolation and reverse transcription 
RNA was isolated by an affinity column chromatography method with Ambion’s 
RNAqueous4-PCR kit according to the manufacturer’s protocol. For removal of possible DNA 
contamination, isolated RNA was incubated for 1 h at 37°C in 2 Units of DNaseI enzyme (DNA-
free, Ambion). RNA integrity was determined on 0.8 % Agarose-formaldehyde gels. The 
RiboGreen RNA quantification kit (Molecular Probes) was used for determination of RNA 
concentration at 585 nm wavelength. For RNA conversion to cDNA, Invitrogen´s SuperScript II 
reverse transcriptase kit was used with 0.5-1 µg of RNA in 20 µl of total reaction volume in 
presence of 40 units / µl recombinant ribonuclease inhibitor (RNase OUT®). Reverse transcription 
was carried out with 500 µg / ml of Oligo-dT primers, 10 mM dNTPs and 200 units of 
SuperScriptII enzyme in First-Strand Buffer and 0.1 M DTT for 50 min at 42°C followed by an 
extension period of 15 min at 70°C.  
Relative quantitative PCR 
Relative quantitative PCR was carried out with SYBR Green Dye I on ABI 7000 Prism 
Sequence detection system (Applied Biosystems) according to manufacturer’s instructions. Briefly, 
1 µl of cDNA was amplified in 50 µl final volume of 0.2 µM of each primer suspended in SYBR 
green master mix (AB Systems).Amplification parameters were same for all primer pairs and were 
repeated for 40 cycles, denaturation at 95°C for 0.15 min and annealing at 60°C for 1min. Mean 
relative quantification (RQ) value evaluated from three independent experiments was plotted on a 
semi logarithmic graph. RQ values were calculated by the software “RQ study application v1.1” 
(ABI Prism 7000 SDS software v1.1) according to the ∆∆Ct method using ß-Actin as endogenous 
control and undifferentiated MSC (day 0) as calibrator. Primers were designed with either Primer3 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) or “Primer Express” software supplied 
by AB. All primers were manufactured at MWG – Biotech and are listed in Table 1. Prior to RQ 
studies, a CT value (cycle threshold) standard curve, with 10 folds diluted cDNA, was plotted to 
determine PCR efficiency of each primer pair only 90-100 % efficient primers were used. The 
efficiency was determined with 10(1/-S) –1, where S is the slope of the curve19.  
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Statistical Analysis 
One way ANOVA and student t test were employed for quantitative PCR experiments 
performed in triplicate. Results obtained by flow cytometry are the average of 4 independent 
experiments ± standard error of mean. The level of significance was determined by Tukey test. 
 
Table 1: Primers used for quantitative PCR 
Gene / RefSeq# Amplicon (bp)  Primer (5´ - 3´) 
ß-Actin  104  forward -GTAGCCATCCAGGCTGTGTT-3´ 
NM_031144     reverse -CTGTAGGTGAATCGACTGTTGC-3´ 
Col1a1  59  forward -TCCAGGGCTCCAACGAGA-3´ 
RGD61817*     reverse -CTGTAGGTGAATCGACTGTTGC-3´ 
Col2a1  60  forward -CCCCTGCAGTACATGCGG-3´ 
NM_012929     reverse -CTCGACGTCATGCTGTCTCAAG-3´ 
Col10a1  247  forward -CCC TAT TGG ACC ACC AGG TA -3´ 
AJ131848*     reverse -TCT CTG TCC GCT CTT TGT GA -3´ 
COMP  167  forward -TGACTTCGATGCTGACAAGG-3´ 
NM_012834     reverse -GAACGATCTCCATTCCCTGA-3´ 
Sox9   140     forward -CTGAAGGGCTACGACTGGAC-3´ 
XM_343981        reverse -TACTGGTCTGCCAGCTTCCT-3´ 
Cbfa1   86  forward -GGCCGGGAATGATGAGAACTA-3´ 
XM_34016     reverse -AGATCGTTGAACCTGGCCACT-3´ 
*Locus ID 
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RESULTS  
MSC isolation procedure and CD expression profile  
To determine the influence of adherence time of rat bone marrow cells on the presence 
of CD45-positive hematopoietic cells we left the cells to adhere for 3, 4 and 5 days before 
non-adherent and weakly attached cells were removed. Upon immunofluorescence analysis 
the adherent cells showed a D7fib+, CD68+ and CD45+/low expression profile regardless of 
the time of removal of non-adherent cells. Figure 1 shows the representative 
immunomicrographs of the cells left to adhere for 3 days and compares the staining of non-
sorted and MACS- sorted cells after the first passage. Non-sorted cells, left for 3 days to 
adhere before medium removal, are contaminated with CD45-positive cells (Fig.1A-C). After 
magnetic sorting, most of the CD45-positive cells were excluded, leaving a CD45-depleted 
cell fraction (Fig.1D-F). However, we still observe few rounded cells among the CD68 
positively stained fraction (Fig1D) of unknown surface antigen characterization. The CD45-
positive cell fraction includes cells which stain for CD68 and D7Fib (Fig.1G-I). 
Quantification of CD45-positive cell contamination of primary MSC 
cultures 
In order to quantitate the ratio between hematopoietic CD45-positive cells and MSC 
we employed three colour flow cytometry (FACS) which allowed for a distinction between 
the two different cell types according to their surface antigens (CD45, CD29) and dead cells 
(Fig.2). Figure 2b shows that the fraction of CD45-positive hematopoietic cells was not 
influenced by the adherence time after cell isolation. We mostly found about 20-30 % of the 
attached cells in bone marrow cell cultures to be CD45-positive when selected according to 
sole adherence to plastic surfaces. Flow cytometric results were concurrent with the 
observations made after immunofluorescent staining. In one out of four experiments we 
detected variations between 10 and 40 % in individual flasks.  
We observed that CD45-depleted cells expressed CD29 stronger than CD45-positive cells 
(Fig.2a). In cultures where non-adherent cells were removed on days 3 and 4, we obtained a 
significantly increased number of desired CD45-depleted MSC compared to removal on day 1 and 2 
(Fig.2c). Apparently, 3 to 4 days were a more appropriate duration for the adherent fraction to get 
acclimated to the cell culture conditions, hence exhibit a firmer attachment to the cell culture plastics.  
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Figure 1: Morphological characterization of MSC  
Immunofluorescence imaging of heterogeneous adherent MSC (A, B, C) and CD45-depleted MACS 
sorted cells (D, E, F), showing typical fibroblast like spindle shaped cells, while CD45-positive cells 
(G, H, I) are small and rounded in appearance. All 3 cell types are CD68- and D7fib- positive while 
the CD45-depleted cell population does not exhibit CD45 harbouring cells (E). 
Magnification is 20x for all panels, bars are 10 µm. 
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Figure 2: FACS analysis of bone marrow derived stem cells prepared by adherence to plastic  
(A) Representative dot-plot (out of 3 experiments) of rat MSC isolated by adherence to plastic after 
7 days of cell culture. The lower right quadrant contains CD29 –highly positive and CD45-
depleted MSC while the upper right quadrant contains HC with a CD45 – positive and CD29-
low expression profile. 
(B) Proportion of CD45-positive (black bars) and CD45-depleted (open bars) cells from rat MSC 
isolated by adherence to plastic in relation to the time of the first medium change and therefore, 
removal of non-adherent cells. 
(C) Total yield of CD45-depleted (open bars) and CD45-positive (black bars) bone marrow derived 
cells after 7 days of cell culture (*p< 0,05; **p< 0,01). Yield of cells is normalized to cell 
number achieved when the non-adherent cells were removed on day 4. 
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Effect of CD45-positive cells on gene expression levels of Col1a1, 
Col2a1, Col10a1, COMP, Sox9 and Cbfa1 
During the time course of cell culture we observed a strong increase in relative mRNA levels 
of COMP and collagen II, while Sox9 mRNA levels exhibited a moderate up regulation (Fig.3A, B, 
D). Collagen X gene expression remained undetectable the first three weeks of cell culture, however, 
at day 28 expression of this collagen was found to be induced (Fig.3C). The internal control gene, ß-
Actin, remained unaltered during the time course of cell culturing (Fig. 3G). Comparing gene 
expression of CD45-depleted cells and the non-sorted population, we found collagen I gene 
expression to be increased in the non-sorted cell population during the culture period, while it became 
decreased in CD45-depleted MSC. However, in CD45-depleted cells collagen I was still expressed at 
a relative higher level as in freshly isolated hip articular chondrocytes (Fig.3E). Notably, the non-
sorted cells displayed a strikingly higher up regulation of collagen II, COMP and Sox9 gene 
expression compared to the CD45-depleted MSC throughout the culture period. In the non-sorted 
population collagen II gene expression is up regulated at average about 25 fold, COMP gene 
expression about 10 fold, collagen X expression about 23 fold and Sox9 mRNA levels about 3 fold if 
compared to CD45-depleted MSC. For collagen I gene expression we have observed a significant 
difference only between the two groups at day 14 and 28, where the adherent MSC demonstrated an 
up regulation resulting in a 3-5 fold higher gene expression if compared to CD45-depleted MSC. 
Collagen I remained up regulated from day 14 on in adherent cells while CD45-depleted MSC exhibit 
an increasingly down regulation during the time course of cell culture. We also observed a striking 
difference in the collagen X expression pattern between non-sorted and CD45-depleted cells. The 
collagen X mRNA expression profile of CD45-depleted cells experienced only a moderate increase of 
about 3.3 fold at the end of the culture period while adherent cells up regulated their mRNA level 
about 76 fold compared to day 0. Notably, Cbfa1 gene expression is differentially regulated with 
respect to the two cell populations (Fig.3F). On day 1 Cbfa1 mRNA level is significantly higher in 
adherent cells (4.7 fold) and also in chondrocytes (ca. 2.0 fold) compared to CD45-depleted cells. This 
pattern became inverted at day 28 with CD45-depleted cells exhibiting an elevated expression (1.7 
fold) compared to the adherent MSC. In between these time points, relative gene expression of Cbfa1 
is similarly regulated in both cell populations. In remixed control cells (30 % CD45-positive cells with 
70 % CD45-depleted cells) collagen II, X, I, Sox9 and Cbfa1 gene expression profile resembles 
closely that of adherent cells (Fig.3B, C, D, E, F) and exhibits no significant differences. Only COMP 
gene expression at day 14 of the culture period significantly differs from adherent cells but the level at 
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day 21 and 28 shows no difference to non-sorted cells (Fig. 3A). ß-actin gene expression profile is 
similar for all three culture conditions (Fig.3G).  
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Figure 3: Chondrogenic gene expression profile of adherent MSC, CD45-depleted MSC 
and remixed control cells.  
Relative quantitative mRNA expression level of chondrogenesis specific genes as COMP (A) 
Col2a1(B) and Col10a1 (C), Sox9 (D), Col1a1(E), and Cbfa1 (F) was determined by 
employing the ∆∆CT method using SYBR I Green dye. Expression level of housekeeping gene, 
ß-actin was determined as a controlling indicator of cell viability (G) and is expressed as 
positive logarithm of CT-values. 
Expression level of each gene was compared between adherent (black bars), CD45-depleted 
(open bars) and remixed control cells (striped bars). Grey shaded bars indicate relative gene 
expression level of freshly isolated hip articular chondrocytes.  
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DISCUSSION 
Adult bone marrow is the major source of hematopoietic stem cells and mesenchymal 
stem cells20. In animal studies, adherence to tissue culture plastic is accepted as a satisfactory 
parameter for attaining marrow stromal cell population depleted of hematopoietic cells. However, 
when employing FACS analysis for surface antigen characterization we observed a contamination 
of these non-sorted MSC with 20-30% of CD45-positive cells. For additional characterization of 
sorted and non-sorted cell population we applied immunofluorescence staining for CD68 and 
D7Fib. The D7Fib antigen constitutes a fibroblast specific molecule of yet unknown function, 
supposedly a specific marker for MSC as suitable as Stro-1 and CD10521. We observed 
expression of the D7Fib antigen on adherent CD45-positive cells; however, these cells displayed a 
rounded morphology compared to the fibroblast-like CD45-depleted cells. CD68 and its murine 
analogue macrosialin, a member of the lamp family, appear to have a rather limited tissue 
distribution, being found on macrophages, Langerhans cells and dendritic cells22. Notably, we 
have found all adherent cells CD68-positive suggesting that in non-committed, undifferentiated 
cells, this protein might exhibit a different distribution pattern and possibly exert functions related 
to cell–cell or cell–ligand interactions23.  
CD45-positive hematopoietic cells were always detected in MSC cultures, regardless of 
the time of the first change of culture medium. This indicated a persistent presence and attachment 
of CD45-positive cells in the MSC environment when no further selection based on specific 
surface antigens is carried out. Adherence to the tissue culture plastic alone is a weak 
discriminating criterion for a homogeneous MSC population, because neural cells, monocytes and 
macrophages are also known to be isolated according to their adherence to plastic surfaces24-26. 
The presence of CD45-positive hematopoietic cells and the variation of their proportion in 
primary cultures of MSC could explain the occurrence of extensive variations usually seen in 
differentiation experiments with bone marrow derived cells. 
The fact, that CD45-depleted cells expressed CD29 stronger than CD45-positive cells 
offered us an easier separation of two populations and limited the possible existence of more than 
two major subpopulations in our cultures. The integrin ß1 subunit CD29 exhibits a broad tissue 
distribution, including lymphocytes, endothelia, smooth muscle, and epithelia27 and plays an 
important role in cellular processes, e.g. embryogenesis and HSC development. Although we did 
not find the hematopoietic cell fraction to vary according to the time of removal of non-adherent 
cells we observed a correlation between adhesion time and yield of CD45-depleted marrow 
stromal cells. In parallel, cell adhesion plus proliferation could also be promoted by the prolonged 
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presence of the non-adherent fraction via cytokine release and / or cell-cell contacts. A 
comparable effect of hematopoietic cells on MSC proliferation has been observed for 
megakaryocytes and platelets28. According to our results we decided to leave the cells to adhere 
for 3 days for differentiation experiments. 
Differentiation studies of hematopoietic stem cells have demonstrated, that the small 
number of adherent MSC present in total bone marrow aspirates provide an important 
microenvironment for growth of HSC and their differentiation into several blood borne cell types. 
In long-term cultures of HSC, these adherent cells even interact directly with the hematopoietic 
precursors 29. Here, we could show that vice versa adherent CD45-positive hematopoietic 
precursor cells create a microenvironment which may enhance expression of particular marker 
genes in MSC. For studying the effects of contaminating CD45-positive cells we prepared a 
relatively homogeneous population of CD45-depleted MSC by immunogenic depletion of CD45-
positive cells. Both, the heterogenic adherent cells and the CD45-depleted subpopulation were 
subjected to chondrogenic favourable 3-D environment by formation of a cell alginate amalgam. 
For control purposes in order to assure that difference in gene expression profile between sorted 
and unsorted MSC is due to depletion of CD45-positive cells and not because of general depletion 
of differentiation competent cells or due to cell damage caused by the sorting process, we 
prepared a third population of remixed cells (30 % CD45-positive versus 70 % CD45-depleted 
cells) following MACS preparation which was treated according to the differentiation protocol 
used for adherent and sorted cells.  
We monitored relative gene expression of collagen II30 and COMP31,32 as examples for 
structural extracellular matrix proteins highly specific for hyaline cartilage. Additionally, we have 
investigated Sox9 as a master transcription factor imperative for chondrogenic differentiation33 
and collagen I as differentiation control for a gene normally not active in healthy hyaline 
cartilage34 but occurring together with collagen II in fibrocartilage35. Gene expression of collagen 
X, specific for terminal differentiated hypertrophic chondrocytes in the calcifying zone of 
cartilage and secondary ossification centres within the growth plate36 indicates maturation of 
MSC towards an undesired cartilage condition. 
Gene expression of Cbfa1, a transcriptional activator for osteoblastic differentiation during 
the process of endochondral ossification is analyzed for monitoring differentiation towards 
osteogenic condition. Cbfa1 is also expressed in pre-condensation stage during early development 
in a cell type with the potential to become either a chondrocyte or an osteoblast. In later 
developmental stages expression of this transcription factor is restricted to prehypertrophic and 
hypertrophic chondrocytes where it acts as a hypertrophic differentiation factor37,38. 
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The observed gene expression profile indicates not only a beneficial influence of CD45-
positive cells on the differentiation process of MSC towards the chondrogenic lineage. It also 
shows that when culture time is extended beyond 28 days chondrogenically differentiating MSC 
might enter the prehypertrophic / hypertrophic differentiation cascade and proceed towards 
terminal differentiation. Interestingly, usage of chondrogenic culture medium does not prevent up 
regulation of Cbfa1 and collagen X. This indicates either a not yet defined influence of medium 
components (i.e. TGF-ß or dexamethasone) on intrinsic cell derived factors (i. e. signalling 
molecules, proteases, transcription factors) which are involved in regulation of the chondrogenic 
differentiation cascade or a medium independent process occurring by default through paracrine 
interaction of MSC. A variety of growth factors i.e. members of the TGF-ß superfamily, IGF-1 
and bFGF could account for gene modulating effects in our system39 40 41 42.   
In conclusion, we demonstrated that bone marrow derived fibroblast like CD45-depleted 
rat MSC share a heterogeneous cellular environment with ~20-30% CD45-positive HC, if no 
other selection procedure than adherence to plastic is employed. Our differentiation results 
indicate that adherent CD45-positive hematopoietic cells may create a microenvironment 
promoting differentiation of MSC towards the chondrogenic lineage by up regulating specific 
genes. However, expression of undesired genes as collagen I and collagen X is likewise promoted 
by HC. On the contrary, at early condensation stage HC strongly increase gene expression of 
Cbfa1 thus supporting chondrogenic differentiation of MSC, while at a later differentiation stage 
when Cbfa1 plays an integral role in hypertrophy the regulation appears to be independent of the 
presence of HC. 
We speculate that the stromal CD45-positive population in toto is responsible for 
regulation of gene expression. The heterotrophic nature of bone marrow derived cells suggest that 
in vivo interactions of different cell types is very likely and should be addressed accordingly. 
Characterization of additional subpopulations of CD45-positive cells according to their surface 
antigens and determination of their potential influence on gene expression may elaborate this 
point further more. Studies using conditioned media are needed to clarify whether physical 
contact between cells or paracrine factors, alone or in concurrence, are necessary for promoting 
gene expression leading to chondrogenic differentiation and maturation of MSC. Identification 
and isolation of factors which are capable of modulating genes involved in differentiation and 
dedifferentiation processes of chondrocytes will be important tools for in vitro engineering of 
cartilage repair tissue. 
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ABSTRACT 
Primary cultures of bone marrow stromal cells (MSC), selected by adhesion to tissue 
culture plastic, contain populations of adherent hematopoetic cells (HC) and endothelial cells. 
However, little is known about the effect of HC on the differentiation of CD45- MSC to 
mesenchymal lineages.  
Whole rat bone marrow was seeded in tissue culture flasks and selected by adhesion to 
cell culture plastics. Adherent cells were cultured for seven days in alpha MEM supplemented 
with 10% fetal bovine serum (FBS). After trypsinization cells were characterized by flow 
cytometry and separated into CD45+ and CD45- populations using immunomagnetic labeling. 
Both cell populations were mixed in predetermined proportions and further cultured under 
osteo-inductive conditions in 2-D and 3-D cultures. Alkaline phosphatase activity (ALP), 
calcium accumulation, and osteogenic gene expression profiles were examined to assess 
differentiation.  
Flow cytometry showed that CD45- cells from primary MSC cultures expressed 
CD90, CD29, and CD44, which are markers characteristic for MSC. Additionally, flow 
cytometry revealed a contamination with CD45+/CD11bc+ HC, referred to as myeloid cells, 
but not with CD31+ endothelial cells. Purified CD45- cells showed strongly improved 
differentiation compared to non-separated populations. ALP and calcium accumulation were 
dose-dependently decreased with increasing percentages of HC. Control experiments 
excluded an effect of separation procedure or initial cell number. Real time RT-PCR showed 
increased expression of osteogenic markers in groups without HC in 2-D and 3-D cultures. 
Finally, trans-well experiments allowed the determination that the observed effect was due to 
soluble factors.  
This study shows that myeloid cells, which contaminate primary rat MSC cultures, 
modulate osteogenic differentiation negatively, in a fashion independent of heterotypic cell-
cell contacts.  
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INTRODUCTION 
Mesenchymal progenitor cells (MPC), or colony forming unit fibroblasts (CFU-F), are 
a clonogenic subpopulation of bone marrow stromal cells (MSC), that can proliferate in vitro 
as undifferentiated cells up to fifty population doublings1 and differentiate into cells of 
connective and supportive tissues like osteoblasts, chondrocytes, adipocytes, myocytes, 
tenocytes, fibroblast, and haematopoiesis-supporting stromal cells2-6. The usual enrichment 
criterion for bone marrow derived MSC utilizes their ability to adhere to tissue culture plastic, 
separating them from non-adherent hematopoietic cells, which form the major population 
isolated from bone marrow. Nevertheless, adherent hematopoietic and endothelial cells 
contaminate the primary MSC cultures7,8, although the degree of contamination can be 
decreased by passaging or medium pre-selection9. The MSC phenotype is characterized by the 
expression of some typical non-specific surface markers, while cultured MSC lack typical 
hematopoietic markers like CD34, CD45, CD11c and the endothelial marker CD312-6. 
Bone and bone marrow are anatomically continuous and exhibit marked functional 
interdependence. Bone marrow contains hematopoietic and non-hematopoietic stem cells, 
which are progenitors of osteoclasts and osteoblasts, respectively. Non-hematopoietic stromal 
cells, as well as osteoblasts, create a microenvironment for hematopoietic stem cell 
proliferation and maturation10. Commitment, proliferation, and differentiation of osteogenic 
or hematopoietic precursor cells are regulated by multiple factors, including cytokines, growth 
factors, systemic hormones, and transcriptional regulators, which can function in an autocrine 
or paracrine fashion. In addition, cell-cell and cell-matrix interactions are responsible for the 
communication between stromal/osteoblastic cells and osteoclast precursors as well as other 
hematopoietic cells in the bone marrow11. MSC have been shown to express interleukins (IL-
1α, IL-6, IL-7, IL-8, IL-11, IL-12, IL-14 and IL-15), leukemia inhibitory factor (LIF), stem 
cell factor (SCF), Flt3 ligand (FL), as well as the granulocyte macrophage- (GM-CSF), 
granulocyte- (G-CSF), and macrophage-colony stimulating factors (M-CSF). Receptors for 
IL-1, IL-3, IL-4, IL-6, IL-7, LIF, SCF, G-CSF, interferon γ (IFNγ, tumor necrosis factor 
(TNFI, TNFII), transforming growth factors (TGFβ1, TGFβ2), basic fibroblast growth factor 
(bFGF), platelet derived growth factor (PDGF) and endothelial growth factor (EGF) have also 
been detected2,6. However, most data have been recorded from studies investigating the 
hematopoietic microenvironment, whereas no comprehensive data on the properties of the 
microenvironment for mesenchymal progenitors, both in the bone marrow and in other 
mesenchymal tissues, is available. 
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Rat MPC have been characterized by Javazon et al.12 as cells sensitive to plating 
density, showing rapid expansion at low density culturing. Furthermore, when seeded at 
densities of 5,000 cells /cm2 and passaged up to P5, rat MPC express CD90 and CD59, and 
are negative for CD31, CD4, CD11b, CD43, CD45, and mononuclear phagocyte marker. 
Assays on colony forming units-fibroblast (CFU-F), CFU-alkaline phosphatase (CFU-ALP), 
and CFU–osteogenic (CFU-O) have been performed with primary and secondary rat bone 
marrow cultures. The estimated frequency of CFU-F in secondary cultures was 1/100-1/250 
when cultured without dexamethasone, whereas with dexamethasone 1/50-1/100 CFU-F 
frequencies were found13. The frequency of osteoprogenitors CFU-O in the secondary 
cultures is 1/300-1/500 when stimulated with dexamethasone and less than 1/1000 when no 
stimulation is applied13. Considering all nucleated cells in rat bone marrow, the final 
frequency of CFU-O is only 1/30,000-1/100,00013.  
This study was performed to investigate the effect of contaminating plastic adherent 
hematopoietic cells (HC) on the osteogenic differentiation of bone marrow stromal cell 
cultures in vitro. Primary MSC cultures were immunomagnetically separated into CD45+ HC 
and CD45- MSC. Different percentages of HC were mixed with CD45- cells and cultured 
under osteo-inductive conditions, using standard osteogenic medium supplements. In the first 
experiment, we compared the osteogenic differentiation of pure CD45- cells with cultures 
containing different percentages of CD45+ HC, maintaining a total seeding density of 50,000 
cells / cm². We noted a dose-dependant decrease in ALP activity and calcium accumulation 
with increasing HC percentages. A second experiment was performed as a control, 
investigating the possible impact of the antibody labeling and separation procedure. 
Additionally, this second experiment indicated whether the observed effects were caused by 
the difference in CD45- cell number per well. Neither procedure nor cell number seemed to 
have an influence on osteogenic differentiation. A third experiment, investigating the gene 
expression of osteogenic markers in pure CD45- cultures and non-separated cultures 
containing 20 % HC, confirmed the results of the first two experiments. Finally, to elucidate 
whether the effect relied upon heterotypic cell-cell contacts or soluble factors, trans-well 
experiments were performed. 
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MATERIALS AND METHODS 
Suppliers 
Gibco, Invitrogen, UK: Foetal calf serum, FCS (Lot No.: 40F7430K); Penicillin-Streptomycin 
(10,000 units / mL penicillin G sodium and 10,000 µg / mL streptomycin sulphate); Trypsin-EDTA 
(0.25 % Trypsin and 1 mM EDTA.4Na); TRiZOL 
Sigma Aldrich, Germany: L-glutamine (200 mM); Minimum essential medium Eagle, alpha 
modification (α-MEM; 10.1 g / L); 7-Aminoactinomycin D (7-AAD); Trizma ® base (C4H11NO3). 
Corning, Netherlands: tissue culture flasks and wells. Millipore, USA: MilliCell-CM, trans-well 
inserts. 
Polymer scaffolds 
For the 3-D experiments, sponge-like scaffolds consisting of poly(DL-lactic-co-glycolic acid) 
(PLGA, molar ratio 75:25, Resomer® RG756, Boehringer Ingelheim, Ingelheim, Germany) 
with a pore size of 100 - 300 µm were used. They were fabricated by Solid Lipid Templating 
published by Hacker et al.14. 
Cell isolation and primary cell culture 
Rat bone marrow was isolated from femur and tibia of six week old (150 – 200 g) male Sprague-
Dawley rats (Institut für Labortierkunde und -genetik, Medical University Vienna, Austria) by 
centrifugation15. Freshly isolated bone marrow cells were re-suspended in primary medium (10 % 
FCS, 1 % Penicillin/Streptomycin, 0.5 % L-glutamine, and α-MEM). For each experiment, bone 
marrow cells of at least three animals were pooled. Cells obtained from one rat (two tibias and two 
femurs) were seeded in 4 x 150 cm2 flasks (approx. 1.5x 105 nucleated cells / cm2) and cultured in a 
humidified atmosphere with 5 % CO2 at 37°C. After three days, non-adherent cells were removed 
by rinsing twice with 16 mL / flask PBS. The medium was changed three times a week. On day 
seven after cell isolation (90 – 100 % confluence), the cells were detached from the flasks using 
trypsin-EDTA. After trypsin deactivation, cells were passed through a 40 µm cell strainer, 
centrifuged, re-suspended, and counted using a haemocytometer. 
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Flow cytometry 
The cell suspension was first incubated for fifteen minutes at 4°C with 10 % v/v sheep serum 
and then for thirty minutes at 4°C with antibodies against rat CD markers or with 
corresponding isotype controls. Antibodies against the rat markers CD90, CD29, CD11bc, 
CD3, CD4, CD8b, NKRP1a, CD45RA, and granulocytes were purchased from BD 
Pharmingen, USA, CD44 and CD45 were obtained from Acris, Germany. Cells were washed 
and re-suspended in PBS containing sodium azide and bovine serum albumin (BSA) before 
the measurements, 20 % v/v 7-AAD (20 µg / mL) was added to each sample for three minutes 
to stain the dead cells, which were then excluded from the evaluation. All measurements were 
performed on a FACSCalibur® instrument and data acquired using the CellQuest software 
(both from BD Biosciences, USA). Measurements were evaluated with WinMDI 2.8 Software 
(free access from http://facs.scripps.edu/software.html). A minimum of 1 x 104 viable cells 
were acquired per data set. The percentage of positive cells was determined as the percentage 
of cells having a measured fluorescence greater than that of 99.5 % of the cells that had been 
stained with each associated isotype control. A population was considered positive for a 
surface marker when the percentage of positive cells for that surface marker was ≥ to 5 %. 
Magnetic cell separation 
Primary cultures of rat MSC are usually contaminated with CD45+ hematopoetic cells. To 
separate CD45+ and CD45- cells, cells were re-suspended in separating buffer (PBS pH 7.2 
supplemented with 0.5 % BSA and 2 mM EDTA) and incubated with primary phycoerythrin 
(PE)-labeled antibody against rat CD45 (Acris Antibodies; Hiddenhausen, Germany; Cat. Nr. 
SM274R) at 4°C in the dark for thirty minutes. After washing, the cell suspension was 
incubated with secondary anti-PE antibody-coupled magnetic beads (MACS® MicroBeads, 
Miltenyi Biotec, Bergisch Gladbach, Germany) for 15 minutes at 4°C in the dark. After 
washing, cells were re-suspended in separating buffer and applied onto the LS column, which 
was then placed in the magnet (MidiMACS Separation Unit, Miltenyi Biotech). The negative 
fraction was first collected (CD45- MSC) and then, after the removal of the column from the 
magnet, the CD45+ fraction was obtained. Both cell fractions were washed with medium, the 
viable cells were counted, and the viability and purity of both populations were determined by 
flow cytometry.  
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Osteogenic differentiation 
For 2-D experiments, cells were plated in well plates at a density of 50,000 cells / cm2 in primary 
medium for 24 hours, if not indicated differently. In order to check for the influence of released 
cytokines, a 3-D experiment was performed. To this end, CD45- cells were dynamically seeded 
onto 3-D scaffolds in spinner flasks for 24 h16. Cell loaded scaffolds (1.8 x 106 CD45- cells/scaffold) 
were placed onto 6-well culture plate inserts (0.4 µm pore size), while CD45+ cells were co-
cultured on the bottom of the 6-well plates (1.2 x 106 CD45+ cells / well). CD45- cells that were not 
co-cultured were equally treated, but no CD45+ cells were seeded onto the bottom of the wells.  
On day one after seeding, the cells received complete medium (primary medium 
supplemented with 50 mg / L ascorbic acid, 2.16 g / L β-glycero-phosphate (7mM), and 10-8 
M dexamethasone). The medium was changed every two to three days and samples were 
taken at different time points. Wells were washed with PBS and frozen at –20°C. 
Cell number 
A fluorimetric assay17 was performed to measure the total amount of DNA and, subsequently, 
to determine the cell number. The samples were thawed and the cells scraped off the surface 
and dispersed in PBS. After digestion with papain solution for 18 h at 60°C, the released 
DNA was quantified using Hoechst 33258 dye. Cell number was calculated using a DNA 
standard curve (calf thymus DNA (Sigma)) and a predetermined factor of 10 pg DNA / cell. 
Alkaline Phosphatase (ALP) 
Cells were thawed and kept on ice during preparation of the samples. After thawing, cells 
were scraped and dispersed in TRIS buffer (1 M Trisma base, pH 8). After sonication, the 
kinetics of p-nitro phenyl phosphate degradation to phosphate and p-nitro phenol was 
determined using a RANDOX Kit (Randox Laboratories Ltd., Crumlin, UK), measuring the 
absorbance at 405 nm, and calculating the ALP activity. 
Calcium deposition 
For the quantification of calcium content, the reaction of the cation with the chromogenic 
agent o-cresolphtalein complexone to a red complex with an absorbance maximum at 575 nm 
was employed (Calcium Liquicolor, Rolf Greiner BioChemica, Flacht, Germany). For the von 
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Kossa stain, cells were fixed with neutral buffered formalin solution (10 %) and incubated 
with 5 % AgNO3 solution under exposure to day light. 
RNA isolation and reverse transcription 
Samples were immediately washed with PBS, dispersed, and homogenized in 1 mL TRiZOL. 
Subsequently, samples were frozen at –70°C. After thawing, samples were transferred into PhaseLock 
Gel tubes (Eppendorf, Germany) and RNA isolation was performed according to the manufacturer’s 
instructions (TRiZOL, Invitrogen). RNA concentration and purity were determined by absorption 
measurements at 260 and 280 nm, respectively. Reverse transcription was performed with the High 
Capacity cDNA Archive Kit (Applied Biosystems, USA) in a thermal cycler (Eppendorf, Germany) 
for ten minutes at 25°C and 2 h at 37°C. Replicated DNA was stored at –20°C. 
Real time PCR 
Relative quantitative PCR was performed with TaqMan Gene Expression Assays (Table 1) 
and TaqMan 2X Universal Master Mix (both Applied Biosystems) in 96-well optical reaction 
plates on an Applied Biosystems 7300 Real-Time PCR System according to the 
manufacturer’s instructions. Thermal cycling parameters were an initial incubation at 95°C 
for ten min, followed by forty PCR amplification cycles of denaturation at 95°C for 15 s, and 
annealing / extension for one min at 60°C. 
Mean relative quantification (RQ) values were calculated according to the ∆∆Ct method, 
using ribosomal 18S RNA as an endogenous control. The results are the average of three (2-D 
experiment) or four (3-D experiment) samples with double determination.  
 
Table 1: TaqMan assays for the real time PCR provided by Applied Biosystems (USA). 
Target    RefSeq  TaqMan Assay ID 
ALP    NM_037191  Rn00564931_m1 
BSP    NM_012587  Rn00561414_m1 
Cbfa-1 (Runx2)  AB115746  Rn01512296_m1 
Collagen 1   Z78279  Rn00801649_g1 
Osteocalcin (Bglap2)  NM_013414  Rn00566386_g1 
Osteonectin (Sparc)  NM_012656  Rn00561955_m1 
Osteopontin (Spp1)  NM_0128812  Rn00563571_m1 
Endogenous control 
Ribosomal 18s mRNA X03205  4319413E 
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Experimental Designs 
Experiment 1: Aim: Examine the influence of CD45+ HC contamination on osteogenic 
differentiation at constant total seeding density of 50,000 cells / cm². Methods: ALP activity, Ca2+-
content, van Kossa staining. Groups: (1) 100 % CD45- MSC, (2) 85 % CD45- MSC with 15 % 
CD45+ HC, (3) 71 % CD45- MSC with 29 % CD45+ HC, (4) 57 % CD45- MSC with 43 % 
CD45+ HC and (5) 42 % CD45- MSC with 58 % CD45+ HC. 
Experiment 2: Aim: Control experiment to determine the influences of the antibody labeling and 
separation procedures on the cell number of CD45- MSC. Methods: ALP activity, van Kossa 
staining. Groups: (1) separated cells and non-separated in the same proportion as before separation, 
(2) non-separated cells, which were processed like the separated cells, but without the addition of 
antibodies, (3) non-separated cells, (4) only CD45- MSC. Groups (1)-(4) were seeded at 50,000 
cells / cm². 
(5) CD45- MSC seeded at 50,000 cells / cm² with addition of 12,500 CD45+ HC / cm², (6) CD45- 
MSC only, seeded at 62,500 cells / cm².  
Experiment 3: Aim: Examine the influence of CD45+ HC contamination on osteogenic 
differentiation at constant total seeding density of 50,000 cells / cm².  Methods: 2-D culture, real 
time on day seven. Groups: (1) non-separated cells containing 20 % CD45+ cells, (2) only CD45- 
MSC. 
Experiment 4: Aim: Examine the influence of CD45+ HC contamination in separated co-culture. 
Methods: trans-well culture, real time on day seven. 3-D: Groups: (1) only CD45- MSC, cultured as 
monoculture, (2) only CD45- MSC, co-cultured with CD45+ HC, separated by a membrane. 
Statistical evaluation 
One-way ANOVA and Student t-tests were employed for quantitative PCR experiments and Tukey test 
was used for multiple group comparisons. 
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RESULTS 
The presented data result from four independent experiments. Each of them showed 
that purified rat CD45- MSC from primary bone marrow cultures differentiated to the 
osteogenic lineage significantly better than primary bone marrow cultures containing CD45+ 
hematopoietic cells (HC).  
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 Granulocyte CD45RA CD161a CD45 
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Figure 1: Flow cytometric adherent bone marrow cell phenotype determination. 
Representative histograms show the expression of some hematopoietic markers and 
endothelial marker CD31. The open histograms show the fluorescence intensity of the cells 
with isotype control and the closed histograms show the fluorescence intensity of the cells 
with each CD antibody. Dot-plots show the expression of markers on CD45+ and CD45- 
populations simultaneously. Gray: isotype control, black: CD antibody. 
Flow cytometric characterization of primary cultures 
After one week of cultivation, rat bone marrow cultures contained 10-40% CD45+ HC, 
whereas no CD31+ endothelial cells were detected (Figure 1). We did not detect cells positive 
for CD3, CD4, CD8b, NKRP1A (CD161a), CD45RA, or granulocyte marker (Figure 1). Most 
of the primary cells, CD45- as well as CD45+, were positive for both integrin subunit β1 
CD29, CD90 and CD44. Most of the cells were identified as CD45-, showing fibroblast-like 
morphology18 and expressing MSC markers. The contaminating, generally round-morphology 
cells were CD45+ HC18, which co-expressed the myeloid marker CD11b/c.  
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Effect of HC contamination on osteogenic differentiation of CD45- cells 
Since the percentage of HC contamination in primary MSC cultures varied18, we 
investigated the influence of different HC proportions on osteogenic differentiation. ALP 
activity of pure CD45- cultures peaked earlier and was significantly higher than in CD45- 
cultures containing HC (Figure 2a). Calcium quantification (Figure 2b) and von Kossa 
staining (Figure 3) supported this delay in differentiation.  
Other osteogenic markers were also affected by HC, as seen in figure 4. In that 
experiment, we compared the gene expression of pure CD45- cultures with that of non-
separated cultures (containing 20% CD45+ HC). On day seven, measured mRNA expression 
of ALP, bone sialoprotein (BSP), and osteocalcin (OC) was four-, five- and six- times greater, 
respectively, in the pure CD45- group than in the non-separated group (all p<0.001). 
Additionally, the expression of transcription factor Cbfa1, collagen 1 (Col1), osteopontin 
(OP) (all p<0.001) and osteonectin (ON; p<0.05) was significantly enhanced in group without 
CD45+ HC. 
Influence of immunomagnetic separation  
To confirm that the observed effects were not only a consequence of antibody labeling 
or the separation procedure, a control experiment was performed (Figure 5, groups one to 
four). Neither cell labeling with antibodies nor separation procedure affected ALP or cell 
proliferation significantly. A slightly lowered cell count observed on day one (Figure 5b) in 
groups one and two (separation procedure), as compared to group three (non-separated 
group), was probably due to the delay in seeding as a result of the separation procedure. 
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Figure 2: Influence of CD45+ cell proportion on: A: alkaline phosphatase (ALP) activity and 
B: calcium accumulation at a total seeding density of 50,000 cells / cm². Results are from the 
first 2-D experiment, which was preformed in 12-wells. Results are mean (n = 4) ± standard 
deviation. 
* Significant difference (p<0,01) to 100% MSC group and $: significant difference (p< 0.01) 
to 85%MSC+15%HC group. 
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Figure 3: Von Kossa staining of calcium deposition.  
Upper wells show results of the 1st experiment after 24 days. (a) 100% CD45- MSC, (b) 85% 
CD45- MSC with 15% CD45+ HC, (c) 71% CD45- MSC with 29% CD45+ HC, (d) 57% 
CD45- MSC with 43% CD45+ HC and (e) 42% CD45- MSC with 58% CD45+ HC. 
Lower wells show results of the 2nd experiment after 21 days in osteogenic medium.  
In groups containing CD45+ HC(all 20%), single bone nodules could be seen whereas in 
groups with CD45- MSC only, the whole cell layer in wells stained positive for calcium. Pure 
CD45- MSC often tended to detach (4) or rolled together forming coils (6) probably because 
of higher extracellular matrix production. Groups: (1) separated cells and joined in the same 
proportion as before separation, (2) non-separated cells, which were processed as the 
separated, only without antibodies addition, (3) non-separated cells, (4) only CD45- MSC. 
Groups 1-4 were seeded at 50,000 cells / cm². (5) CD45- MSC seeded at 50,000 cells / cm² 
with addition of 12,500 CD45+ HC / cm², (6) CD45- MSC only, seeded at 62,500 cells / cm².  
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Figure 4: Relative mRNA gene expression of 2-D cultured cells (6-wells) on day 7.  
Control (grey bars): non-separated cells with 20% CD45+ cells, CD45 - group (black bars). 
Results are mean (n = 3) ± standard deviation; significant difference: *: p < 0.001 and $: p 
< 0.05. ALP: alkaline phosphatase, BSP: bone sialoprotein, Cbfa1: transcription factor, 
Col1: collagen 1, C: osteocalcin, ON: osteonectin, OP: osteopontin. 
Effect of CD45- cell number  
In the first experiment, the total number of CD45- cells in the different groups had 
been varied to maintain a total cell density of 50,000 cells / cm². Therefore, we evaluated the 
influence of CD45- cell seeding number, with or without CD45+ HC (Figure 5), on 
osteogenic differentiation in the control experiment. Groups four and five contained the same 
number of CD45- cells at the beginning of differentiation, with group five additionally 
containing 20 % CD45+ cells. We found that pure CD45- cells (group four) showed 
significantly higher ALP than group five, which contained HC (Figure 5). No difference in 
ALP and cell number was observed when the initial CD45- cell number was increased from 
100 to 125 parts (group four vs. group six). Comparing group one and five – which have the 
same percentage of CD45+ cells, but different numbers of CD45- cells – revealed no 
difference.  
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Figure 5: Second experiment performed 2-D in 12-wells.  
A: Alkaline phosphatase activity during osteogenic induction of CD45- MSC and CD45- MSC co-
cultured with CD45+ HC.  
B: Proliferation of the cells in osteogenic medium.  
Results are mean (n = 4) ± standard deviation.  
* Significant difference (p < 0.01). Grey bars represent the comparison of maximal ALP activity. 
Groups: (1) separated cells and joined in the same proportion as before separation, (2) non-separated 
cells, which were processed as the separated, only without antibodies addition, (3) non-separated 
cells, (4) only CD45- MSC. Groups 1-4 were seeded at 50,000 cells / cm². (5) CD45- MSC seeded at 
50,000 cells / cm² with addition of 12,500 CD45+ HC / cm², (6) CD45- MSC only, seeded at 62,500 
cells / cm². 
Effects in separated co-culture  
One week after the passage, we could still observe cells with round morphology 
“sitting” on the layer of MSC in groups containing HC, as shown in Figure 6. To find out 
whether CD45+ cells influence CD45- differentiation by heterotypic cell-cell contacts, or if 
this influence is through released cytokines, we performed another experiment in which we 
separated CD45- cells from CD45+ cells using 0.4 µm trans-well membranes. CD45- cells 
were cultured on three-dimensional scaffolds made of PLGA on top of the trans-well 
membranes, while HC were seeded into the bottom of wells. All cultures received 
osteoinductive treatment. CD45- cells cultured in absence of CD45+ cells showed increased 
expression of osteogenic markers as compared to separated, co-cultured cells (Figure 7). In 
particular, the measured mRNA expression of osteocalcin was forty times, and the expression 
of ALP and BSP three times, higher than in co-cultured CD45- cells.  
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Figure 6: Interference contrast photographs after 7 days in osteogenic medium. Left: non-
separated cells, where round HC-like cells could be observed. Right: CD45- group without 
round cells.  
Bar = 250 µm. 
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Figure 7: Effect of soluble factors. Relative mRNA gene expression of 3-D cultured cells. The 
expression profile of osteogenic markers on day 7 in CD45- group (black bars) and CD45- group 
which was co-cultured with hematopoietic cells (grey bars), separated with a trans-well membrane. 
Results are mean (n = 4) ± standard deviation; significant difference: *: p < 0.001 and $: p < 0.05. 
ALP: alkaline phosphatase, BSP: bone sialoprotein, Cbfa1: transcription factor, Col1: collagen 
1, C: osteocalcin, ON: osteonectin, OP: osteopontin. 
 
Breda Vogel 
 74 
DISCUSSION 
It is known that early cultures of bone marrow stromal (MSC) cells also contain 
hematopoietic cells (HC)7. With repeated sub-culturing, the frequency of hematopoietic cells 
decreases, with the rate of decrease depending on the species and culture conditions7. One 
important difference between primary cultures and passaged MSC is, therefore, the presence 
of hematopoietic cells19. The proportion of HC in rat MSC cultures can also be diminished by 
dexamethasone supplementation20. Regarding the influence of hematopoietic cells on 
osteogenic differentiation, it is known that either non-adherent bone marrow cells or their 
conditioned media can increase rat bone nodule formation13. Specifically, megakaryocytes 
and platelets are known to support MSC proliferation and differentiation21,22.  
In a first step, we characterized the fraction of adherent CD45+ cells in our cultures. 
We used antibodies against common hematopoietic markers, such as CD45 and CD11b/c, as 
well as several lineage markers. CD45 is a leukocyte-common antigen (LCA) and, therefore, 
a widely used marker for the detection of hematopoietic cells in general. CD45+ cells in our 
cultures co-expressed another general leukocyte/myeloid marker, the integrin subunit 
CD11b/c. The antibody employed (anti CD11b/c, clone OX-42) reacts with the CR3 
complement (C3bi) receptor, which is found on most monocytes, granulocytes, macrophages, 
and dendritic cells23,24. This antibody recognizes a common epitope shared by CD11b and 
CD11c (integrin αM and αX chains) 24, which is present in both mature and immature cells. 
Because we detected no cells positive for granulocyte marker or NKR-P1A+, typical markers 
for dendritic cells, we assumed that cells of monocytic-macrophage lineage prevailed in our 
cultures. Additionally, the detection of a low level of co-expression for the rat Thy-1 antigen 
CD90, a commonly stated marker for progenitor cell types25, also indicates the presence of 
hematopoietic progenitors. We detected no expression of CD3, CD4, CD8b, CD45RA, 
NKRP1A, or granulocyte positive cells, which indicated that mature cells did not adhere and 
that precursor cells did not differentiate to these subpopulations (B and T lymphocytes, 
dendritic cells, granulocytes, erythroblasts) during one week of cultivation under the 
conditions used. Taking this surface marker profile into consideration, we assume that CD45+ 
cells in our cultures were a mixed cell population consisting of mature (monocyte-
macrophage) and immature (progenitor) cells of the myeloid lineage, which arose from the 
bone marrow. Additionally, many publications describe similar “primitive” myeloid 
progenitor cells, or so called “cobblestone area” cells, that adhere to tissue culture plastic in 
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hematopoietic stem cell studies19,25. The other major population in our primary cultures was 
CD45-/CD11bc-/CD31-, but expressed CD90, CD44 and CD29, markers typical for MSC. 
Tissue engineering publications utilizing the rat animal model often use primary 
cultures of plastic adherent, enrichedMSC, for further differentiation and matrix production 
studies. Primary adherent rat bone marrow cells have been employed for bone26, fat27 and 
cartilage28 tissue engineering studies without the determination of other bone marrow 
subpopulations. Because of a loss in their differentiation potential with increasing number of 
passages29, early passages that commonly contain adherent hematopoietic cells are generally 
used. Since we detected varying proportions of CD45+ cells in primary cultures (mostly 10-
30%), we assume that this could be one reason for variations observed in osteogenic 
differentiation experiments. Additionally, effects of some growth factors used for improved 
bone tissue formation (e.g. TGF-β1) are probably due to the sum of effects on both 
hematopoietic and mesenchymal populations.  
The CD45 marker clearly distinguished both cell populations using flow cytometry 
(Figure 1). Applying secondary magnetic-bead-coupled antibody against fluorochrom 
phycoerythrin (PE) enabled specific binding to the anti-CD45 antibody. The efficiency of the 
magnetic separation procedure was always determined after the separation and the exact 
proportions were calculated or set for further experiments. First, we wanted to determine if 
there was an observable effect of hematopietic cells on osteogenic differentiation and whether 
the strength of this effect depended on the percentage of contamination with hematopoietic 
cells. Cultures without HC showed remarkably higher alkaline phosphatase activity levels 
(ALP) than cultures with HC. In the groups containing HC, ALP increased at later time 
points, which correlated to the proportion of HC contamination. An earlier onset of ALP in 
pure CD45- cultures was accomplished through earlier mineralization and, consequentially, 
higher calcium accumulation after 21 and 24 days (Fig. 2b and Fig. 3a).  
During the cultivation, we observed some dead cells in cultures containing HC, 
possibly caused by HC labeling or the separation procedure. To determine the cause, a second 
experiment was performed (Fig. 5). We compared the differentiation of pure CD45- cells 
(group four) with that of (1) non-separated cells (group three, control), (2) magnetically 
labeled and separated cells, which were reunited in the same ratio as before separation (group 
one), and (3) cells that had experienced the separation procedure without magnetic labeling 
(group two). We saw that neither labeling of HC nor the separation procedure itself influenced 
ALP activity profile and proliferation. The only observable difference on the first day after 
passage and separation was a slightly reduced cell number, which could be explained by the 
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delay caused by the separation procedure. All groups containing HC showed an ALP activity 
profile similar to that observed in the first experiment. Again, groups containing CD45- MSC 
only showed significantly higher (p < 0.01) ALP activity than groups with HC. In some wells 
of the groups with pure CD45- MSC, we observed detaching and aggregating cell layers, 
possibly caused by cross linking of the secreted collagen matrix and extensive proliferation, 
that resulted in higher deviations and lowering of ALP activity on day thirteen.  
To make sure that the observed improved differentiation of pure CD45- cells was not 
only due to the higher number of CD45- cells compared to the number in mixed cultures, we 
analyzed the differentiation of cultures containing confluent numbers of CD45- cells and 20 
% additional HC (Fig. 5, group 5). We saw that, within the chosen limits, the initial number of 
CD45- MSC had no influence on ALP and cell count (Fig. 5).  
Alkaline phosphatase is a marker for osteogenic differentiation that increases at the 
beginning of differentiation and decreases when mineralization has significantly 
progressed30. With the exception of osteocalcin and cbfa-1, the expression of frequently 
assayed osteoblast-associated genes such as collagen 1 (COLLI), alkaline phosphatase 
(ALP), osteopontin (OPN), and bone sialoprotein (BSP) is up-regulated prior to cessation of 
proliferation in osteoblast precursors30. We determined the mRNA expression for these 
genes on day seven, when the cultures had nearly reached their maximum cell number. By 
choosing this time point, we were able to detect differences between the gene expression of 
early and late differentiation markers. We compared the expression of pure CD45- cells 
with that of a non-separated control containing 20 % HC. Confirming ALP and calcium 
accumulation, pure CD45- cells showed significantly increased mRNA expression for all 
investigated markers (Fig. 4).  
Similar effects on human MSC have been observed in co-cultures with dermal 
fibroblasts31. The effects have been described as dilution effects and are explained by reduced 
cell-cell contacts between the MSC. To elucidate whether the observed effects of our study 
also depended on cell dilution, we performed a trans-well co-culture experiment that spatially 
separated the CD45- cells from the HC. We decided to seed CD45- cells onto three-
dimensional scaffolds of poly-(lactic-glycolic acid) primarily to avoid detachment of cell 
layers and secondarily to enhance osteogenic differentiation. Separated CD45+ hematopoietic 
cells were plated on the bottom of 6-wells and CD45- MSC seeded constructs were cultured 
in a 0.4 µm-membrane trans-well insert that was subsequently placed over the HC to prevent 
cell migration but allow cytokine transport. We compared the mRNA expression of CD45- 
MSC cultured without HC to that of those co-cultured with HC. We saw that all osteogenic 
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marker mRNAs were significantly higher in the group that was cultured without HC, 
suggesting an involvement of cytokines in HC inhibition of CD45- MSC osteogenic 
differentiation.  
Osteoblasts and MSC are known to support haematopoiesis by secreting hematopoietic 
cytokines that work in both a paracrine and an autocrine way. Some molecules that are known 
to influence bone metabolism are colony stimulating factors (IL-3, GM-CSF, G-CSF) and IL-
1, TNF, lymphotoxin, IFNγ, IL-8, IL-10, IL-4, and the LIF/IL-6 family along with others32. 
Their influence on osteogenesis is still not clearly understood because the studies have been 
either been performed in vivo, where systemic hormones play additional roles, or in vitro with 
osteogenic precursors at different degrees of maturation. Taichman et al.33 co-cultured human 
bone marrow CD34+ hematopoietic cells and osteoblasts and showed that HC stimulated 
osteoblasts to produce higher levels of IL-6 and LIF in a cell-cell contact independent way. 
On the other hand, levels of G-CSF, GM-CSF, and TGF-β1 remained under the detection 
limit. The maximal accumulation of IL-6 and LIF occurred within the first 24 hours and 
correlated with the CD34+ cell number. In rat calvaria (RC) osteoprogenitor cultures, LIF 
showed an inhibiting effect on bone nodule formation and ALP activity both in the presence 
or absence of dexamethasone34. Moreover, in case of IL-6/LIF cytokines, the receptors seem 
to play crucial roles. With the exception of the oncostatin M receptor (OSMR), all LIF/IL-6 
family receptors, which share a gp130 subunit (LIFR, IL-6R, IL-11R, OSMR), seem to 
suppress differentiation to the osteogenic line35. It has been observed, that when a 
glucocorticoid is added to the MSC cultures, the expression of IL-6, IL-11 and LIF is 
reduced9. It has been further suggested that TGF-β1 and IL-1 inhibit bone nodule formation in 
RC cell cultures through the stimulation of LIF production (discussed in 34). There is little and 
controversial information, however, on the influence of IL-6/LIF on osteogenic differentiation 
of early MSC cultures32,36,37. Since our experiments were performed with early CD45- cells, 
we propose that the presence of MSC as well as osteoprogenitors in our culture and, therefore, 
IL-6 / LIF involvement in the observed effects is possible. 
There are several other mechanisms involving HC that could inhibit osteogenic 
differentiation. For instance, granulocyte-colony stimulating factor (G-CSF) is known to play 
an important role in bone remodeling. When administered in rats, it produces osteoporosis as 
a consequence of two mechanisms, an increase in osteoclast numbers and reduced bone 
formation32. Additionally, macrophage-colony stimulating factor (M-CSF) enhanced 
osteoclast formation and inhibited MSC osteoblast formation in vitro38. Since MSC are 
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impacted to varying degrees by cytokines, growth factors, glucocorticoids, and many other 
effector-molecules in the in vivo bone marrow microenvironment, determining the influence 
of these effectors on MSC, either individually or in combination, is essential to enable 
understanding and manipulation of MSC involvement in bone formation and bone resorption9. 
In our case, screening studies could bring us a step closer to the identification of the factors 
that caused the observed effects.  
It has already been proposed that in vivo MSC need some ”protective mechanism” 
against the autocrine effects of their secreted growth factors and cytokines to maintain them in 
an undifferentiated state as stem/progenitor cells9,36. These mechanisms may very likely 
involve other bone marrow populations, particularly hematopoietic stem and progenitor cells. 
We have to keep in mind the heterogeneity of bone marrow adherent and non-adherent 
populations and therefore the complexity of already made in vitro observations. Beside 
hematopoietic stem cells, the non-adherent bone marrow fraction in vitro contains platelets 
and megakaryocytes, which stimulate the differentiation and proliferation of MSC, potentially 
through PDGF and some other mitogenic factors1,9, whereas our results show that the 
adherent myeloid cells suppressed osteogenic differentiation. 
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ABSTRACT 
Plastic-adherent bone marrow cells are often used as a source of marrow stromal cells 
(MSC) that can differentiate into cells of supportive tissue. We isolated rat bone marrow cells, 
seeded them in tissue culture flasks and cultured 3-day adherent cells in alpha MEM 
supplemented with 10 % fetal bovine serum up to a week. We characterized adherent rat bone 
marrow cells using 6-parameter flow cytometry in order to determine stem cell markers and 
adhesion molecules on MSC, as well as the presence of other bone marrow subpopulations. 
We found that after 1-week in culture; plastic–adherent rat bone marrow cells contained 
CD45- cells with MSC-like surface marker expression, and a minor population of CD45+ 
hematopoietic cells (10 – 30 %), while no CD31+ endothelial cells was found. CD45- MSC 
expressed CD29, CD49e, CD54 and CD90 strongly, CD44 and CD49a moderately and 
weakly CD49b, CD49c, CD61 and CD106. Hematopoietic cells in our cultures belonged to 
the myeloid lineage and expressed CD29, CD44, CD49a, CD49e, CD54, and CD90 beside 
CD45 and CD11a, b/c. Adhesion experiments resembled the expression of adhesion 
molecules. CD45- cells adhered strongly to fibronectin, collagen 4 and collagen 1, whereas 
CD45+ cells adhered to fibronectin, vitronectin and bovine serum albumin strongly, while 
adhesion to laminin and collagens 1 and 4 was weak, making collagens selective substrates 
for MSC adhesion in the presence of myeloid cells.  
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INTRODUCTION 
Since Friedenstein1 and his colleagues reported about in vitro colony forming 
fibroblasts from the bone marrow, which form bone when implanted, these cells have been 
investigated for different kinds of cellular therapies and tissue engineering. Tissue 
engineering approaches involve biomaterials, the surface of which offers means to influence 
cell adhesion and function. Modification with adhesion promoting ligands, such as Arg-Gly-
Asp (RGD) peptide, facilitate tissue ingrowths and to a certain degree support cell type 
selective adhesion2. The RGD sequence is expressed in many extracellular matrix (ECM) 
molecules like fibronectin, vitronectin, bone sialoprotein, osteopontin, thrombospondin, 
fibrinogen, laminin, collagen, nectinepsin and in other molecules3. Cell receptors for these 
proteins include integrins, which belong to a widely distributed family of cell surface 
molecules that mediate cell adhesion. Integrins are heterodimeric glycoproteins consisting of 
an α  (17 known)and a β subunit (9 known), forming 23 distinct heterodimers4. Integrins 
interact with many peptide motivs in ECM molecules and so are through inside-out and 
outside-in signaling involved in a range of physiological processes, including embryogenesis, 
morphogenesis, wound repair, inflammation, tumor cell migration and leukocyte trafficking. 
Integrin-mediated adhesion also involves other binding sites, e.g. heparin binding site3. In 
addition to matrix proteins, integrins can bind to other cell surface receptors, e.g. members of 
the imunoglobulin (Ig) superfamily ICAM-1/CD54, VCAM-1/CD106, and soluble proteins 
like fibrinogen and inactivated complement component C35.  
First step towards selective osteoprogenitor cell immobilization on peptide-modified 
biomaterials is to determine which integrins are actually expressed on the cells to be attached. 
Additionally, the level of receptor expression has to be high enough to enable adequate cell 
adhesion. After that the decision has to be made which integrin-specific ligand needs to be 
bound on the biomaterial surface.  
Marrow stromal cells (MSC) are plastic adherent fibroblastoid cells isolated from bone 
marrow, which are often used as cell source for tissue engineering applications. These cells 
are a heterogeneous population of precursor cells including cells showing stem-cell like 
characteristics. They are therefore often referred to as mesenchymal stem / progenitor cells 
(MPC). MPC-like cells have been isolated from bone marrow, periosteum, trabecular bone, 
adipose tissue, synovium, skeletal muscle and deciduous teeth6, but are reported to occur in 
highest frequencies in adult bone marrow7,8. They can replicate as undifferentiated cells and 
have the potential to differentiate to lineages of mesenchymal tissues, including bone, 
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cartilage, fat, tendon, muscle, and marrow stroma9. MPC express a large spectrum of cell 
adhesion molecules of potential importance in cell binding and homing interactions. The 
characterization of freshly isolated MPC (Stro-1 positive immunoselection) from the human 
bone marrow showed the expression of α1β1 (CD49a/CD29), α2β1 (CD49b/CD29), α5β1 
(CD49e/CD29), α6β1 (CD49f/CD29), αVβ3 (CD51/CD61) and αVβ5 integrins and substrate 
/ integrin dependent colony formation10. For in vitro expanded human MPC it was shown, that 
they highly express integrins α1, α5 and β1, low α2, α3 (CD49c), α6, αV, β3 and β4, and 
don’t express α4 (CD49d), αL (CD11a) and β2 (CD18)11.  
Rat MPC have been characterized by Javazon et al.12 as cells sensitive to plating 
density showing rapid expansion at low density culture. Furthermore, when seeded at 
densities of 5,000 cells / cm2 and expanded up to 5 passages, they express CD90 and CD59 
and are negative for CD31, CD4, CD11b, CD43, CD45 and mononuclear phagocyte marker. 
Data on the integrin expression of primary rat MSC have been reported before, but only after 
osteogenic treatment13. Furthermore, that study did not distinguish between mesenchymal and 
hematopoietic or endothelial cells known to reside in the early cultures.  
For the purpose of tissue engineering using the rat animal model, differentiation of 
MSC to the osteogenic14, chondrogenic15 and adipogenic16 lineage has been established. 
Usually, bone marrow is isolated from femurs and tibias of an animal, and then the cells are 
re-suspended in proliferation medium without any other separation procedures, seeded and 
cultured until sub-confluence. Plastic non-adherent cells are removed with medium changes, 
usually on day 3 or even later. The differentiation medium is generally added to primary or 
secondary cultures and not later, because of decreased differentiation capacity with increasing 
passage number17.  
This study intended to characterize plastic adherent cells of primary rat bone marrow 
cultures after 7 days. Since in a recent study we have shown that CD45+ myeloid 
hematopoietic cells (HC) suppress osteogenic differentiation of MSC, integrin expression of 
MSC and HC was investigated to find ways for selective adhesion of MSC in the presence of 
HC. Confirming these results on different integrin expression patterns on MSC and HC cell 
adhesion to a panel of ECM proteins was performed using immunomagnetically separated HC 
and MSC. 
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MATERIALS AND METHODS 
Suppliers 
Gibco, Invitrogen, UK: Foetal calf serum, FCS (Lot No.: 40F7430K); Penicillin-Streptomycin 
(10,000 units / mL penicillin G sodium and 10,000 µg / mL streptomycin sulphate); Trypsin-EDTA 
(0.25 % Trypsin and 1mM EDTA.4Na); phosphate buffered saline (PBS, w/o Ca and Mg); 
Sigma Aldrich, Germany: L-glutamine (200mM); Minimum essential medium Eagle, alpha 
modification (α-MEM; 10.1 g / L); 7-Aminoactinomycin D (7-AAD); 
Corning, Netherlands: Tissue Culture Flasks. 
Cell isolation and cell culture 
Rat bone marrow was isolated from femur and tibia of 6-week old (150-200g) male Sprague-
Dawley rats (Institut für Labortierkunde und -genetik Himberg, Medical University Vienna, 
Vienna, Austria) by centrifugation18. Freshly isolated bone marrow cells were re-suspended in 
primary medium (10 % FCS, 1 % Penicillin/Streptomycin, 0.5 % L-glutamine and α-MEM). For 
each experiment bone marrow cells of at least 3 animals were pooled. Cells obtained from 1 rat (2 
femurs and 2 tibias) were seeded in 4 x 150 cm2 flasks (approx. 1,5 x 105 nucleated cells / cm2) 
and were cultured in humidified atmosphere with 5 % CO2 at 37°C. After 3 days, non-adherent 
cells were removed by rinsing twice with 16 mL / flask PBS. The medium was changed three 
times a week. On day 7 after cell isolation (90 - 100% confluence), the cells were detached from 
the flasks using trypsin-EDTA. After trypsin deactivation cells were passed through 40 µm cell 
strainer, centrifuged, resuspended, and counted using haemacytometer.  
Flow cytometry 
The cell suspension was first incubated for 15 minutes at 4°C with 10 % v/v sheep serum and 
then for 30 minutes at 4°C with antibodies against rat CD markers or with corresponding 
isotype controls (Table 1). Because of the constant presence of CD45+ hematopoietic cells, 
all the stains were done simultaneously with anti-CD45 antibody. Cells were washed and 
resuspended with PBS containing sodium azide and bovine serum albumin (BSA) before the 
measurements. Short before measurements 20 % v/v 7-AAD (20 µg / mL) was added to each 
sample for 3 minutes to stain the dead cells, which were then excluded from the evaluation. 
For the stains with antibodie against CD49c the cells were fixed and permeabilized using 
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Fix&Perm® kit (An der Grub, Kaumberg, Austria) according to the manufacturer’s 
instructions. When the stains requested incubations with anti mouse secondary antibodies, 
anti-CD45 was added at the end, following a blocking step with normal mouse serum. 
All measurements were preformed on a FACSCalibur® instrument and data acquired using 
the CellQuest software (both BD Biosciences, USA). Measurements were evaluated with 
WinMDI 2.8 Software (free access on http://facs.scripps.edu/software.html). A minimum of 
1x104 viable cells of each population (CD45- and CD45-) were acquired per data set.  
The Percentage of positive cells was determined as the percentage of cells having a measured 
fluorescence greater than that of 99.5 % of the cells that had been stained with each associated 
isotype control. A population was considered positive for a surface marker when the 
percentage of positive cells for that surface marker was ≥ to 5 %. The level of marker 
expression (LME) was calculated as the ratio between geometric mean fluorescence intensity 
(MFI) of sample cells and that of the isotype control19. Quantitative results represent mean 
values of 3 independent experiments ± standard deviation. 
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Table 1: Antibodies used in the flow cytometric experiments.  
Antigene / 
CD 
Other 
name 
species Clone Ig class Label Producer Cat. Nu. 
CD11a αL integrin Ms WT.1 IgG2a κ PE Pharmingen 550972 
CD11b/c αM/X integrin Ms OX-42 IgG2a κ FITC Pharmingen 554861 
CD29 β1 integrin Ham Ha2/5 IgM κ FITC Pharmingen 555005 
CD31 PECAM-1 Ms TLD-3A12 IgG1 FITC Acris SM272F 
CD44 H-CAM Ms OX-50 IgG1 PE Acris SM273R 
CD45 LCA Ms MRC OX-1 IgG1 PE Acris SM274R 
CD49a α1 integrin Ham Ha31/8 IgG2 λ - Pharmingen 555001 
CD49b α2 integrin Ham Ha1/29 IgG2 λ FITC Pharmingen 554999 
CD49c α3 integrin Ms 42 IgG1 - Pharmingen 611044 
CD49d α4 integrin Ms TA-2 IgG1 FITC Serotec MCA1383F 
CD49e α5 integrin Ham HMα5-1 IgG1 κ - Pharmingen 553350 
Hu CD51/β5 αVβ5 integrin Ms P1F6 IgG1 FITC Chemicon MAB1961F 
CD54 ICAM-1 Ms 1A29 IgG1 κ PE Pharmingen 554970 
CD61 β3 integrin Ham 2C9.G2 IgG1 κ PE Pharmingen 553347 
CD90 Thy-1 Ms OX-7 IgG1 κ FITC Pharmingen 554897 
CD106 VCAM-1 Ms MR106 IgG1 κ PE Pharmingen 559229 
Ham IgG 2nd step Ms G70/204, G94-90.5 IgG1 κ PE Pharmingen 554056 
Ms Ig 2nd step Goat * * APC Pharmingen 550826 
Mineral oil isotype     Ms MOPC-31C IgG1 κ - Pharmingen 557273 
Unknown isotype Ms MOPC-21 IgG1 κ FITC Pharmingen 555748 
Unknown isotype Ms * IgG1 PE Cymbus Biotech. CBL 600P 
TNP-KLH isotype Ms G155-178 IgG2a κ FITC Pharmingen 553456 
TNP isotype Ms G155-178 IgG2a κ PE Pharmingen 555574 
TNP-KLH isotype Ham A19-3 IgG1 κ - Pharmingen 553969 
TNP-KLH isotype Ham A19-3 IgG1 κ PE Pharmingen 553972 
KLH isotype Ham Ha4/8 IgG2 λ - Pharmingen 553962 
KLH isotype Ham Ha4/8 IgG2 λ FITC Pharmingen 553964 
TNP-KLH isotype Ham G235-1 IgM λ FITC Pharmingen 553960 
Legend: *: not stated; Ms: mouse; Ham: hamster; Hu: human; FITC: fluorescein-isothiocyanat; PE: 
phycoerythrin; APC: allophycocyanin; TNP: trinitrophenol; KLH: keyhole limpet hemocyanin.  
Magnetic cell separation 
To separate CD45+ and CD45- cells, cells were re-suspended in separating buffer (PBS pH 
7.2 supplemented with 0.5 % BSA and 2 mM EDTA) and incubated with primary 
phycoerythrin (PE)- labeled antibody against rat CD45 at 4°C in the dark for 30 minutes. 
After washing, the cell suspension was incubated with secondary anti-PE antibody-coupled 
magnetic beads (MACS® MicroBeads, Miltenyi Biotec, Bergisch Gladbach, Germany) for 15 
minutes at 4°C in the dark. After washing, the cells were re-suspended in separating buffer 
and applied onto the LS column placed in a magnetic field (MidiMACS separator, Miltenyi 
Biotech). The negative fraction was first collected (CD45- MSC) and then, after the removal 
of the column from the magnet, the CD45+ fraction was obtained. Both cell fractions were 
washed with α-MEM, the viable cells were counted and the viability and purity of both 
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populations was determined by flow cytometry. The purity of the negative fraction was 99-
100 % and 90-95 % of the positive fraction. 
Adhesion experiments 
After magnetic sorting, the cells were tested for adhesion onto different ECM proteins. 
We used a 96-well CytoMatrix screening kit (Chemicon, USA) and determined the proportion 
of adherent cells after crystal violet staining and dye solubilization, with absorbance 
measurement at 544 nm using a micro plate reader. The assay was performed according to the 
manufacturer’s instructions. Cell densities of 32,000 (CD45-) or 36,000 (CD45+) cells / well 
and a 3- hour adhesion time were used. Adherence to bovine serum albumin (BSA) and to 
tissue culture polystyrene (Costar, Corning) in the presence of 10% FBS served as controls. 
 A 
 
 B 
 
 C 
 
 D 
 
Figure 1: Representative Dot-Plots of the primary cultures of rat marrow stromal cells. A: 
forward (FSC) vs. sideward scatter (SSC); B: 7-AAD positive cells (dead cells) marked as R1 
were excluded from the evaluation; C and D: differentiation between both cell populations 
was achieved with CD45-PE or CD45-FITC staining. R2 represents CD45+ hematopoietic 
cells and R3 CD45- rat MSC. 
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RESULTS 
In a previous study we have shown that primary cultures (up to 7 days) of rat MSC 
always contain population of CD45+ HC (10-30 %)20 if no other separation procedure than 
adherence to tissue culture plastic was used (Fig.1). No CD31 positive cells (including 
endothelial cells) were detected and according to optical observations, there were no 
preadipocytes in our cultures (data not shown). By 6-parameter flow cytometry we were able 
to determine the surface marker expression on HC and MSC separately without the need to 
mechanically separate the populations. Double staining with antibodies against CD45, a 
common leukocyte antigen, enabled us to distinguish between HC and MSC. The quantitative 
results are presented in Fig. 2. CD45- MSC expressed CD29, CD49e, CD54 and CD90 
strongly (LME>10), CD44 and CD49a intermediate (5<LME<10) and CD49b, CD49c, CD61 
and CD106 low (LME<5). They did not express the hematopoietic markers CD45, CD11a, 
and CD11b/c. We did not detect any expression of CD49d and CD51 or αV/β5 on MSC. 
CD45+ hematopoietic cells expressed CD11a, CD29, CD44, CD49a and CD90 low, CD49e 
and CD11b/c intermediate and strongly CD54.  
Adhesion experiments (Figure 4) showed that CD45- MSC adhered well to tissue 
culture plastic in the presence of FBS, followed by adhesion to fibronectin. CD45- MSC 
adhered also well to collagen 4, collagen 1, and on vitronectin and weaker to laminin. CD45- 
MSC didn’t adhere to BSA coated wells.[MSOffice38] On the contrary, CD45+ cells showed 
strong adhesion to BSA-coated wells and to tissue culture plastic in the presence of FBS. The 
adhesion of CD45+ HC to fibronectin was also high and surprisingly also adhesion to 
vitronectin. CD45+ cells showed, however, low adhesion to laminin, collagen 1 and collagen 
4 (figures 4B-D). 
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Figure 2: Quantitative evaluation of flow cytometric measurements. Grey bars represent 
CD45+ cells and black bars represent CD45- MSC. Represented values are an average of 3 
independent experiments ± standard deviation. 
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Figure 3: Representative histograms of the marker expression. CD45+ and CD45- cells are 
separated on the basis of CD45 staining, as seen in Figure 1. Empty histograms represent fluorescent 
intensity of the isotype controls. 
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Figure 4: Adhesion of separated cell populations (CD45+ and CD45-) to 
extracellular matrix coated wells, as assessed with crystal violet absorbance 
measurements. Figure 4A shows the adhesion of CD45- MSC and 4B of CD45+ HC. 
The results are an average of 3 independent experiments performed in triplicate + 
standard error of the mean. Statistical significance as determined with Tukey-test is 
marked with * (p < 0.05) or ** (p < 0.01) compared to FBS and $ (p < 0.05) as 
compared to fibronectin. Fibr.: fibronectin, Vitr.: vitronectin, Lam.: laminin, Coll.1: 
collagen I, Coll.4: collagen IV, FBS: fetal bovine serum, BSA: bovine serum 
albumin. 
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Figure 4, continued: C, D: Representative photographs of the wells with CD45+ HC. Figure 
4C shows the cell density on a vitronectin coated well, and the Figure 4D the cell density on a 
collagen I coated well. Bar = 1mm. 
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Figure 5: Morphology of CD45- MSC (A) and CD45+ cells (B) after separation procedure. 
Cells were seeded for 3 hours on tissue culture polystyrene in medium supplemented with 10% 
FBS. Bar=250µm. 
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DISCUSSION 
It is known from studies on human and murine MSC, that primary cultures are often 
contaminated with hematopoietic cells of macrophage morphology and endothelial cells9,22. 
The presence of hematopoietic cells in primary cultures of rat marrow derived stromal cells 
has also been reported23. In our cultures of plastic-adherent rat bone marrow cells we detected 
varying proportions of CD45+ cells (10 - 30 %)20. Stem cell characteristics of rat MSC, 
concerning frequency of CFU-F and osteoprogenitors, have been already studied12,18,23. 
However, detailed surface marker characterization on early-passage-rat MSC is still missing.  
Characteristic non-integrin adhesion receptors 
CD45- cells from our cultures were positive for CD90, CD44 and CD106, being 
characteristic markers for MSC. It is known that CD106 interacts with CD49d/CD29 (α4β1 
integrin, VLA-4) and α4β7 integrin playing an important role in leukocyte extravasation24. Through 
CD49d/CD29 CD106 also promotes early hematopoietic cell adhesion on human MSC25.  
CD44 was expressed by both CD45- MSC and CD45+ HC. The presence of CD44 on 
human MSC distinguishes them from CD44- bone marrow fibroblasts26. CD44 is also weakly 
expressed on osteoblasts, but stronger on osteocytes and osteoclasts. Its role in bone biology 
is still poorly known 4,27. The receptor is important in cell adhesion to hyaluronate, laminin, 
collagen and[MSOffice39] fibronectin4. It is involved in leukocyte attachment and rolling on 
endothelial cells, homing to the peripheral lymph organs and sites of inflammation and 
leukocyte aggregation28. Similarly it was shown that CD90 interacts with CD11b/CD18 in 
leukocyte adhesion to endothelium29. The Ig superfamily glycoprotein CD90 is rat Thy-1 
antigen, and a commonly stated marker for progenitor cell types30,31. It was highly expressed 
on our CD45- MSC, confirming their progenitor character and weakly or not on CD45+ HC 
suggesting the presence of more mature cells. 
Another marker, known to be expressed by human MSC and osteoblasts is CD54 
(ICAM-1)32,33. We detected high expression of this marker on both, CD45+ HC and CD45- 
MSC. In rat it was found on vascular endothelium in lymphoid tissues, thymic stromal cells, 
monocytes, macrophages, mast cells and weakly on peripheral lymphocytes34,35. CD54 is a 
ligand for the hematopoietic integrins CD11a/CD18 and CD11b/CD18, and, additionally, 
together with CD106, CD54 may play a role in the interactions of osteoclast precursors with 
stromal cells in the bone marrow microenvironment4. 
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CD106, CD44, CD90 and CD54 can all promote cell-cell adhesion, and, whether 
expressed by CD45- MSC or CD45+ HC, might contribute to the secondary “adherence” of 
HC to the already adherent cells in our cultures. Leukocyte integrins (CD11a, CD11b and 
CD11c/CD18) in general appear to mediate the attachment that accompanies rolling and 
conversion of leukocytes from circulating cells to adherent tissue cells. By that leukocyte 
integrins are activated, and the endothelium expresses increased amounts of CD545. Similar 
interactions have been suggested between MSC and hematopoietic stem cells in the bone 
marrow and in the culture, since the adhesion receptor pattern on MSC is comparable to that 
on endothelial cells36. 
 
β1- and β3 associated integrins on MSC and HC 
CD29 is integrin subunit β1 and is expressed on the cell surface as a heterodimer with one 
of the distinct integrin α chains. With CD49a through CD49f (α1 through α6), it forms the VLA 
(very late antigen) complexes (VLA-1, etc.), which are adhesion receptors for various extracellular 
matrix proteins e.g. collagens, fibronectin, laminin, vitronectin, osteopontin. As a result, CD29 has a 
broad tissue distribution, including lymphocytes, endothelia, smooth muscle, and epithelia37 and 
plays an important role in cellular processes, including embryogenesis and hematopoietic stem cell 
development3. Therefore it was expected that both types of cells found in our cultures expressed 
CD29, though CD45- cells expressed CD29 stronger than CD45+ cells.  
Among the tested α subunits of CD29 complexes, we found CD49a (α1) to be stronger 
expressed on CD45- MSC than on CD45+ HC. CD49a/CD29 is a receptor for collagens 1, collagen 
4 and laminin38, and it promotes proliferation upon activation39. CD49a positive selection of human 
MSC from fresh bone marrow results in plastic-adherent CD45+ and CD45- colonies40 correlating 
with our observations, that both, CD45+ and CD45- cells expressed this marker. CD49a is 
otherwise expressed on activated T cells, monocytes, smooth muscle cells and endothelial cells41. 
Another collagen receptor, CD49b/CD29, was only weakly expressed on CD45- MSC, whereas it 
was not expressed on CD45+ cells. CD49b/CD29 is a receptor for laminin and collagens 1 to 438. In 
rat it is expressed on activated lymphocytes, epithelial cells and platelets41. CD49b is connected with 
matrix remodeling, collagenase gene expression in osteoclasts and regulating collagen type I and 
other osteogenic marker expression in osteoblasts4,39. We tested 2 lots of Ha1/29 antibodies and the 
level of CD49b integrin expression was low or negative by both lots (data shown for one lot only). 
The third collagen receptor CD49c/CD29 was expressed only on CD45- MSC and not on CD45+ 
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HC. Almost all cultured cell lines express CD49c, as well as basal epidermal cells, epithelial cells, B 
lymphocytes, monocytes, platelets, hematopoietic progenitor cells, and early osteoblastic cells4,46. It 
binds fibronectin, collagen 1, laminin and some other proteins38. 
The fibronectin receptor CD49e/CD29 (α5β1) is an often studied integrin, with a proven 
role in extracellular fibronectin assembling43. We found CD49e to be strongly expressed on both 
cell populations, CD45+ and CD45-, which is in agreement with the broad cellular distribution of 
this integrin. CD49e is also strongly expressed by human MSC33,36. CD49e/CD29 binding appears 
to be necessary for osteoprogenitor cell survival and bone development4. 
Integrin subunit CD61 (β3) was detected only on CD45- MSC and not on CD45+ HC from 
our cultures. It associates with subunit CD51 (αV) to form the vitronectin receptor and with CD41 
(αIIb) chain to form the gpIIb/IIIa complex44. Both receptors mediate adhesion to fibronectin, 
fibrinogen, vitronectin, trombospondin, von Willebrand factor, and CD51/CD61 also to 
thrombospondin, osteopontin and bone sialoprotein 138,44. It was shown that CD51/CD61 also binds 
to endothelial CD31/PECAM51. In rat CD61 is expressed on platelets46, megacaryocytes47, T 
lymphocytes48 and on granulocytes49. The importance of CD61 for bone formation can be assumed, 
since human MSC33, as well as MSC derived osteoblasts and HC derived osteoclasts express this 
marker3.  
Characterization of plastic-adherent hematopoietic cells 
Hematopoietic cells in our cultures were positive for other general leukocyte / myeloid 
markers like integrin subunits CD11b/c and CD11a. CD18 (β2) integrin forms a heterodimer with 
any of the three distinct CD11 α subunits (CD11a or αL, CD11b or αM, CD11c or αX) to form, 
respectively, LFA-1, Mac-1 and gp150,9535. Like CD45, CD11a/CD18 is also found on the 
majority of the leukocytes and mediates a variety of heterotypic and monotypic intercellular 
adhesions through interaction with CD54 and CD10235. Beside cell-cell adhesion, CD11b/CD18 
mediates binding to fibrinogen and some other proteins5. The OX-42 (anti CD11b/c) antibody reacts 
with the CR3 complement (C3bi) receptor, found on most monocytes, granulocytes, macrophages 
and dendritic cells34,35. It appears to recognize a common epitope, shared by CD11b and CD11c 
(integrin αM and αX chains)35, mature and immature cells. CD45+ HC were further negative for 
CD3, CD4, CD45RA, CD161a and a granulocyte marker50, which lead us to assume that our 
CD45+ cells represent a mixed cell population of mature and immature cells of the myeloid lineage, 
including monocytes, macrophages and their progenitor cells50. 
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Adhesion of MSC and hematopoetic cells (HC) to ECM 
After isolation, cell attachment to culture surfaces in vitro is usually mediated by 
adhesion proteins contained in serum-supplemented medium. Beside unspecific adhesion to 
tissue culture polystyrene, the initial adhesion and spreading of osteoblastic and various other 
cell types depends primarily on adsorbed vitronectin and fibronectin51, whereas hematopoietic 
cells adhere also on other serum proteins (e.g. serum IgG, von Willebrand factor52). Both cell 
populations found in our cultures expressed among ECM-binding integrins fibronectin-
binding integrin CD49e/CD29 strongly and MSC additionally vitronectin-binding integrin 
subunit CD61. The expression of these integrins could be both, the reason for cell adherence 
or the consequence of culture conditions used in this study51. The adhesion experiments 
showed that CD45-, as well as CD45+ cells adhered strongly to tissue culture polystyrene in 
the presence of FBS.  
The adherence of CD45- MSC correlated well with the level of distinct integrin 
expression, determined by flow cytometry. Among tested ECM coatings, CD45- cells adhered 
to fibronectin, followed by collagen IV, collagen I and vitronectin, similar as it was reported 
for human MSC53.  
Also CD45+ HC adhered in the correlation to their integrin expression. CD45+ cells 
showed only low expression of integrins alpha 1, alpha 2, and alpha 3, and consequently 
didn’t adhere to a relevant extent to collagen I, collagen IV and laminin. Shen and Horbett54 
showed that blood monocytes adhere to a similar proportion to the uncoated tissue culture 
polystyrene (TCPS), or to TCPS coated with serum, fibronectin or BSA, which is comparable 
to our observations of CD45+ HC adhesion. However, due to the smaller size of CD45+ HC 
(Figure 6), we hit upon the assay detection limit, resulting from lower dye uptake per cell. 
Generally CD45+ HC adhered to a lesser extent than CD45- MSC. Additionally, the 
separation procedure might have reduced the HC adhesion. Therefore, no statistical 
significant differences in adhesion of CD45+ HC could be proved. Nevertheless, the results 
shown in Figure 4b could be confirmed with optical observations, as shown on representative 
photographs of CD45+ cells on vitronectin and collagen I coated wells (Fig. 4c and 4d). 
However, we detected no expression of CD61 by CD45+ HC, known to mediate the adhesion 
of HC to vitronectin38. Some additional studies would help us to precisely analyze vitronectin-
receptor expression on HC, before we can exclude CD61- or CD51-involved adhesion to 
vitronectin.  
Breda Vogel 
 100
The data on CD29- and CD61- associated integrin expression allow for the following 
assumptions. Whereas surfaces with immobilized vitronectin or fibronectin would not cause 
the adhesion of desired CD45- MSC only, but also adhesion of undesired CD45+ HC, we 
expected a more selective adhesion to collagen-coated surfaces mediated by collagen / 
laminin integrins, if CD29 integrin-independent binding mechanisms55,56 remain negligible. 
Adhesion experiments confirmed our expectations, because HC didn’t adhere to collagen I or 
IV. Therefore collagen I and IV could serve as selective substrates for MSC adhesion. 
However, it is necessary to keep in mind that HC do not only attach via ECM, but also by 
cell-cell interactions. Nevertheless, a decrease in HC adhesion to a substrate appears to be 
possible by a proper substrate choice, e.g. collagens. 
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CONCLUSION 
In vitro studies on communication between MSC and HC can help us to better understand 
observed effects in vitro and maybe some in vivo circumstances in which cells normally 
function. For their maintenance the cells use integrins and other adhesion receptors to 
communicate with ECM and other cells. We found that some hematopoietic cells from the 
bone marrow remain adherent in primary rat MSC cultures. They may use different 
mechanisms than MSC to adhere, since they express a different pattern of adhesion 
molecules. Our adhesion experiments showed that collagen coated surfaces represent 
substitutes for selective CD45- MSC adhesion. Apart from that, in this study rat MSC were 
characterized by means of surface marker expression in an extend that brings the 
characterization of rat MSC a step closer to human and mouse MSC.  
Breda Vogel 
 102
REFERENCES 
    (1)  Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast 
colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell 
Tissue Kinet. 1970;3:393-403. 
 (2)  Knight MA, Evans GR. Tissue engineering: progress and challenges. Plast Reconstr 
Surg. 2004;114:26E-37E. 
 (3)  Schaffner P, Dard MM. Structure and function of RGD peptides involved in bone 
biology. Cell Mol Life Sci. 2003;60:119-132. 
 (4)  Horton MA, Nesbitt SA, Bennett JH, Stenbeck G. Integrins and Other Cell Surface 
Attachment Molecules of Bone Cells. In: Bilezikian JB, Raisz LG, Rodan GA, eds. 
Principles of Bone Biology. San Diego, San Francisco, New York, Boston, London, 
Sydney, Tokio: Academic Press; 2002:265-286. 
 (5)  Ruoslahti E. Integrins. J Clin Invest. 1991;87:1-5. 
 (6)  Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological 
characterization. The International Journal of Biochemistry & Cell Biology. 
2004;36:568-584. 
 (7)  Deans RJ, Moseley AB. Mesenchymal stem cells: Biology and potential clinical uses. 
Experimental Hematology. 2000;28:875-884. 
 (8)  Prockop D.J. Marrow stromal cells as stem cells for nonhematopoetic tissues. Science 
276, 71-74. 1997.  
 (9)  Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca RD et al. 
Multilineage Potential of Adult Human Mesenchymal Stem Cells . Science 284, 143-
147. 1999.  
 (10)  Gronthos S, Simmons PJ, Graves SE, Robey PG. Integrin-mediated interactions 
between human bone marrow stromal precursor cells and the extracellular matrix. 
Bone. 2001;28:174-181. 
 (11)  Majumdar MK, Keane-Moore M, Buyaner D et al. Characterization and functionality 
of cell surface molecules on human mesenchymal stem cells. J Biomed Sci. 
2003;10:228-241. 
 (12)  Javazon EH, Colter DC, Schwarz EJ, Prockop DJ. Rat marrow stromal cells are more 
sensitive to plating density and expand more rapidly from single-cell-derived colonies 
than human marrow stromal cells. Stem Cells. 2001;19:219-225. 
 (13)  ter Brugge PJ, Torensma R, De Ruijter JE, Figdor CG, Jansen JA. Modulation of 
integrin expression on rat bone marrow cells by substrates with different surface 
characteristics. Tissue Eng. 2002;8:615-626. 
 (14)  Lieb E, Milz S, Vogel T et al. Effects of transforming growth factor beta1 on bonelike 
tissue formation in three-dimensional cell culture. I. Culture conditions and tissue 
formation. Tissue Eng. 2004;10:1399-1413. 
 (15)  Crevensten G, Walsh AJ, Ananthakrishnan D et al. Intervertebral disc cell therapy for 
regeneration: mesenchymal stem cell implantation in rat intervertebral discs. Ann 
Biomed Eng. 2004;32:430-434. 
Chapter 4: Towards selective adhesion of marrow stromal cells: phenotype characterization  
and adhesive properties of plastic adherent rat bone marrow cells 
 
 103
 (16)  Neubauer M, Fischbach C, Bauer-Kreisel P et al. Basic fibroblast growth factor 
enhances PPARgamma ligand-induced adipogenesis of mesenchymal stem cells. 
FEBS Lett. 2004;577:277-283. 
 (17)  ter Brugge PJ, Jansen JA. In vitro osteogenic differentiation of rat bone marrow cells 
subcultured with and without dexamethasone. Tissue Eng. 2002;8:321-331. 
 (18)  Dobson KR, Reading L, Haberey M, Marine X, Scutt A. Centrifugal isolation of bone 
marrow from bone: an improved method for the recovery and quantitation of bone 
marrow osteoprogenitor cells from rat tibiae and femurae. Calcif Tissue Int. 
1999;65:411-413. 
 (19)  Diaz-Romero J, Gaillard JP, Grogan SP et al. Immunophenotypic analysis of human 
articular chondrocytes: Changes in surface markers associated with cell expansion in 
monolayer culture. J Cell Physiol. 2004. 
 (20)  Ahmed N. VB, Rohde E, Strunk D, Schulz MB, Grifka J, Grässel S. CD45-positive 
cells of hematopoietic origin enhance chondrogenic marker gene expression in rat 
marrow stromal cells. Chapter 2.  
 (21)  Wang QR, Wolf NS. Dissecting the hematopoietic microenvironment. VIII. Clonal 
isolation and identification of cell types in murine CFU-F colonies by limiting 
dilution. Exp Hematol. 1990;18:355-359. 
 (22)  Herbertson A, Aubin JE. Cell sorting enriches osteogenic populations in rat bone 
marrow stromal cell cultures. Bone. 1997;21:491-500. 
 (23)  Aubin JE. Osteoprogenitor cell frequency in rat bone marrow stromal populations: 
role for heterotypic cell-cell interactions in osteoblast differentiation. J Cell Biochem. 
1999;72:396-410. 
 (24)  Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol. 
1993;11:767-804. 
 (25)  Patrick CW, Jr., Juneja HS, Lee S, Schmalstieg FC, McIntire LV. Heterotypic 
adherence between human B-lymphoblastic and pre-B-lymphoblastic cells and 
marrow stromal cells is a biphasic event: integrin very late antigen-4 alpha mediates 
only the early phase of the heterotypic adhesion. Blood. 1995;85:168-178. 
 (26)  Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of 
mesenchymal stem cells: functional discrimination between cellular responses to 
alloantigens and recall antigens. J Immunol. 2003;171:3426-3434. 
 (27)  Reyes-Botella C, Montes MJ, Vallecillo-Capilla MF, Olivares EG, Ruiz C. Antigenic 
phenotype of cultured human osteoblast-like cells. Cell Physiol Biochem. 
2002;12:359-364. 
 (28)  Cuff C, Kothapalli D, Azonobi I, Chun S, Zhang Y, Belkin R et al. The Adhesion 
Receptor CD44 Promotes Aterosclerosis by Mediating Innflamatory cell Recruitment 
and Vascular Cell Activation. J.Clin.Invest. 108, 1031-1040. 2001.  
 (29)  Wetzel A, Chavakis T, Preissner KT et al. Human Thy-1 (CD90) on activated 
endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 
(CD11b/CD18). J Immunol. 2004;172:3850-3859. 
 (30)  Lucas T, Krugluger W, Samorapoompichit P et al. Self-renewal, maturation, and 
differentiation of the rat myelomonocytic hematopoietic stem cell. FASEB J. 
1999;13:263-272. 
Breda Vogel 
 104
 (31)  Crook K, Hunt SV. Enrichment of early fetal-liver hemopoietic stem cells of the rat 
using monoclonal antibodies against the transferrin receptor, Thy-1, and MRC-OX82. 
Dev Immunol. 1996;4:235-246. 
 (32)  Horton MA, Nesbitt SA, Benett JH, Stenbeck G. Integrins and Other Cell Surface 
Attachment Molecules of Bone Cells. Principles of Bone Biology. 2002:265-286. 
 (33)  Minguell JJ, Erices A, Conget P. Mesenchymal Stem Cells. Experimental Biology and 
Medicine. 2001;226:507-520. 
 (34)  Banuls MP, Alvarez A, Ferrero I, Zapata A, Ardavin C. Cell-surface marker analysis 
of rat thymic dendritic cells. Immunology. 1993;79:298-304. 
 (35)  Tamatani T, Kotani M, Miyasaka M. Characterization of the rat leukocyte integrin, 
CD11/CD18, by the use of LFA-1 subunit-specific monoclonal antibodies. Eur J 
Immunol. 1991;21:627-633. 
 (36)  Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac 
therapeutics. Circ Res. 2004;95:9-20. 
 (37)  Springer TA. Adhesion receptors of the immune system. Nature 346, 425-434. 1990.  
 (38)  Anselme K. Osteoblast adhesion on biomaterials. Biomaterials. 2000;21:667-681. 
 (39)  Heino J. The collagen receptor integrins have distinct ligand recognition and 
signaling functions. Matrix Biol. 2000;19:319-323. 
 (40)  Deschaseaux F, Gindraux F, Saadi R et al. Direct selection of human bone marrow 
mesenchymal stem cells using an anti-CD49a antibody reveals their CD45med,low 
phenotype. Br J Haematol. 2003;122:506-517. 
 (41)  Hemler ME, Huang C, Schwarz L. The VLA protein family. Characterization of five 
distinct cell surface heterodimers each with a common 130,000 molecular weight beta 
subunit. J Biol Chem. 1987;262:3300-3309. 
 (42)  Takada Y, Murphy E, Pil P et al. Molecular cloning and expression of the cDNA for 
alpha 3 subunit of human alpha 3 beta 1 (VLA-3), an integrin receptor for fibronectin, 
laminin, and collagen. J Cell Biol. 1991;115:257-266. 
 (43)  Magnusson MK, Mosher DF. Fibronectin: structure, assembly, and cardiovascular 
implications. Arterioscler Thromb Vasc Biol. 1998;18:1363-1370. 
 (44)  Kieffer N, Phillips DR. Platelet membrane glycoproteins: functions in cellular 
interactions. Annu Rev Cell Biol. 1990;6:329-357. 
 (45)  Piali L, Hammel P, Uherek C et al. CD31/PECAM-1 is a ligand for alpha v beta 3 
integrin involved in adhesion of leukocytes to endothelium. J Cell Biol. 1995;130:451-
460. 
 (46)  Ashkar S, Weber GF, Panoutsakopoulou V et al. Eta-1 (osteopontin): an early 
component of type-1 (cell-mediated) immunity. Science. 2000;287:860-864. 
 (47)  Miao D, Murant S, Scutt N, Genever P, Scutt A. Megakaryocyte-bone marrow stromal 
cell aggregates demonstrate increased colony formation and alkaline phosphatase 
expression in vitro. Tissue Eng. 2004;10:807-817. 
 (48)  Moulder K, Roberts K, Shevach EM, Coligan JE. The mouse vitronectin receptor is a 
T cell activation antigen. J Exp Med. 1991;173:343-347. 
Chapter 4: Towards selective adhesion of marrow stromal cells: phenotype characterization  
and adhesive properties of plastic adherent rat bone marrow cells 
 
 105
 (49)  Frieser M, Hallmann R, Johansson S et al. Mouse polymorphonuclear granulocyte 
binding to extracellular matrix molecules involves beta 1 integrins. Eur J Immunol. 
1996;26:3127-3136. 
 (50)  Vogel B, Vogel T, Rohde E, Strunk D, Goepferich A, Schulz MB. Myeloid Cells 
Supress in vitro Osteogenic Differentiation of Rat Mesenchymal Progenitor Cells.  
Chapter 3.  
 (51)  Wilson CJ, Clegg RE, Leavesley DI, Pearcy MJ. Mediation of biomaterial-cell 
interactions by adsorbed proteins: a review. Tissue Eng. 2005;11:1-18. 
 (52)  Jenney CR, Anderson JM. Adsorbed serum proteins responsible for surface dependent 
human macrophage behavior. J Biomed Mater Res. 2000;49:435-447. 
 (53)  Conget PA, Minguell JJ. Phenotypical and functional properties of human bone 
marrow mesenchymal progenitor cells. J Cell Physiol. 1999;181:67-73. 
 (54)  Shen M, Horbett TA. The effects of surface chemistry and adsorbed proteins on 
monocyte/macrophage adhesion to chemically modified polystyrene surfaces. J 
Biomed Mater Res. 2001;57:336-345. 
 (55)  Koenigsmann M, Griffin JD, DiCarlo J, Cannistra SA. Myeloid and erythroid 
progenitor cells from normal bone marrow adhere to collagen type I. Blood. 
1992;79:657-665. 
 (56)  Garnotel R, Rittie L, Poitevin S et al. Human blood monocytes interact with type I 
collagen through alpha x beta 2 integrin (CD11c-CD18, gp150-95). J Immunol. 
2000;164:5928-5934. 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER 5 
PILOT STUDY TO MODULATE INTEGRIN 
EXPRESSION ON RAT MARROW  
STROMAL CELLS 
Breda Vogel1,2, Thomas Vogel2, Achim Göpferich1  and Michaela B. Schulz2 
1 Department of Pharmaceutical Technology, University of Regensburg, Germany 
2
 Institute of Pharmaceutical Sciences, Pharmaceutical Technology, Karl-Franzens 
University Graz, Austria 
 
Breda Vogel 
 108
INTRODUCTION 
The objective of this pilot study was to find ways to modulate the expression of cell 
adhesion receptors in order to investigate if we can modulate and improve marrow stromal cell 
(MSC) adhesion to peptides and matrices used in tissue engineering. It is known that integrins and 
growth factor receptors “communicate” with each other. When integrins are clustered and activated 
by extracellular matrix (ECM) proteins, they also recruit growth factor receptors and can amplify 
the signaling effect of growth factors. This synergy is important in cell cycle progression and cell 
migration1. It has been reported that vice versa supplementation with certain cytokines and growth 
factors can change the integrin expression pattern2,3. Hence, we used this approach to modulate 
integrin expression in CD45-negative rat MSC. Transforming growth factor-β1 (TGF- β1) has 
already been successfully used for improvement of collagen 1 production in rat MSC cultures and 
was therefore considered as an interesting candidate for this study4,5. Furthermore, we evaluated the 
influence of platelet-derived growth factor (PDGF), for which it has been shown to enhance 
osteoprogenitor cell proliferation6. Atorvastatin, a lipid-lowering drug with osteoinductive 
properties7, was also tested in this study. 
It is known that with progression of differentiation cells can change their integrin expression 
pattern1. Along these lines, dexamethasone, which induces osteogenic differentiation, is known to 
cause changes in integrin expression1. Cultured osteoblasts, for example, express high levels of 
vitronectin integrins αVβ3 and αVβ51,8,9. Their adhesion can therefore be enhanced by surface 
immobilization of cyclic RGD peptides (cRGDfK)10 selective for these integrins. Many integrins 
show RGD-dependent binding, though some other binding sequences have been found and could be 
therefore used to enhance cell adhesion; e.g. DGEA and GER for integrin α2β1 and EILDV for 
α4β1 integrin11.  
Since the published data are derived from different methods of analysis, no truly useful 
information about modulating integrin expression during MSC osteogenesis is available. In addition 
to immunohistochemistry and gene expression analysis, flow cytometry can also be used. Rat MSC 
already express β3 integrin12, but in contrast to osteoblasts, they do not adhere well to RGD-
modified polymer films10; two possible reasons can be hypothesized: low integrin expression or 
insufficient ligand density13. The aim of this pilot study was to find out if the addition of growth 
factors and the supplementation with the differentiating medium can increase β3 integrin expression 
or change the expression of other integrins in a way that may be useful for selective surface 
modification of biomaterials. 
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MATERIALS AND METHODS 
Suppliers 
Fetal calf serum (Gibco, Invitrogen, UK; Lot No.: 40F7430K); Penicillin-Streptomycin (Gibco, 
Invitrogen, UK; 10,000 units / mL penicillin G sodium and 10,000 µg / mL streptomycin sulphate); 
L-glutamine (Sigma Aldrich, Germany; 200 mM); Trypsin-EDTA (Gibco, Invitrogen, UK; 0.25 % 
Trypsin and 1mM EDTA.4Na); Minimum essential medium Eagle, alpha modification (Sigma 
Aldrich, Germany; 10.1 g / L); simvastatin (MSD, Germany); atorvastatin (Pfizer, USA). 
Cell culture 
Rat bone marrow was isolated from the femur and tibia of 6- to 8-week-old (150-200 g) male 
Sprague-Dawley rats by the centrifugal method14. Freshly isolated bone marrow cells were 
resuspended in primary medium (10 % FCS, 1 % Penicillin/Streptomycin, 0.5 % L-glutamine and 
minimal essential medium, alpha modification). Cells obtained from one rat (2 tibias and 2 femurs) 
were seeded in four T150 flasks. The cells were cultured in a humidified atmosphere with 5 % CO2 
at 37°C and left to adhere 3 days before non-adherent cells were removed. Media was changed 3 
times a week and when the cultures reached 80 - 100 % confluence, cells were detached from the 
surface with trypsin-EDTA and counted. 
Modulation of integrin expression 
After seven days, primary culture cells were depleted of CD45-positive cells by the 
immunomagnetic procedure (described in Chapter 4). CD45-negative cells were seeded at a density 
of 1 x 106 per T150 flask for 24 hours in primary media. Thereafter cells received complete 
differentiation media (primary medium supplemented with 50 mg / L ascorbic acid, 7 mM β-
glycero-phosphate and 10 nM dexamethasone) supplemented with either growth factors or statins. 
Control cultures were grown in primary media. We added platelet-derived growth factor (PDGF-
BB; 20 ng / mL, R&D systems, USA), transforming growth factor-beta1 (TGFβ1; 1 ng / mL; Tebu-
Bio, Offenbach, Germany), and atorvastatin (5 µM, Pfizer, USA). On the 4th day, cells were 
detached with trypsin-EDTA and the expression of various integrins was determined by flow 
cytometry (see Chapter 4 for detailed description). 
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RESULTS 
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Figure 1: Flow cytometric data on the influence of various growth factors and statin on MSC 
integrin expression after supplementation with PDGF (20 ng / mL), TGFβ1 (1 ng / mL), and 
atorvastatin (5 µM). Primary cultures of rat bone marrow cells were depleted of CD45+ cells 
(MACS); CD45- MSC were seeded in T150 flasks (1 x 106 cells / flask) and cultured for 4 
days in supplemented media until analyzed. Gray bars: % positive cells; white bars: level of 
marker expression. 
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Influence of PDGF, TGF-β1 and statins on integrin expression 
None of the supplements had an influence on the expression of integrin β1 (CD29), and α2 
(CD49b) as shown in Figure 1. The expression of α1 (CD49a) in all secondary cultures, was lower 
than the expression in primary cultures, which was 74.9 ± 13 %12. Supplementation of osteogenic 
medium with PDGF, TGFβ1 and atorvastatin caused a slight reduction of the α1 (CD49a) 
expression. All cells cultured in complete media showed increased α4 (CD49d) expression, 
compared to cells cultured in primary media. On the contrary, β3 (CD61) expression was lower in 
cultures with complete media than in primary media. 
Influence of PDGF, TGF-β1 and statins on cell proliferation 
Cell proliferation for all tested conditions was determined as well (Figure 2). We saw 
that complete media slowed down the proliferation, but the addition of PDGF caused even 
faster expansion than primary media.  
Cell number per T150 flask 
0.E+00
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2.E+06
3.E+06
4.E+06
5.E+06
primary 0 PDGF TGFb1 Ator.
complete medium
 
Figure 2: Proliferation of CD45- MSC in primary medium or in complete medium 
supplemented with PDGF (20 ng / mL), TGFβ1 (1 ng / mL), atorvastatin (5 µM). After 
depletion of CD45+ cells, CD45- MSC were seeded in T150 flasks (1x106 cells / flask) and 
cultured for 4 days until analyzed. 
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DISCUSSION 
In this screening study, we tried to find ways to modulate the level of integrin 
expression for subsequent MSC immobilization on surfaces modified with integrin-specific 
peptides, starting with the finding that rat MSC in contrast to human osteoblasts showed only 
sparse adhesion to surfaces modified with cyclic RGD peptide (cRGDfK). This peptide is 
specific for the integrins αVβ3 and αVβ510. The poor adhesion could be due to lower 
expression of specific integrins on rat MSC. Hence, we determined β3 (CD63) expression in 
primary cultures of rat MSC12 (Chapter 4) and compared this to results obtained in this study. 
While CD45-negative cells from primary cultures contained 56.0 ± 20.5% CD61-positive 
cells, about 85% of the cells were positive for this integrin when further cultured in primary 
medium. Similar results were found in complete medium in the presence of TGF-β1, while 
less cells expressed this marker in complete medium alone or with PDGF and atorvastatin 
supplementation (Figure 1). Nevertheless, CD61 is expressed in human osteoblasts, as well as 
in osteoclasts11 and its in vitro expression seems to rely on culture conditions, especially 
supplementation with serum, which includes CD61-binding protein, vitronectin9. It has been 
suggested that osteoblasts do not express integrin αVβ3 in vivo, but express it only under 
certain in vitro culture conditions9. It is known that some differentiated cells, like 
chondrocytes, lose their phenotype after isolation and 2-dimensional culturing 
(dedifferentiation). Therefore, higher expression of CD61 could correlate with lower 
differentiation grade of the cells in our experiments. Nevertheless, further studies could 
confirm these observations.  
Interestingly, the expression of α4 (CD49d) was increased in the osteogenic media 
cultures, compared to primary and secondary cultures in proliferation media (Chapter 4). 
CD49d is expressed in osteoblasts8 and could be, based on our observations, an early marker 
for osteogenic differentiation. The most interesting results were obtained when the cultures 
were treated with PDGF: (1) cells showed very high CD49d expression, and (2) the cell 
number was twice as high as without PDGF. The cell number in PDGF treated group was 
even higher than in the control group with primary medium (no osteogenic treatment). 
Although the data presented here are only preliminary, they show some interesting results, 
especially in the case of CD49d.  
Concerning the expression of collagen integrins CD49a/α1 and CD49b/α2, opposing 
roles have been described; whereas α1 is connected with cell proliferation, α2 is coupled with 
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osteogenic differentiation15. We detected no significant differences in α2 expression 
compared to primary CD45- cells (Chapter 4). On the other hand, α1 expression was lower in 
all secondary cultures than in primary cultures (Chapter 4), without significant differences 
between groups. In some cases, the reduction of α1 expression could be connected with 
increased α4 expression (Figure 1), however studies have to be repeated to precisely evaluate 
these findings. 
Overall, we conclude that the experimental setup to study differences in surface 
marker expression was appropriate. As discussed in previous chapters, the primary cultures 
were always contaminated with CD45-positive hematopoietic cells, which can influence MSC 
proliferation and differentiation16. We therefore isolated CD45-negative cells and cultured 
them further. This isolation also eliminated the need for simultaneous staining of 
hematopoietic cells for flow cytometry. It is known that high density culturing or 100% cell 
confluence also induces osteogenesis17. A single cell suspension from tightly packed cells, 
obtained using trypsin-EDTA or Accutase® (PAA, Pasching, Austia), yielded results not 
significantly different from primary culture cells (data not shown). We speculate that using 
detachment methods designed for less confluent monolayer cultures resulted in the 
detachment of cells from the periphery only, which are probably less differentiated than cells 
from the center of bone nodules17. We therefore decided to grow the cells at lower cell density 
and only for a short time, to prevent cell-cell contacts and to avoid cell-aggregate formation. 
Integrins play an important role in cell biology, since each integrin has a specific 
effect on cell proliferation and differentiation. The role of integrins differs from cell type to 
cell type. Here we demonstrated how the integrin expression pattern could be modulated with 
changes in culture media and then detected by flow cytometry. Future studies that monitor 
integrin expression, cell adhesion, proliferation and differentiation simultaneously will give us 
further insight into how to regulate integrin expression and the impact of integrin expression 
level changes on cells in culture. 
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INTRODUCTION 
The rat was one of the first animals from which mesenchymal stem / progenitor cells (MSC) 
were isolated. Despite of this, detailed phenotype characterization of rat MSC is still not complete. 
The frequency of colony-forming unit fibroblasts (CFU-F) has been determined in primary and 
secondary cultures of rat bone marrow cells1, which are known to be contaminated with adherent 
endothelial and hematopoietic cells (HC)2,3. Surface marker characterization was performed on 
cells after 5 passages4, because HC are lost from cultures after multiple passages and that 
clonogenic cells are enriched with rapid passaging. The problem with characterizing MSC is that 
they are usually described as cultured cells that can change their phenotype with extensive 
subculturing. Cultured cells express some typical markers like vitronectin receptor-integrin αVβ3 
and/or α3 integrin subunit5,6. Markers such as these are likely the result of culturing the cells in 
the presence of fetal bovine serum (FBS) containing vitronectin and fibronectin, which mediate 
cell adhesion to the culture surface5,6.  
The standard protocol for rat MSC isolation uses whole bone marrow isolated from femurs 
and tibias of an animal. Until recently, a flushing method was used to flush the bone marrow from 
bones using a syringe and media7. Dobson et al.8 showed that bone marrow could be easily 
isolated by centrifuging the bones, with the CFU-F yield increased 100 % compared to the 
flushing method. We compared both methods and our results confirmed published data (data not 
shown). Furthermore, contamination with hematopoietic cells was not elevated using the 
centrifugal method (data not shown).  
Since bone tissue engineering requires several dozens of millions of cells for 3-dimensional 
experiments, enrichment and expansion of MSC in the shortest amount of time is needed. As 
observed in our previous study (Chapter 2), contamination with HC cannot be diminished by 
simply varying adherence time after cell isolation. One successful alternative for isolation of a 
pure MSC population is immunomagnetic depletion of HC using magnetic-associated cell sorting 
(MACS). However, this method can be expensive if routinely used, especially if large numbers of 
cells need to be separated. Therefore, isolation of MSC from cultures earlier than day 7, such as 
day 3, could be more cost-effective. Another option for MSC enrichment would be subculturing 
over several passages. However, cell culture and cell adhesion are both known to alter antigen 
expression9. For studies on the adhesive properties of MSC, the integrin expression pattern of 
cells used for the experiments needs to be unchanged and to this end we examined the surface 
marker expression of adherent cells after 3 days in culture, cells of the first passage and of cells 
passaged for four times. 
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Most of the commercially available antibodies for flow cytometry were developed for the 
characterization of hematopoietic cells, which are most commonly isolated from blood or bone 
marrow. Freshly isolated cells, however, have different characteristics than cultured cells; they are 
on average smaller, and can be divided into granulocyte, monocyte and lymphocyte fractions 
based upon size and granularity (Figure 1, left panel). Freshly isolated blood or bone marrow cells 
are also not typically adherent, whereas when analyzing cultured cells, adherent cells need to be 
first detached from the surface using enzymatic or other methods, which can “damage” surface 
antigens. Hematopoietic cell surface marker expression is better characterized than that of 
cultured MSC, therefore freshly isolated bone marrow cells were used as a positive control to 
determine the optimal concentration of antibodies to use in our flow cytometry experiments for 
MSC characterization. The phenotype of rat MSC freshly isolated by the indirect selection 
method is still largely unknown9. 
Rat bone marrow is often analyzed to evaluate preclinical and toxicological effects of diverse 
therapies on the hematopoietic system10. Microscopic evaluation of rat bone marrow (smear) 
shows that the HC ratio in normal bone marrow between myeloid and erythroid cells is between 
1.07 and 1.93. Variations in this ratio can indicate abnormalities in hematopoiesis10. Rat 
megakaryocytes are the largest hematopoietic cells, with a frequency of 0.40 - 0.77 % of total 
nucleated cells in rat bone marrow10. Reported percentages of erythroid precursors in rat bone 
marrow vary from 20 % to almost 40 % of nucleated cells, whereas myeloid/granulocyte 
precursors comprise 33.6 - 52%. Monocytes and their precursors are present in low numbers in 
healthy rat bone marrow, in contrast to lymphocytes, which comprise 7.34 to 21.10 % of total 
nucleated cells10. Non-hematopoietic cells in the bone marrow include mast cells (1 %), 
osteoblasts and osteoclasts, as well as endothelial cells10. These data are based on cell morphology 
and could be improved with differential cell staining using antibodies against some typical rat cell 
antigenes. An overview of rat marker expression is presented in Table 1 (source: BD 
Pharmingen). Flow cytometry, however, could enable to get more precise data, because more 
cells could be evaluated in the shortest time. In our case, the characterization of rat hematopoietic 
cells was inevitable, because they share the same microenvironment with MSC in the bone 
marrow, as well as in vitro, and, hence, could play an important role in MSC biology. 
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This chapter includes: 
1. Characterization of freshly isolated rat bone marrow cells including evaluation of 
percentages of hematopoietic subclasses and estimation of MSC-like cell 
frequency. 
2. Comparison of CD45-negative cells in adherent populations harvested on day 3, 
day 7 and several-times passaged cells (MSC phenotype tracing). 
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MATERIALS AND METHODS 
Suppliers 
Gibco, Invitrogen, UK: Fetal calf serum, FCS (Lot No.: 40F7430K); Penicillin-
Streptomycin (10,000 units / mL penicillin G sodium and 10,000 µg / mL streptomycin 
sulphate); Trypsin-EDTA (0.25 % Trypsin and 1 mM EDTA.4Na); Sigma Aldrich, Germany: 
L-glutamine (200 mM); Minimum essential medium Eagle, alpha modification (α-MEM; 10.1 
g / L); 7-Aminoactinomycin D (7-AAD); Corning, Netherlands: tissue culture flasks. 
Cell isolation and cell culture 
Rat bone marrow was isolated from the femur and tibia of six-week-old male Sprague-
Dawley rats (Institut für Labortierkunde und -genetik Himberg, Medical University Vienna, 
Austria) by the method described in Dobson et al.8. Briefly, femurs and tibias were removed under 
aseptic conditions and cleaned of any muscle and tendon tissue. The bones were cut in the middle 
and the parts distal from knee were discarded. The epiphyses were pierced with an 18 gauge syringe 
and bones placed in Eppendorf tubes with a broad piece of a pipette tip inserted to hold the bone. 
The bones were centrifuged for 1 minute at 400 g and bone marrow cells were resuspended in 
medium, collected using a 23 gauge syringe and centrifuged (5 min at 1350 rpm).  
For the analysis of the bone marrow, freshly isolated bone marrow cells were incubated with 
lysing buffer (0.8 % NH4Cl, pH 7.3) at room temperature for 5 minutes to lyse the erythrocytes5,6, 
followed by two wash steps with PBS. For cell culture, freshly isolated bone marrow cells were 
resuspended in primary medium (10 % FCS, 1 % Penicillin / Streptomycin, 0.5 % L-glutamine and 
α-MEM). Cells obtained from 1 rat (2 tibias and 2 femurs) were seeded in two 150 cm2 (3-day 
adherence only) or four 150 cm2 (3-day adherence and proliferation) flasks and were cultured in a 
humidified atmosphere with 5 % CO2 at 37°C. After adhesion for 3 days, nonadherent cells were 
removed and the adherent fraction washed twice with 16 mL PBS per flask to remove spare 
attached cells. Cells were further cultured with media changes 3 times a week. 
Passage: On day 3 or 7 after cell isolation, the media was removed from the flasks, flasks 
were flushed with 16 mL / flask PBS, and 5 mL / flask 0.2 % trypsin-EDTA was added. The cells 
were left to detach for 5 minutes at 37°C. Trypsin was deactivated by addition of 25 mL primary 
medium. For the analysis of passaged cells (e.g. passage 4), day 7 cells were subcultured with or 
without depletion of CD45+ hematopoietic cells (HC) for several passages. 
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Single-cell suspensions were passed through a 40µm cell strainer, centrifuged, resuspended 
in PBS, counted using a hemacytometer and analyzed with flow cytometry. 
Flow cytometry 
The cell suspension was first incubated for 15 minutes at 4°C with 10% v/v sheep 
serum and then for 30 minutes at 4°C with antibodies against rat CD markers or with 
corresponding isotype controls (Table 1). Cells were washed with PBS containing sodium 
azide and bovine serum albumin and resuspended in the same buffer before measurements. 
Just prior to making measurements, 20 % v/v 7-AAD (20 µg / mL) was added to each sample 
for 3 minutes to stain the dead cells, which were excluded from the evaluation. For cell 
staining with antibody against CD49c, the cells were fixed and permeabilized using a 
Fix&Perm® kit (An der Grub, Kaumberg, Austria) according to the manufacturer’s 
instructions. When staining required incubations with anti-mouse secondary antibodies, anti-
CD45 was added at the end, following a blocking step with normal mouse serum. 
All measurements were preformed on a FACSCalibur® instrument and data acquired 
with CellQuest software (both BD Biosciences, USA). Measurements were evaluated with 
WinMDI 2.8 Software (free access on http://facs.scripps.edu/software.html). A minimum of 
1x104 viable cells was acquired per data set. Positive cells were defined as having a measured 
fluorescence greater than that of 99.5 % of the cells stained with each associated isotype 
control. A population was considered positive for a surface marker when the percentage of 
positive cells for that surface marker was equal to or greater than 5 %11.  
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Figure 1: A: FSC-SSC or size-granularity dot-plot of freshly isolated rat bone marrow cells 
and the distribution of lymphocyte- (R1), monocyte- (R2), and granulocyte-like fraction (R3); 
B: propidium iodine (PI) staining of dead cells detected in 3rd fluorescence channel. LL 
quadrant contains cells negative for both types of fluorescence. The UR quadrant contains cells 
positive for both types of fluorescence. UL and LR are positive for one fluorescence and 
negative for the other one. 
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Table 1: List of antibodies used for flow cytometric characterization of rat cells. 
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RESULTS 
Freshly isolated bone marrow cells 
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Figure 2: Flow cytometric evaluation of rat bone marrow. Measurements to determine % 
positive cells for distinct markers were repeated up to 5 times. Ten thousand events were 
collected for every measurement. 
 
 
To determine the appropriate antibody concentration for flow cytometric applications, 
rat bone marrow and spleen cells were used, since it is known that hematopoietic cells express 
a number of different surface markers. Data on spleen cells are not presented. Additionally, 
rat bone marrow subpopulations were determined. Single measurement results are presented 
in Figure 2. Approximately 60 % of the bone marrow cells expressed CD45. Not all CD45+ 
cells co-expressed hematopoietic integrins (CD11a, b/c) (data not shown). Most cells of the 
granulocyte fraction (high SSC) expressed CD11a, 11b/c and CD18 (Figure 3). Cells positive 
for the granulocyte marker were found in the granulocyte fraction.  
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Figure 3: Flow cytometric rat bone marrow analysis: expression of single markers (green) on 
FSC-SSC dot-plots. The whole bone marrow was subjected to an erythrocyte lysis, therefore 
erythrocytes are not present in the dot-plots.  
 
Almost all cells from bone marrow expressed CD29 and around 70 % expressed CD54 
(ICAM-1; Figure 2). Stem cell marker CD90 was also highly expressed (57 – 68 %), as was CD49d 
(46 %). CD45RA+ cells comprised 18 – 38 % of bone marrow nucleated cells, whereas other more 
mature hematopoietic markers (CD3, CD4, CD8b, CD161a) comprised < 10 %. The presence of 
cells positive for MSC markers CD49a and CD106 in the bone marrow was below 2.5 % and their 
expression as well as size and granularity were broadly distributed. Fewer than 2 % of the cells 
expressed CD49b, 6 % expressed CD49c, and 14-24 % of the cells expressed CD49e. The 
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distribution of rat bone marrow cells positive for distinct markers is presented in FSC-SSC dot-plots 
in Figure 3. 
   
Figure 4: Distribution of plastic-adherent cell populations. Left and middle plots show “day 
3” adherent cells and right plot shows “day 7” cells. R1: CD45- MSC; R2: CD45+ HC; R3 
and R4 are two additional populations detected on day 3. The size and distribution of all 
populations are shown in the left FSC vs. SSC dot-plot, where the low granularity and size of 
R3 and R4 are evident. 
 
Cultured bone marrow cells: day 3, day 7 and passage 4 
 After detailed characterization of plastic-adherent cells after one week of expansion 
(Chapter 3), we tried to detect similar patterns of surface marker expression (CD45- / CD11a- 
/ CD11bc- and CD29+ / CD54+ / CD90+ / CD44+ / CD106+ / CD61+ / CD49a+ / CD49b 
low / CD49c low / CD49e+) in adherent cells passaged on day three after isolation and in 
cells passaged four times. On day 7 we observed two main cell populations: CD45- MSC (80 
%) and CD45+ cells (20 %). Interestingly, cells detached on day 3 contained two additional 
populations (Figure 4); based on FSC and SSC, we observed small non-granulated cells (31-
52 %); one of these was CD45low and co-expressed CD11a (R4 population; Figure 4, middle 
plot). The other small population was negative for all hematopoietic markers (R3 population; 
Figure 4, middle plot). The CD45- population detected on day 3 and on day 7 (Figure 4, R1; 
green) expressed MSC-specific markers and was therefore described as MSC. MSC showed a 
constant phenotype on day 3, day 7 and after several passages, as seen in Figure 5. On day 3, 
CD61 expression was slightly lower than on day 7. Also on day 3, a hematopoietic cell 
population with surface marker expression similar to that observed on day 7 could be 
detected, comprising the majority of the larger cells on day 3. Whereas on day 7, the ratio of 
the two major populations, CD45- MSC and CD45+ HC, was approximately 4 : 1, on day 3, 
the ratio between these two populations was 0.7 ± 0.2 : 1 (mean of n = 4 ± sd).  
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 One way to enhance the MSC yield is the expansion over several passages. However, 
the phenotype of the several-times passaged cells should be similar to the phenotype of often 
studied primary culture MSC to ensure comparable results. Therefore, for the characterization 
of cells passaged for four times, the primary cultures (day 7) were depleted of CD45+ cells 
and CD45- MSC seeded at the density of 1,000 cells cm2. The proliferation kinetics was not 
affected by passaging, as shown in Figure 6. After 4 passages, surface marker expression was 
determined. No significant differences were observed in MSC phenotype compared to 
primary culture MSC, with the exception of CD106, which was lower at higher passage. 
Breda Vogel 
 128
 
 Adherent cells-day 3 Adherent cells-day 7 CD45- MSC-passage 4 
   
CD
45
 
 
  
   
CD
29
 
 
  
   
CD
44
 
 
 
 
Figure 5: Comparison of surface marker expression in rat plastic-adherent cells during 
cultivation. Dot–plots show the distribution of adherent cells positive for a distinct marker 
(stained blue or green). The histograms show the distribution of the CD45- population (gray) 
separately from CD45+ population (black). 
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Figure 5, continued: Comparison of surface marker expression on rat plastic-adherent cells 
during cultivation. Dot–plots show the distribution of adherent cells positive for distinct 
marker (stained blue or green). The histograms show the distribution on CD45- population 
(gray) separately from CD45+ population (black). 
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Figure 5, continued: Comparison of surface marker expression on rat plastic-adherent cells 
during cultivation. Dot –plots show the distribution of adherent cells positive for a distinct 
marker (stained blue or green). The histograms show the distribution on CD45- population 
(gray) separately from CD45+ population (black). 
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Figure 5, continued: Comparison of surface marker expression on rat plastic-adherent cells 
during cultivation. Dot–plots show the distribution of adherent cells positive for a distinct 
marker (stained blue or green). The histograms show the distribution on CD45- population 
(gray) separately from CD45+ population (black). 
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DISCUSSION 
Cell yield 
For optimal cell yield, several parameters, ranging from cell isolation to the culture 
conditions, needed to be optimized. It appears that the length of time from bone dissection to 
bone marrow isolation with centrifugation plays a crucial role, as does the temperature of the 
media: the length of time from animal sacrifice to placing the cell suspension into flasks has 
to be as short as possible and the media temperature should be kept at 37°C. The centrifugal 
method of bone marrow isolation was successfully established, resulting in a much higher cell 
yield than obtained by the standard “flushing” method. On day 3, single adhered cells could 
be observed, some of which might have begun forming colonies already. Bone marrow cell 
seeding density was high enough to enable the cells to enhance each other’s proliferation, 
resulting in rushed fibroblast-colony formation and cell proliferation. Cells from a single 
colony remain close, sometimes even in cell-cell contact, forming multi-layered colonies. 
This makes it difficult to determine the confluence of the whole flask. Nevertheless, the 
proliferation capacity seems not to be influenced by the high cell density at the end of the 7-
day primary cultures, as seen in Figure 6 showing continuous cell proliferation up to passage 
4. 
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Figure 6: Proliferation curves of rat MSC (high density (arrows): 6,667 cells / cm2; low 
density (without arrows): 1,000 cells / cm2). Low density curve is obtained from CD45-
depleted MSC and the high density curve is from cells that have not undergone separation 
(HC are probably lost within first 2 passages).  
 
Chapter 6: Tracing MSC phenotype: from bone marrow to several passages 
 
 133
Freshly isolated bone marrow cells 
Whereas whole bone marrow cells are seeded in flasks, flow cytometry was performed 
with cells after erythrocyte (Ery) lysis. Nevertheless, some Ery were still in the samples, 
observed as cells with low SSC and FSC and negative for CD4512 (Figure 3). CD45 is higher 
expressed in mature cells (e.g. spleen cells, shown in our preliminary studies) and therefore 
detected in lower levels in bone marrow known to be a source of hematopoietic progenitor 
cells. However, CD45 expression levels in rat hematopoietic stem cells (HSC) are still not 
well characterized. We observed an even distribution of CD45+ cells in FSC-SSC dot-plots, 
as seen in Figure 3. Hematopoietic integrins CD18/CD11a and CD18/CD11bc were expressed 
on bone marrow cells in lower proportions than CD45. All subunits, CD11a, CD11bc and 
CD18, were strongly expressed on granulated cells, and CD11a/CD18 was also expressed on 
the lymphocyte and monocyte fractions as seen in Figure 3. The hematopoietic integrins are in 
general present on all rat hematopoietic cell lineages, except on Ery12; CD11bc is also not 
detected on lymphocytes12. This correlates with our observations of positive-cell distributions, 
but not with our measured percentages: we detected 26 – 40 % CD11a+ cells and 11 - 61% 
CD18+ cells, but 36 – 68 % CD11bc+ cells. Additional multi-color staining needs to be done 
to evaluate co-expression of these integrins. Nevertheless, cells positive for those markers 
dominated the bone marrow granulocyte fraction, which was additionally positive for the 
granulocyte marker (Figure 3). Granulocyte marker is known to be expressed not only on 
granulocytes but also on Ery progenitors, CD45- erythroblasts12. We detected 18 - 38% 
CD45RA+ cells, known to be B lymphocytes, distributed in the lymphocyte fraction of bone 
marrow cells. T lymphocytes, identified by CD3, CD4 and CD8b expression (Table 1), 
accounted for fewer than 5 % of the cells, suggesting that B lymphocytes were the 
predominant cell type in the bone marrow lymphocyte population. The amount of 
lymphocytes that we detected correlated well with smear evaluations, where 7 – 21 % 
lymphocytes are usually found10. Literature data10 mention 34 - 52% granulocyte progenitors 
in the rat bone marrow which together with lymphocytes, comprise a major fraction (up to 73 
%) of bone marrow nucleated cells. Our results showed 40 - 53% granulocyte+ cells, which 
corresponded only to the granulocyte precursor amount10. Whereas the same antibody stains 
Ery progenitor also, we were not able to distinguish between granulocytes and Ery 
progenitors. The latter are reported to be present in a high proportion in the rat bone marrow 
as well10. Ery progenitors could be destroyed by the lysis and therefore could not be detected 
quantitatively.  
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CD29+, CD90+ and CD54+ cells were distributed throughout all cell fractions in the 
FSC-SSC dot-plot (Figure 3). 57 – 68 % of the cells expressed stem cell marker CD90 and 
were present in both the granulocyte (Ery progenitors) and monocyte fractions, in addition to 
the lymphocyte fraction, where the true stem cells are expected to be found. Megakaryocyte-
platelet marker CD61 was co-expressed on granulocyte-positive cells (data not shown). 
Determined proportions of CD61+ cells varied, which could be a consequence of strong 
nonspecific antibody labeling observed with isotype control.  
To date, only a few surface antigenic markers have been described that have been used in 
the purification of MSC (CFU-F) from the bone marrow (Stro-1, CD49a, D7-FIB, BMPRIA, 
LNGFR)14. The markers commonly claimed to be specific for cultured MSC, such as CD29 
and CD44, have, in fact, broad cell reactivity and, hence, are unsuitable for the detection of 
MSC in vivo. Whereas the typical MSC markers, CD29, CD90, CD54, and CD44, were 
present on many cell types from the bone marrow (Table 1, Figure 3), other, more specific 
markers like CD49a and CD106 were present in very low percentages (< 2.5 %), less than the 
amount of CD45- cells (42 – 83 %). Therefore CD49a and CD106 may be more suitable 
markers for the estimation of MSC-like cells. For the exact determination of fresh bone 
marrow MSC phenotype, at least 10,000 MSC-like cells needed to be examined, meaning that 
at least 4 x 105 bone marrow cells need to be evaluated for every measurement. Boiret et al.15 
enriched CFU-F from human bone marrow using CD49a or CD73-positive selection and 
CD45+ cell depletion. However, Deschaseaux et al.9 and Jones et al.16 obtained human MSC-
enriched populations (CD49a+ or D7-FIB+ cells) in a CD45low fraction, suggesting that 
CD45+ cell depletion from the fresh bone marrow might reduce the presence of MSC-like 
cells also. 
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Figure 7: Comparison of studied populations: Size (FSC) and granularity (SSC) distribution.   
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Cultured plastic-adherent rat bone marrow cells 
Using standard culture conditions for MSC proliferation, positive-selected human MSC 
(CFU-F) continuously express D7-FIB, CD13, CD10 and CD105, but lose the expression of 
Stro-1, LNGFR, and HLA-DR16. When cultured, CD45 and CD34 are also lost, but CD49a+ 
is retained9. Rat MSC have been phenotypically characterized after several passages4 or as 
primary cultures of plastic-adherent bone marrow cells17,18. We wanted to compare the 
expression of surface markers on early bone marrow cultured cells (3 days and 7 days) with 
cells passaged for 4 passages. In Figure 7, the SSC-FSC dot-plots of bone marrow and 
cultured cells are compared. Although the parameters used for the measurements were unique 
for each population, a difference in average cell size could be observed; freshly isolated cells 
are much smaller than cultured cells (bone marrow vs. adherent cells-d3), which grow larger 
with each passage. With adherent cells, the FSC attenuation needed to be reduced to observe 
the whole population. Small non-granulated cells from d3 (low SSC and FSC) most likely 
correspond to the lymphocyte fraction of fresh bone marrow. The differences in cell size and 
auto-fluorescence required population-specific instrument settings, therefore also some 
deviations in population location in fluorescence dot-plots (Figure 5) could be observed. 
Primary cultures of adherent bone marrow cells, cultured until sub-confluence (7 days), 
contained two main cell populations, as resolved with CD45 expression; CD45+ cells and 
CD45- cells expressing MSC-like markers (CD29, CD49a, CD49e, CD61, CD90, CD44, 
CD106). In adherent cells passaged 3 days after isolation, a population with a similar surface 
marker profile to the CD45- MSC fraction from day 7 could be observed. This fraction is 
marked as R1 in Figure 4 and comprised 23.5 ± 3.9 % (average of n = 4 ± sd) of cells 
passaged on day 3. Estimated MSC-like cell frequency is therefore 1.3% of nucleated bone 
marrow cells, based on cell counts performed on day 3 and after isolation (Table 1), under the 
assumption that in 3 days after isolation cells did not proliferate. This percentage is higher 
than the published frequency of CFU-F19 and indicates that probably not all cells which 
express MSC markers are “true” stem cells or CFU-F. On day 3, a hematopoietic population 
similar to the CD45+ population detected on day 7 (Figure 4, R2) was observed, in addition to 
two other populations with low SSC and FSC. One population (Figure 4, R4), 
CD45low/CD11a+, could be megakaryocytes/platelets; a similar population was weakly 
positive for CD61, confirming this assumption (data not shown). Since 
megakaryocytes/platelets are primarily nonadherent, these cells could reside in the flasks after 
incomplete removal of nonadherent cells before analysis. The fourth population found on day 
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3 (Figure 4, R3) did not show significant expression of any of tested markers. Nevertheless, 
these cells could be small, rapidly self-renewing stem cells, an MSC subpopulation, described 
in low cell density cultures with low FSC and SSC4,20,21. However, for more detailed 
characterization of all populations, including the two additional populations found on day 3, 
many more cells have to be evaluated, separated and further cultured. However, our culture 
conditions favor the expansion of larger cells, particularly MSC-like cells, as illustrated by the 
increased MSC proportion comparing day 3 and day 7. 
The expression of CD61 on CD45- MSC was higher on day 7 than on day 3, which 
confirms the connection of CD61 expression with in vitro culture conditions in the presence 
of FBS. CD61 expression did not change, however, from passage 1 to passage 4. In contrast, 
CD106 expression was lower in passaged cells than in primary culture cells (Figure 3).  
MSC show limited in vitro proliferation capacity, which can be prolonged with low 
density culturing and special culture conditions. Figure 7 shows that, when seeded at 1,000 
cells / cm2, CD45- cells did not change their proliferative capacity with time (low density 
curve), maintaining 0.8 - 1 population doublings / day (PD / day). The second, high density 
curve was obtained by replating unseparated cells, at a density of 6,667 cells / cm2 for the first 
three times, followed by 1,000 cells / cm2. The low initial doubling rate (0.4 PD / day) could 
be due to high seeding density or due to the presence of hematopoietic cells, which probably 
did not proliferate in the culture and therefore disappeared from the MSC cultures within the 
first few passages22. Nevertheless, high density subculturing resulted in a lower PD / day and 
lower cell numbers compared to low density culturing.  
Passaged cells (CD45-, passage four, low density) did not differ significantly from first 
passage CD45- MSC (Figure 3, day 7) with regard to surface marker expression (integrins 
and other markers). For successful tissue engineering applications, however, extensive-
expanded MSC used should beside constant surface marker expression retain their 
differentiation potential. Ter Brugge et al. 23 showed that rat MSC lose osteogenic potential 
dramatically from passage 1 to passage 2. However, they did not discuss cell density at 
replating and confluence at the passage. It would be therefore important to determine the 
dependence of CD45- MSC differentiation on the passage number when the cells are 
proliferated at low densities, preventing the formation of dense colonies; the passages should 
be therefore performed at least twice a week.  
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CONCLUSION 
This chapter shows that the culture conditions used favor the expansion of CD45- cells 
with MSC-like surface marker expression. Whereas less than 1.3 % cells from the bone 
marrow nucleated cells adhere within 3-days and show MSC-like phenotype, these cells 
proliferate rapidly and could be maintained in the culture over 30 days without changes in 
their proliferation kinetics. Four-times passaged cells showed similar phenotype to primary 
cultured CD45- cells (day 7), which are usually used for tissue engineering studies using rat 
cells. However, for tissue engineering applications also the differentiation capacity of 
passaged cells should remain unchanged. The contaminating hematopoietic cells found in 
primary cultures on day seven showed similar phenotype to cells found in the granulocyte and 
monocyte fraction of the fresh bone marrow. These cells could be partly eliminated by density 
gradient centrifugation. As we tried to determine the phenotype of freshly isolated MSC, we 
first analyzed adherent cells detached 3 days after isolation. With the exception of lower 
CD61 expression on day 3, CD45- MSC showed similar phenotype on day 3 as on day 7. The 
attempt to detect these cells in the fresh bone marrow showed that the expression of markers 
like CD49a and CD106 could indicate the presence of MSC-like cells. Additionally, at least 4 
x 105 bone marrow cells need to be evaluated for every measurement. After the determination 
of MSC-like cell phenotype in the bone marrow, the strategies to isolate MSC by direct or 
indirect immunolabeling could be discussed.  
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INTRODUCTION 
In vitro bone tissue engineering utilizes three-dimensional cell carriers of metal alloys, 
hydroxyapatite or tricalciumphosphate ceramics, demineralized natural bone, or synthetic 
materials (e.g. poly-lactic acid, poly-lactic-co-glycolic acid) seeded with osteoblastic cells of 
different maturity grades from marrow stromal cells (MSC) to osteobasts1. However, the 
developing tissue suffers from insufficient differentiation and production of mineralized 
extracellular matrix (ECM)2. Therefore, growth factors like transforming growth factor β1 
(TGF-β1), bone morphogenic protein-2 (BMP-2), and platelet derived growth factor (PDGF) 
have been more or less successfully used to overcome the sparse ECM production by several 
different mechanisms, like increased collagen I production, enhanced osteogenic 
differentiation, and enhanced proliferation, respectively3. Recent studies have suggested that 
statins, which are well established lipid-lowering drugs, influence bone turnover by 
stimulating bone formation and inhibiting bone resorption4. Several statins, including 
lovastatin, simvastatin, mevastatin, and fluvastatin, have been shown to increase bone 
formation in bone explant cultures. The mechanism of action bases on inhibition of 3-
hydroxy-3-glutaryl-coenzyme A (HMG-CoA) reductase and blocking of the mevalonate 
pathway4,5 (Figure 1). Nitrogen-containing bisphosphonate drugs also inhibit the mevalonate 
pathway, preventing the production of the isoprenoids and protein prenylation (Figure 1), 
which result in inhibition of osteoclast formation and function5. The proposed mechanism by 
which statins stimulate bone formation involves an increase in the expression and synthesis of 
bone morphogenic protein 2 (BMP-2)6-9, which can be completely inhibited when adding 
mevalonate10. It was shown that lovastatin, simvastatin, fluvastatin, and mevastatin can 
increase new bone formation approximately 2- to 3-fold, an increase comparable to that seen 
after treatment with BMP-2 and fibroblast growth factor-1 (FGF-1)8. 
Rat MSC are suitable cells for bone tissue engineering, because they are easily 
accessible and can differentiate in vitro to the osteoblastic phenotype after dexamethasone 
supplementation11,12. Moreover, ascorbic acid and β-glycero-phosphate provide the chemical 
substrates for osteogenic matrix production12. MSC are a heterogenous cell population, 
including multipotential mesenchymal stem / progenitor cells, which can differentiate into 
osteoblasts, adipocytes, chondrocytes, myocytes, tenocytes, and cells of other mesenchymal 
tissues13-15. Supplementation with varying agents can result in differentiation to discrete cell 
types, e.g. the addition of dexamethasone is required for in vitro osteogenesis and 
adipogenesis, whereas supplementation with statins favors differentiation into the osteogenic 
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lineage, while inhibiting adipogenesis16. Beside in vivo studies on statin effects on net bone 
formation, in vitro studies are limited more or less to the osteoblastic or mesenchymal cell 
lines. There are insufficient data17,18 on in vitro effects of statins on the osteogenesis of 
primary cultures of immature osteoprogenitors like MSC. Therefore, we investigated the 
influence of simvastatin and atorvastatin (Figure 2) supplementation on rat MSC cultures, in 
order to evaluate their potential for in vitro tissue engineering. Whereas simvastatin is often 
used as a statin standard control, atorvastatin is believed to show even better effects in vivo 
due to better distribution to bone tissue9. The effect of three different concentrations of both 
statins on cell proliferation, alkaline phosphatase (ALP) and calcium accumulation was 
investigated. 
 
 
Figure 1: Inhibition of the mevalonate pathway by statins results in inhibition of protein 
prenylation and consequential lost of protein function.( from Bauer D.C.19) 
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MATERIALS AND METHODS 
Suppliers 
Fetal calf serum (Gibco, Invitrogen, UK; Lot No.: 40F7430K); Penicillin-
Streptomycin (Gibco, Invitrogen, UK; 10,000 units / mL penicillin G sodium and 10,000 µg / 
mL streptomycin sulphate); L-glutamine (Sigma Aldrich, Germany; 200 mM); Trypsin-
EDTA (Gibco, Invitrogen, UK; 0.25 % Trypsin and 1 mM EDTA.4Na); Minimum essential 
medium Eagle, alpha modification (Sigma Aldrich, Germany; 10.1 g / L); simvastatin (MSD, 
Germany); atorvastatin (Pfizer, USA). 
Cell culture 
Rat bone marrow was isolated from the femur and tibia of 6-8 weeks old (150-200g) male 
Sprague-Dawley rats using the centrifugal method20. Freshly isolated bone marrow cells were 
resuspended in primary medium (10 % FCS, 1 % Penicillin / Streptomycin, 0.5 % L-glutamine and 
minimal essential medium, alpha modification). Cells obtained from a single rat (2 tibias and 2 
femur) were seeded in 4 x T150 flasks. The cells were cultured in humidified atmosphere with 5 % 
CO2 at 37°C and left to adhere for three days before non-adherent cells were removed. Medium was 
changed three times a week and when the cultures reached 80 – 100 % confluence, they were 
detached from the surface with trypsin-EDTA and counted. 
For the differentiation the cells were plated in 12-well plates at a density of 50,000 cells / 
cm2 in primary medium for 24 hours. On day 1 the cells received complete medium (primary 
medium supplemented with 50 mg / L ascorbic acid, 2.16 g / L β-glycero-phosphate and 10-8 M 
dexamethasone). The medium was changed every 2 - 3 days and the samples were taken at different 
time points for the assays. Wells were washed with PBS and frozen at –20°C until all the samples 
were collected.  
During the differentiation phase, the cultures received statins continuously with every media 
change. We tested three concentrations for each statin and the groups were: 
Control, without statin: C, 
Atorvastatin or simvastatin in 0.5 µM concentration: A05 or S05, 
Atorvastatin or simvastatin in 1 µM concentration: A1 or S1, 
Atorvastatin or simvastin in 5 µM concentration: A5 or S5. 
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Cell number 
A fluorimetric assay21 was performed to measure the total amount of DNA and, 
subsequently, to determine the cell number. The samples were thawed and the cells scraped 
off the surface and dispersed in PBS. After digestion with a papain solution for 18 h at 60°C, 
the released DNA was quantified using Hoechst 33258 dye.  
Alkaline Phosphatase (ALP) 
Cells were thawed and kept on ice during preparation of the samples. Cells were 
scraped, dispersed in TRIS buffer (1M Trisma base (Sigma, Germany), pH 8) and sonicated. 
A kinetics-based assay was performed to determine the enzymatic activity (RANDOX Kit, 
Randox Laboratories Ltd., Crumlin, UK) by measuring the absorbance of released product at 
405 nm. 
Von Kossa staining 
After 18 days of osteogenic differentiation, wells were rinsed with PBS and the cells 
fixed with 10 % neutral buffered formalin. Samples were incubated with 5 % aqueous silver 
nitrate solution, exposed to natural light for 30 min, and counterstained with 0.5 % safranin O. 
ImageJ was used to evaluate the % area positively stained for calcium. 
Statistical analysis 
Results are an average of 4 experiments ± standard deviation, unless otherwise stated. 
The level of significance was determined by Tukey test. 
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Figure 2: Structural formula of atorvastatin (left) calcium salt and simvastatin (right). 
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RESULTS 
Influence of statins on proliferation in osteogenic medium 
Statins were supplemented in three different concentrations with every media change, 
3-times a week during the differentiation phase. Figure 3 shows the influence of statins on cell 
number during osteogenic differentiation. The addition of either simvastatin or atorvastatin in 
the investigated dose range decreased cell number after day 10 compared to the control. As 
early as day 10, cultures supplemented with 0.5 µM and 1 µM simvastatin showed 
significantly lower (p < 0.01) cell numbers compared to the control. The influence of the 
same concentrations of atorvastatin and simvastatin on cell number indicated that simvastatin 
is a stronger inhibitor of proliferation than atorvastatin, as seen on days 10 and 14. Both 
statins caused cell death and declining cell numbers after day 10, compared to the control, in 
which the cell number over the examined period was more or less constant. In the group 
treated with the highest dose of simvastatin (5 µM), detachment of cells from the wells and 
cell death were already evident after the first treatment. By day 10, all of the cells from this 
group had detached from the surfaces and therefore no further evaluation was possible. On 
day 14 we observed a decrease in cell number with increasing concentrations of both statins. 
0.0E+00
2.0E+05
4.0E+05
6.0E+05
8.0E+05
1.0E+06
1.2E+06
10 14 18
Days in osteogenic medium
Ce
ll 
n
u
m
be
r 
/ 1
2-
w
e
ll
C
S05
A05
S1
A1
A5
*
*
*
x
 
Figure 3: Proliferation in osteogenic medium. C: control without statin; S: simvastatin; A: 
atorvastatin; 05: 0,5 µM; 1: 1 µM and 5: 5 µM concentration.  
Significant difference compared to C: * : p < 0.01 and x:  p < 0.05. 
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Influence of statins on osteogenic differentiation 
The extent of osteogenic differentiation was assessed by determining an alkaline 
phosphatase (ALP) time profile, von Kossa staining of calcium deposition, and its 
quantification using the image analysis software. ALP time profile was assessed between days 
10 and 18. As shown in Figure 4A, maximum ALP was determined on day 10. The lower 
proliferation after simvastatin addition was accompanied by significantly higher ALP activity 
per cell (Figure 4B) in both remaining simvastatin groups, compared to the control. The 1 µM 
simvastatin group showed higher ALP activity per cell than all groups supplemented with 
atorvastatin (Figure 4B). Interestingly, atorvastatin supplementation did not result in 
significant increases in the ALP activity per cell, compared to the control.  
Mineralization (calcium phosphate deposition) was determined by von Kossa staining 
of the cultures after 18 days in osteogenic medium (Figures 5 and 6). We observed the 
detachment of cell layers, which then formed coils, in groups with simvastatin (Figure 5, S05 
and S1), most likely resulting from extensive collagen matrix production and cross-linking. In 
the remaining simvastatin-treated wells showing no detachment, the mineralization was more 
extensive than in the control group (Figure 6). Groups supplemented with atorvastatin showed 
a slight dose-dependent increase in mineralization (Figure 6).  
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Figure 4: Alkaline phosphatase activity. A: time profile, per well; B: day 10, per cell.  
The ALP activity was the highest on day 10 for the time points that we considered (A). 
Significant differences are marked as ** when p < 0.01 compared to S1, * when p < 0.05 
compared to S05, and ° when p < 0.01 compared to S05. 
 
Breda Vogel 
 148
A05 
 
S05 
 
    
A1 
 
S1 
 
    
A5 
 
C 
 
Figure 5: Von Kossa silver nitrate staining of calcium deposition on day 18. 
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Figure 6: Von Kossa silver nitrate staining: percentage of mineralized area after 18 days in 
osteogenic medium. Columns and error bars represent mean of (n = 2 or 3) ± standard 
deviation (only for n = 3). 
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DISCUSSION 
The osteogenic differentiation of marrow stromal cells (MSC) is a continuous process, 
triggered by dexamethasone, which induces MSC to differentiate into osteoprogenitors, which still 
proliferate. Osteoprogenitors begin to express alkaline phosphatase, an early osteogenic marker and 
large amounts of collagen I, which slowly mineralizes. With progressing maturation, the 
proliferation ceases as the cells develop into mature osteoblasts. Only mature osteoblasts secrete the 
late differentiation marker osteocalcin. Osteoblasts embedded in matrix become osteocytes or die by 
apoptosis22. Therefore, for a large part of osteoblasts differentiation is physiologically accompanied 
by cell death. Bone tissue engineering utilizing 3-dimensional cell carriers suffers from insufficient 
matrix production and distribution, caused in part by a lack in growth factor supply23,24. However, 
osteogenic growth factors are expensive and prone to cause side effects. Therefore, we tested the 
potential osteoinductive agents, simvastatin and atorvastatin, known as well tolerated lipid-lowering 
drugs, to determine which dosages may be appropriate for in vitro tissue engineering. 
Our results show that cell proliferation up to day 10 was not inhibited by 0.5 and 1 µM 
atorvastatin, whereas a negative influence was found at the 5 µM dose. Simvastatin inhibited 
proliferation or caused cell death in all tested concentrations, with 5 µM being the most devastating. 
With increasing culture time, the negative effect on cell number was even more evident, suggesting 
that continuing treatment with statins over the entire differentiation period is not desired, but it might 
be beneficial during the early differentiation period. Mundy et al.8 reported that 5 µM statin 
supplementation is the optimal concentration for rat calvaria osteoblast explant cultures, even 
resulting in increased osteoblast proliferation. Using more immature rat primary bone marrow cells, 
Maeda et al.17 showed an osteoinductive effect of simvastatin at concentrations even below 1 µM. 
However, he and some other groups exposed the cultures to statins only for a couple days (3 - 7 
days), in which period our cultures also show only the positive effects. Most of the studies used cell 
lines and exposed the cells to the statins for shorter time periods and analyzed the cultures 
immediately thereafter6,17,18. Only Baek et al.25 reported a negative effect of simvastatin on the 
proliferation of human MSC after more than 10 day treatment, which could, together with our 
observations, indicate that (1) immature MSC are more sensitive to simvastatin supplementation 
than more mature cells and (2) the prolonged exposure to statins (more than 7 days) seem to have a 
negative effect on cell number. 
On the other hand, we observed heightened alkaline phosphatase activity on day 10 in 
statin-supplemented groups compared to the control group, especially in simvastatin treated groups. 
This indicates that statins positively influenced the early phase of differentiation. Statin addition 
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only in the early differentiation phase might be sufficient, because it has been proposed that statins 
produce prolonged biological effects after only brief exposure9. In our study, statins also increased 
the mineralization. Unfortunately, the assessment of mineralization was performed only on day 18, 
where all groups treated with statins exhibited lower cell numbers. In other words, statins probably 
improved differentiation of rat MSC and mineralization, which was concealed by the toxic effects of 
prolonged exposure to statins.  
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This thesis considered aspects of cells and biomaterials required for effective tissue 
engineering of bone. Along these lines, we investigated cell characteristics decisive for the 
control of cell-biomaterial interactions and adhesion to three-dimensional carriers. While 
previous and cooperative work within group1,2 concerning this subject dealt with the control 
of protein adsorption to biodegradable PEG-PLAs and mechanisms of surface modification, 
this thesis focused on cell characteristics required for selective cell adhesion. 
Bone marrow stromal cells are a promising source of osteoprogenitor cells and can 
easily be obtained by bone marrow aspiration in humans or by bone centrifugation in rodents 
followed by cell selection based on adherence to tissue culture plastic. We characterized the 
populations found in the adherent cell fraction of the rat bone marrow. We found that 
adherent cells included marrow stromal cells (MSC), which are a source of the progenitors of 
mesenchymal cell types, and hematopoietic cells (HC). To determine if the HC fraction had 
positive or negative effects on osteogenic differentiation, we separated MSC and HC 
immunomagnetically and combined them in controlled and varied proportions. Because we 
found that co-culturing the MSC with HC hindered MSC differentiation, we focused on 
enrichment strategies for MSC. We first varied the adhesion time of bone marrow cells after 
isolation. In the second step we focused on selective adhesion of MSC to the extracellular 
matrix (ECM) proteins in the presence of HC. A rational approach to selective cell adhesion is 
the characterization of the ECM receptor expression pattern, i.e. integrin expression on the 
cell surface. We therefore investigated the integrin expression on MSC and HC depending on 
the time in culture. Moreover, we initiated investigations into the induced modification of 
integrin expression following the addition of growth factors. Since bone formation in vitro is 
often a problem in tissue regeneration, we finally explored the effects of statins, known to be 
beneficial for bone homeostasis in vivo, on osteogenic differentiation. 
 This work based on marrow stromal cells of rat origin. The rat model bears several 
advantages over the human model. First, rat cells are easily available, show lower 
interindividual variations than the human system, and provide immuncompetent animal defect 
models. Plastic-adherent rat bone marrow cells have been used for bone, cartilage, and fat 
tissue engineering studies1,3,4, since they provide a population enriched for MSC. Since 
human and mouse MSC have been already phenotypically characterized, but less data were 
available on rat MSC, our first aim was to determine surface marker expression on in vitro 
expanded rat MSC. Focusing on the characterization of this population, we detected the 
presence of significant amounts (10 – 40 %) of CD45+ HC in primary cultures. In Chapter 2 
the adherence time after cell isolation was varied in order to reduce HC contamination. 
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Whereas the percentage of HC could not be significantly reduced, the adherence time of 3 - 4 
days lead to significant higher cell yields than the adherence time of 1 - 2 days. This may be 
due to the adherence time itself allowing for more cells to adhere or due to the presence of 
non-adherent cells, known to contain platelets and megakaryocytes, which can induce 
adherent-cell proliferation5. Both mechanisms likely contributed to the improved MSC yield 
after prolonged initial adherence time. This is an important fact, since the cell number is 
crucial for tissue engineering applications. Therefore, we decided to allow bone marrow cells 
to adhere for 3 days after isolation, before non-adherent cells were removed. The adherent 
cells were further cultured until day 7 after isolation. Endothelial cells, which have also been 
found in primary MSC cultures6, were not present in our cultures (Chapter 4).  
The experiments presented in Chapter 3 investigated the need for selective adhesion 
of MSC to the biomaterials and for the effect of contaminating HC. We studied the influence 
of CD45+ HC, from the primary MSC cultures on osteogenic differentiation. We first 
compared the ALP and calcium accumulation of populations containing different percentages 
of CD45+ cells and CD45- cells, keeping the total (CD45+ and CD45-) cell seeding density 
constant. Differentiation in pure CD45- cultures was strongly improved compared to the 
mixed cultures. With increasing proportions of HC (CD45+), ALP activity and calcium 
accumulation decreased. To exclude an effect of variable CD45- MSC seeding density in the 
first experiment, some additional scenarios were tested. Each of these experiments confirmed 
the negative effect of HC on MSC differentiation to the osteogenic lineage, while MSC 
seeding density and the separation procedure had no significant influence on differentiation 
(Chapter 3).  
MSC dilution with dermal fibroblasts has been shown to cause similar suppression of 
osteogenesis, probably mediated by reduced MSC homotypic cell-cell contacts7. To examine 
whether this was also true for the effect of HC on osteogenic differentiation, we investigated 
the effects in trans-well inserts, where we spatially separated HC from MSC. In these systems 
HC can only interact with MSC by soluble factors (cytokines), but not by cell-cell contacts. 
Osteogenic gene expression was significantly higher in MSC cultured in the absence of HC 
than in the presence of CD45+ HC: The specific osteoblast marker osteocalcin was fourty-
times higher expressed in monocultured MSC. This proves that plastic-adherent CD45+ cells 
secrete some soluble factors that suppress MSC osteogenic differentiation. These factors may 
be identified by screening studies on protein or gene level and confirmed by exogenous 
supplementation to the MSC culture. Some candidates are discussed in Chapter 3. In addition 
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to the tissue engineering applications, these results may have relevance for the understanding 
the “protective” mechanisms against spontaneous MSC differentiation in the bone marrow8,9.  
 In order to enrich MSC in the presence of HC, we characterized the integrin 
expression of both populations to find selective receptors for ECM adhesion. Multi-parameter 
flow cytometry enabled us to characterize both cell populations found in the primary cultures 
of adherent rat bone marrow cells without the need for mechanical separation of the cells, as 
presented in Chapter 4. We found that the majority of adherent bone marrow cells (70 – 90 
%) were CD45- / CD11bc- / CD31- / CD90+ / CD44+ / CD106+ / CD29+, expressing 
markers characteristic for MSC10,11. The same cells co-expressed integrin subunits CD49a, 
CD49b, CD49c, CD49e, and CD61, receptors for ECM molecules such as collagen I-IV, 
fibronectin, and vitronectin. In contrast, CD45+ HC expressed hematopoietic integrins like 
CD11a, CD11bc, and CD18, which are implicated in cell-cell interactions. HC also expressed 
the ECM integrins CD49e and low CD49a, which could, in turn, cause HC adherence to 
fibronectin or collagen, if activated. The adhesion of MSC and HC to the ECM-coated wells 
showed that MSC adherence corresponded to specific integrin expression: fibronectin > 
collagen IV, collagen I > vitronectin > laminin. CD45+ HC adhered strongly in the presence 
of FBS and on fibronectin and vitronectin-coated surfaces, but not to collagen or laminin. 
Moreover, HC exert strong non-specific adhesion to the TC plastic, as seen with BSA coated 
wells. Their adhesion to vitronectin could not be explained with the expression of vitronectin-
specific integrin CD61, but with the possible involvement of non-specific adhesion or other 
mechanisms. On the other hand, collagen-coated substrates would enable the selective in vitro 
adhesion of MSC only (Chapter 4), at least in serum-free media, where fibronectin and 
vitronectin are absent. In Chapter 5 an approach involving growth factor effects to modulate 
integrin expression for the enhancement of MSC adhesion to the modified surfaces is 
presented.  
 In Chapter 6 further methods to enrich MSC for tissue engineering applications are 
proposed. Immunomagnetic depletion of CD45+ HC from the primary cultures (7 days) is 
possible, but separation of earlier cultures could be more cost-effective. The efficacy of MSC 
isolation directly from the bone marrow is debatable, due to their low frequency. We saw that 
the rat MSC phenotype was not greatly affected by cell culturing between day 3 and the 
fourth passage, indicating that multiple passages could be utilized for MSC enrichment. 
However, a potential loss of osteogenic differentiation capacity after each subculture should 
be considered. 
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As in vitro bone tissue engineering with rat MSC suffers from poor tissue production, 
which may be caused by insufficient cell differentiation, growth factors and osteoinductive 
drugs have been tested to overcome the problem. Mundy at al.12 reported in 1999 that statins, 
lipid-lowering drugs, enhance bone formation in vivo and in vitro by rodents. We tested the 
effect of continuous supplementation of simvastatin and atorvastatin on the MSC 
differentiation phase (Chapter 7). We observed a dose-dependent increase in ALP and 
calcium accumulation, but a devastating effect on cell number after exposure to high 
concentrations. Furthermore, all investigated concentrations strongly decreased the cell 
numbers when applied for more than 10 days. Additional studies could confirm whether only 
brief exposure to statins could bring the desired effects: improved osteogenic differentiation 
without cell death. 
 To summarize the thesis, we showed the importance of methods like flow cytometry 
for characterizing heterogenous cell populations yielded both in vitro and in vivo. We showed 
that the contaminating cell populations (CD45+ cells) could be a source of sample variation 
between experiments, because the degree of contamination is also a significant variable. 
Furthermore, an immunomagnetic separation technique (e.g. MACS®) was successfully 
adopted for tissue engineering applications. While the hematopoietic stem cell 
microenvironment is widely studied, there is increasing interest in the MSC 
microenvironment (factors, cells); this thesis contributes to that growing body of knowledge. 
Finally, ways to induce selective MSC adhesion in the presence of contaminating HC are 
described; after the analysis of adhesion receptor expression, the receptor activity was tested 
in experiments on cell adhesion to the ECM-coated substrates.  
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ABBREVIATIONS 
7-AAD  7-aminoactinomycin D, DNA dye 
α-MEM  Minimum Essential Medium Eagle, alpha modification 
Ab   antibody 
Ag   antigene 
ALP   alkaline phosphatase 
APC   allophycocyanin 
BMP   bone morphogenic protein 
BMPR   receptor for BMP 
BSA   bovine serum albumin 
Cbfa-1   core binding factor-1, bone transcription factor 
CD   clusters of differentiation  
(cluster designation of monoclonal antibodies) 
DNA   deoxyribonucleic acid 
ECM   extracellular matrix 
EDTA   ethylene-diamino-tetraacetic acid 
EGF   endothelial growth factor 
ESC   embryonic stem cells 
FACS   fluorescence-activated cell sorting 
FC   flow cytometry 
FBS   fetal bovine serum 
FGF   fibroblast growth factor 
FITC   fluorescein isothyocyanate 
FSC   forward scatter (FC parameter describing cell size) 
HC   hematopoietic cells 
HSC   hematopoietic stem cell 
Ig   immunoglobulin 
IGF   insulin-like growth factor 
IL   interleukin 
LME   level of marker expression (FC parameter) 
LNGFR  low affinity nerve growth factor receptor 
MACS   magnetic-activated cell sorting; trade name of Miltenyi Biotec 
MAPC   multipotent adult progenitor cells 
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MFI   mean fluorescence intensity 
MSC marrow stromal cells, exceptionally: mesenchymal stem / progenitor 
cells 
PBS   phosphate buffered saline, buffer 
PD   population doublings 
PDGF   platelet-derived growth factor 
PE   phycoerythrin 
PGA   poly-glycolic acid 
PLA   poly-lactic acid 
PLGA   poly-lactic-co-glycolic acid 
PI   propidium iodine, DNA dye 
RGD   peptide sequence: arginine-glycine-aspartic acid 
RNA   ribonucleic acid 
RT-PCR  reverse transcription polymerase chain reaction 
sd   standard deviation 
SCT   stem cell therapy 
SEM   standard error of the mean 
SSC   sideward scatter (FC parameter describing cell granularity) 
TC   tissue culture 
TCPS   tissue culture polystyrene 
TE   tissue engineering 
TGF   transforming growth factor 
VEGF   vascular endothelial growth factor 
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